Cyclin-dependent kinase 7 inhibitors and uses thereof
By designing a compound that can selectively inhibit CDK7 activity, using carbocyclic or heterocyclic structures and covalently modifying the cysteine residue of CDK7, the high toxicity and serious side effects of existing CDK inhibitors are solved. , achieving a more efficient and low toxic CDK7 inhibition effect.
Patent Information
- Application Number
- CN201980086903.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2019-12-27
- Publication Date
- 2024-11-29
- Estimated Expiration
- 2039-12-27
AI Technical Summary
Existing CDK inhibitors have high toxicity, serious side effects and drug resistance when treating cancer and other proliferative diseases, and it is difficult to selectively inhibit the activity of CDK7, affecting the therapeutic effect.
Provides a compound that can selectively inhibit the activity of CDK7, with a more efficient, low toxicity and more soluble pharmacokinetic through a carbocyclic or heterocyclic structure and a covalent modification of the cysteine residue of CDK7. Academic nature.
This compound is able to more effectively inhibit the activity of CDK7, reduce the frequency and severity of side effects, improve the adherence and effectiveness of treatment, especially in CDK7-related diseases, showing improved pharmacokinetic properties.
Smart Images

Figure CN113557017B_ABST
Abstract
Description
[0001] Related Applications
[0002] This application claims priority under 35 U.S.C. §119(e) to U.S. Provisional Application USSN 62 / 786,328, filed on December 28, 2018, which is incorporated herein by reference.
[0003] Government support
[0004] This invention was made with Government support under Grant No. W81XWH-16-1-0252 awarded by the Department of Defense. The Government has certain rights in this invention. Background Art
[0005] Members of the cyclin-dependent kinase (CDK) family play a key regulatory role in cell proliferation. There are 20 known mammalian CDKs. CDK7 to CDK13 are associated with transcription. CDK1, 2, 4 and 6 are shown to be associated with the cell cycle. Unique among mammalian CDKs, CDK7 has a combined kinase activity that can regulate both the cell cycle and transcription. In the cytoplasm, CDK7 exists as a heterotrimeric complex and is believed to function as a kinase (CAK) that activates CDK1 / 2, whereby phosphorylation of conserved residues in CDK1 / 2 by CDK7 is required for full catalysis of CDK activity and cell cycle progression (Desai et al., "Effects of phosphorylation by CAK on cyclin binding by CDC2 andCDK2." Mol. Cell Biol. 15, 345-350 (1995); Kaldis et al., "Analysis of CAK activities from human cells." Eur. J. Biochem. 267, 4213-4221 (2000); Larochelle et al., "Requirements for CDK7 in the assembly of CDK1 / cyclin B and activation ofCDK2 revealed by chemical genetics in human cells." Mol. Cell, 25, 839-850 (2007)).In the nucleus, CDK7 forms the kinase core of the RNA polymerase (RNAP) II general transcription factor complex and is responsible for phosphorylating the C-terminal domain (CTD) of RNAP II, which is an essential step for the initiation of gene transcription (Serizawa et al., "Association of CDK-activating kinase subunits with transcription factor TFIIH." Nature, 374, 280-282 (1995); Shiekhattar et al., "CDK-activating kinase complex is a component of human transcription factor TFIIH." Nature, 374, 283-287 (1995); Drapkin et al., "Human cyclin-dependent kinase-activating kinase exists in three distinct complexes." Proc. Natl. Acad. Sci. USA, 93, 6488-6493 (1996); Liu et al., "Two cyclin-dependent kinases promote RNA polymerase II transcription and formation of the scaffold complex." Mol. Cell Biol., 24, 1721-1735 (2004); Akhtar et al., "TFIIH kinase places bivalent marks on the carboxy-terminal domain of RNApolymerase II." Mol. Cell, 34, 387-393 (2009); Glover-Cutter et al., "TFIIH-associated CDK7 kinase functions in phosphorylation of C-terminal domain Ser7 residues, promoter-proximal pausing, and termination by RNA polymerase II." Mol. Cell Biol., 29, 5455-5464 (2009)). In summary, the two functions of CDK7, namely phosphorylation of CAK and CTD, can support key aspects of cell proliferation, cell cycle and transcription.
[0006] Disruption of CTD phosphorylation of RNAP II has been shown to preferentially affect proteins with shorter half-lives, including proteins of the anti-apoptotic BCL-2 family (Konig et al., "The novel cyclin-dependent kinase inhibitor flavopiridol downregulates Bcl-2and induces growth arrest and apoptosis in chronic B-cell leukemia lines." Blood, 1, 4307-4312 (1997); Gojo et al., "The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1." Clin. Cancer Res., 8, 3527-3538 (2002)). Cancer cells have been shown to have the ability to circumvent progenitor cell death signals by upregulating BCL-2 family members (Llambi et al., "Apoptosis and oncogenesis: give and take in the BCL-2 family." Curr. Opin. Genet. Dev., 21, 12-20 (2011)). Therefore, inhibition of human CDK7 kinase activity may lead to antiproliferative activity, and pharmacological inhibition is considered useful for treating proliferative diseases, including cancer.Flavopiridol, a non-selective pan-CDK inhibitor targeting CTD kinase, has been shown to be effective in treating chronic lymphocytic leukemia (CLL), but has poor toxicity properties (Lin et al., "Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease." J. Clin. Oncol., 27, 6012-6018 (2009); Christian et al., "Flavopiridol in chronic lymphocytic leukemia: a concise review." Clin. Lymphoma Myeloma, 9 Suppl. 3, S179-S185 (2009)). There is still a need to treat CLL and other cancers with CDK inhibitors. Summary of the invention
[0007] In one aspect, the present disclosure provides compounds of formula (I):
[0008]
[0009] And pharmaceutically acceptable salts, solvates, hydrates, polymorphs, cocrystals, tautomers, stereoisomers, isotope-labeled derivatives or prodrugs thereof, wherein R 1 ,m,R 2 ,n,Ring A,L,R 3 , Ring B, R 4 , R 5a , R 5b , R 6 , R 7 , R 8 , R 9 , R 10 ,P,RingD,R 11and q are as defined herein. The compounds of the present disclosure can inhibit the activity of kinases. In certain embodiments, the kinase is a cyclin-dependent kinase (CDK) (e.g., CDK7). The compounds of the present disclosure can be used to inhibit kinase activity, inhibit cell growth and / or induce apoptosis. In certain embodiments, the cell (e.g., a cell affected by or contacted with the compound) is a malignant cell or a precancerous cell. In certain embodiments, the cell is in vivo or in vitro. Kinases are associated with a range of diseases in subjects (e.g., proliferative diseases, cystic fibrosis). The compounds of the present disclosure can also be used to treat and / or prevent diseases in subjects in need thereof.
[0010] The compounds disclosed herein can selectively inhibit the activity of a certain CDK (e.g., CDK7) relative to other kinases (e.g., kinases different from CDK, kinases different from CDK7). In certain embodiments, the compounds disclosed herein can selectively inhibit the activity of CDK7 relative to CDK2, CDK9, and / or CDK12. The compounds disclosed herein are more advantageous in treating and / or preventing diseases of subjects in need thereof relative to non-selective or less selective kinase inhibitors. The compounds disclosed herein can selectively inhibit the activity of a certain CDK (e.g., CDK7) relative to other kinases (e.g., kinases different from CDK, kinases different from CDK7) relative to other compounds (e.g., non-selective kinase inhibitors, less selective kinase inhibitors). Compared to other compounds, the compounds disclosed herein may be more powerful, more efficient, and / or less toxic when used to treat and / or prevent diseases of subjects in need thereof, and / or can reduce the frequency of side effects, reduce the severity of side effects, increase the compliance of subjects, and / or reduce drug resistance. In addition, compared with other compounds, the compounds of the present disclosure may be more soluble, more permeable, more micro-stable and / or more bioavailable, and / or may show improved pharmacokinetic properties. The compounds of the present disclosure include a carbocyclic group or a heterocyclic group as ring D. Without wishing to be bound by any particular theory, ring D may contribute to the compounds of the present disclosure having one or more of the above advantages compared to certain other compounds. In addition, certain compounds of the present disclosure may be able to covalently modify the cysteine residue Cys312 of CDK7. Compared to other CDKs and certain other kinases, the Cys312 of CDK7 is unique. Without wishing to be bound by any particular theory, the ability of certain compounds to covalently modify the Cys312 of CDK7 may contribute to the compounds having one or more of the above advantages compared to certain other compounds.
[0011] Exemplary compounds of the present disclosure include:
[0012]
[0013] And pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotope-labeled derivatives and prodrugs thereof.
[0014] In another aspect, the present disclosure provides a pharmaceutical composition comprising a compound of the present disclosure and an optional pharmaceutically acceptable excipient. In certain embodiments, the pharmaceutical composition comprises an effective amount of the compound. In certain embodiments, the pharmaceutical composition comprises an additional agent.
[0015] In another aspect, the present disclosure provides a kit comprising a compound or pharmaceutical composition of the present disclosure; and instructions for use of the compound or pharmaceutical composition. In certain embodiments, the instructions include prescription information.
[0016] In another aspect, the present disclosure provides a method of treating a disease in a subject in need thereof, the method comprising administering to the subject in need thereof an effective amount of a compound or pharmaceutical composition of the present disclosure.
[0017] In another aspect, the present disclosure provides a method for preventing a disease in a subject in need thereof, the method comprising administering to the subject in need thereof an effective amount of a compound or pharmaceutical composition of the present disclosure.
[0018] In certain embodiments, the disease (e.g., a disease treated and / or prevented by the methods of the present disclosure) is a proliferative disease (e.g., cancer, benign neoplasms, diseases associated with angiogenesis, inflammatory diseases, autoinflammatory diseases, autoimmune diseases).
[0019] On the other hand, the present disclosure provides a method for inhibiting kinase activity in a subject, a biological sample, a tissue or a cell, the method comprising administering an effective amount of a compound or pharmaceutical composition of the present disclosure to the subject, or contacting a biological sample, a tissue or a cell with an effective amount of a compound or pharmaceutical composition of the present disclosure. In certain embodiments, the kinase (e.g., a kinase whose activity is inhibited by the compound and pharmaceutical composition) is a CDK (e.g., CDK7).
[0020] In another aspect, the present disclosure provides a method of inhibiting cell growth, the method comprising contacting the cell with an effective amount of a compound or pharmaceutical composition of the present disclosure.
[0021] In another aspect, the present disclosure provides a method of inducing apoptosis in a cell, the method comprising contacting the cell with an effective amount of a compound or pharmaceutical composition of the present disclosure.
[0022] In another aspect, the present disclosure provides a method for down-regulating MYC or MCL-1 transcription in a subject, biological sample, tissue or cell, the method comprising administering an effective amount of a compound or pharmaceutical composition of the present disclosure to the subject, or contacting the biological sample, tissue or cell with an effective amount of a compound or pharmaceutical composition of the present disclosure.
[0023] In certain embodiments, the cell is an abnormally proliferating cell (eg, a malignant cell or a precancerous cell).
[0024] In another aspect, the disclosure provides uses of the compounds and pharmaceutical compositions of the disclosure (eg, uses in the methods of the disclosure).
[0025] The details of one or more embodiments of the present disclosure are set forth herein. Other features, objects, and advantages of the present disclosure will be apparent from the detailed description, examples, drawings, and claims.
[0026] definition
[0027] The definitions of specific functional groups and chemical terms will be described in more detail below. Chemical elements are identified according to the periodic table of the inside cover of the 75th edition of the CAS version of the Handbook of Chemistry and Physics, and specific functional groups are generally defined as described therein. In addition, the general principles of organic chemistry, as well as specific functional moieties and reactivity are described in the following: Thomas Sorrell, Organic Chemistry, University Science Books, Sausalito, 1999; Smith and March, March's Advanced Organic Chemistry, 5th Edition, John Wiley & Sons, Inc., New York, 2001; Larock, Comprehensive Organic Transformations, VCH Publishers, Inc., New York, 1989; and Carruthers, Some Modern Methods of Organic Synthesis, 3rd Edition, Cambridge University Press, Cambridge, 1987. The present disclosure is not intended to be limited in any way to the exemplary listed substituents described herein.
[0028] The compounds of the present disclosure may contain one or more asymmetric centers and may therefore exist in various isomeric forms, such as enantiomers and / or diastereomers. For example, the compounds of the present disclosure may be in the form of a single enantiomer, diastereomer or geometric isomer, or may be in the form of a mixture of stereoisomers, including racemic mixtures and mixtures enriched in one or more stereoisomers. Isomers may be separated from the mixture by methods known to those skilled in the art, including chiral high performance liquid chromatography (HPLC) and the formation and crystallization of chiral salts; or preferred isomers may be prepared by asymmetric synthesis. For example, see Jacques et al., Enantiomers, Racemates and Resolutions (Wiley Interscience, New York, 1981); Wilen et al., Tetrahedron 33:2725 (1977); Eliel, Stereochemistry of Carbon Compounds (McGraw-Hill, NY, 196; and Wilen, Tables of Resolving Agents and Optical Resolutions, p. 268, EL Eliel, ed., Univ. of Notre Dame Press, Notre Dame, IN 197. The present disclosure also includes the compounds of the present disclosure in the form of a single isomer substantially free of other isomers or in the form of a mixture of various isomers.
[0029] When a range of values is listed, it is intended to include every value and subrange within that range. For example, “C 1-6 " is intended to include C1, C2, C3, C4, C5, C6, C 1-6 , C 1-5 , C 1-4 , C 1-3 , C 1-2 , C 2-6 , C 2-5 , C 2-4 , C 2-3 , C 3-6 , C 3-5 , C 3-4 , C 4-6 , C 4-5 and C 5-6 .
[0030] The term "aliphatic" includes saturated and unsaturated straight chain (i.e., unbranched), branched, acyclic, cyclic or polycyclic aliphatic hydrocarbons, which are optionally substituted with one or more functional groups. As understood by those of ordinary skill in the art, "aliphatic" is intended to include alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl and cycloalkynyl moieties in this article. Therefore, the term "alkyl" includes straight chain, branched and cyclic alkyl. Similar conventions apply to other general terms, such as "alkenyl", "alkynyl" and the like. In addition, the terms "alkyl", "alkenyl", "alkynyl" and the like include both substituted and unsubstituted groups.
[0031] In certain embodiments, the alkyl, alkenyl and alkynyl used in the present disclosure contain 1-20 aliphatic carbon atoms. In certain embodiments, the alkyl, alkenyl and alkynyl used in the present disclosure contain 1-10 aliphatic carbon atoms. In certain embodiments, the alkyl, alkenyl and alkynyl used in the present disclosure contain 1-8 aliphatic carbon atoms. In certain embodiments, the alkyl, alkenyl and alkynyl used in the present disclosure contain 1-6 aliphatic carbon atoms. In certain embodiments, the alkyl, alkenyl and alkynyl used in the present disclosure contain 1-4 aliphatic carbon atoms. Thus, exemplary aliphatic groups include, for example, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, -CH2-cyclopropyl, vinyl, allyl, n-butyl, sec-butyl, isobutyl, tert-butyl, cyclobutyl, -CH2-cyclobutyl, n-pentyl, sec-pentyl, isopentyl, tert-pentyl, cyclopentyl, -CH2-cyclopentyl, n-hexyl, sec-hexyl, cyclohexyl, -CH2-cyclohexyl moiety, etc., which may be further substituted with one or more substituents. Alkenyl includes, for example, vinyl, propenyl, butenyl, 1-methyl-2-butene-1-yl, etc. Representative alkynyl includes ethynyl, 2-propynyl (propargyl), 1-propynyl, etc.
[0032] The term "alkyl" refers to a straight-chain or branched saturated hydrocarbon group having 1 to 10 carbon atoms ("C 1-10 In some embodiments, an alkyl group has 1 to 9 carbon atoms (“C 1-9 In some embodiments, an alkyl group has 1 to 8 carbon atoms (“C 1-8 In some embodiments, an alkyl group has 1 to 7 carbon atoms (“C 1-7 In some embodiments, an alkyl group has 1 to 6 carbon atoms (“C 1-6 In some embodiments, an alkyl group has 1 to 5 carbon atoms (“C 1-5 In some embodiments, an alkyl group has 1 to 4 carbon atoms (“C 1-4 In some embodiments, an alkyl group has 1 to 3 carbon atoms (“C 1-3 In some embodiments, an alkyl group has 1 to 2 carbon atoms (“C1-2 In some embodiments, an alkyl group has 1 carbon atom (“C1 alkyl”). In some embodiments, an alkyl group has 2 to 6 carbon atoms (“C 2-6 C 1-6 Examples of alkyl groups include methyl (C1), ethyl (C2), propyl (C3) (e.g., n-propyl, isopropyl), butyl (C4) (e.g., n-butyl, tert-butyl, sec-butyl, isobutyl), pentyl (C5) (e.g., n-pentyl, 3-pentyl, pentyl, neopentyl, 3-methyl-2-butyl, tert-pentyl) and hexyl (C6) (e.g., n-hexyl). Other examples of alkyl groups include n-heptyl (C7), n-octyl (C8), etc. Unless otherwise specified, each example of alkyl is independently unsubstituted ("unsubstituted alkyl") or substituted ("substituted alkyl") with one or more substituents (e.g., halogen, such as F). In certain embodiments, alkyl is unsubstituted C 1-10 Alkyl (such as unsubstituted C 1-6 In certain embodiments, the alkyl group is an unsubstituted C 1-10 Alkyl (such as unsubstituted C 1-6 Alkyl, such as -CF3).
[0033] "Alkenyl" refers to a straight or branched chain hydrocarbon radical having 2 to 20 carbon atoms, one or more carbon-carbon double bonds and no triple bonds ("C 2-20 In some embodiments, an alkenyl group has 2 to 10 carbon atoms (“C 2-10 In some embodiments, an alkenyl group has 2 to 9 carbon atoms (“C 2-9 In some embodiments, an alkenyl group has 2 to 8 carbon atoms (“C 2-8 In some embodiments, an alkenyl group has 2 to 7 carbon atoms (“C 2-7 In some embodiments, an alkenyl group has 2 to 6 carbon atoms (“C 2-6 In some embodiments, an alkenyl group has 2 to 5 carbon atoms (“C 2-5 In some embodiments, an alkenyl group has 2 to 4 carbon atoms (“C 2-4 In some embodiments, an alkenyl group has 2 to 3 carbon atoms (“C 2-3 In some embodiments, an alkenyl group has 2 carbon atoms ("C2 alkenyl"). The one or more carbon-carbon double bonds can be located in the middle (such as in 2-butenyl) or at the terminal ends (such as in 1-butenyl). 2-4 Examples of alkenyl groups include ethenyl (C2), 1-propenyl (C3), 2-propenyl (C3), 1-butenyl (C4), 2-butenyl (C4), butadienyl (C4), and the like.2-6 Examples of the alkenyl group include the aforementioned C 2-4 In some embodiments, alkenyl is an unsubstituted C 1-1, 1-1, 1-1, 1-1, 1-1, 1-1, 1-1, 1-1, 1-1, 1-1, 1-1, 1-1, 1-1, 1-1, 1-1, 1-1, 1-1, 1-1, 1-1, 1-1, 1-1, 1-1, 1-1, 1-1, 1-1, 1-1, 1-1, 1-1, 1-1, 1-1, 1-1, 1-1, 1-1, 1-1, 1-1, 1-1, 1-1, 1-1, 1-1, 1-1 2-10 In certain embodiments, alkenyl is a substituted C 2-10 In alkenyl, a C=C double bond whose stereochemistry is not specified (e.g., -CH=CHCH3 or ) can be an (E)- or (Z)-double bond.
[0034] "Alkynyl" refers to a straight or branched chain hydrocarbon radical having 2 to 20 carbon atoms, one or more carbon-carbon triple bonds, and optionally one or more double bonds ("C 2-20 In some embodiments, an alkynyl group has 2 to 10 carbon atoms (“C 2-10 In some embodiments, an alkynyl group has 2 to 9 carbon atoms (“C 2-9 In some embodiments, an alkynyl group has 2 to 8 carbon atoms (“C 2-8 In some embodiments, an alkynyl group has 2 to 7 carbon atoms (“C 2-7 In some embodiments, an alkynyl group has 2 to 6 carbon atoms (“C 2-6 In some embodiments, an alkynyl group has 2 to 5 carbon atoms (“C 2-5 In some embodiments, an alkynyl group has 2 to 4 carbon atoms (“C 2-4 In some embodiments, an alkynyl group has 2 to 3 carbon atoms (“C 2-3 In some embodiments, an alkynyl group has 2 carbon atoms ("C2 alkynyl"). The one or more carbon-carbon triple bonds can be located in the middle (such as in 2-butynyl) or at the terminal (such as in 1-butynyl). 2-4 Examples of alkynyl groups include ethynyl (C2), 1-propynyl (C3), 2-propynyl (C3), 1-butynyl (C4), 2-butynyl (C4), and the like. 2-6 Examples of the alkenyl group include the aforementioned C 2-4In some embodiments, alkynyl is an unsubstituted C alkynyl, pentynyl (C5), hexynyl (C6), and the like. Other examples of alkynyl include heptynyl (C7), octynyl (C8), and the like. Unless otherwise specified, each instance of an alkynyl group is independently optionally substituted, i.e., unsubstituted (an “unsubstituted alkynyl group”) or substituted (a “substituted alkynyl group”) with one or more substituents. In certain embodiments, an alkynyl group is an unsubstituted C 2-10 In certain embodiments, the alkynyl group is a substituted C 2-10 Alkynyl.
[0035] "Carbocyclyl" or "carbocycle" refers to a non-aromatic cyclic hydrocarbon radical having 3-10 ring carbon atoms ("C 3-10 In some embodiments, the carbocyclyl group has 3 to 8 ring carbon atoms ("C 3-8 In some embodiments, a carbocyclyl group has 3 to 6 ring carbon atoms (“C 3-6 In some embodiments, a carbocyclyl group has 3 to 6 ring carbon atoms (“C 3-6 In some embodiments, a carbocyclyl group has 5 to 10 ring carbon atoms (“C 5-10 "Carbocyclyl"). Exemplary C 3-6 Carbocyclic groups include, but are not limited to, cyclopropyl (C3), cyclopropenyl (C3), cyclobutyl (C4), cyclobutenyl (C4), cyclopentyl (C5), cyclopentenyl (C5), cyclohexyl (C6), cyclohexenyl (C6), cyclohexadienyl (C6), and the like. 3-8 Carbocyclic groups include but are not limited to the above C 3-6 Carbocyclic groups and cycloheptyl (C7), cycloheptenyl (C7), cycloheptadienyl (C7), cycloheptatrienyl (C7), cyclooctyl (C8), cyclooctenyl (C8), bicyclo [2.2.1] heptyl (C7), bicyclo [2.2.2] octyl (C8), etc. Exemplary C 3-10 Carbocyclic groups include but are not limited to the above C 3-8 Carbocyclic groups and cyclononyl (C9), cyclononenyl (C9), cyclodecyl (C 10 ), cyclodecenyl (C 10 ), octahydro-1H-indenyl (C9), decahydronaphthyl (C 10 ), spiro[4.5]decyl (C 10) and the like. As shown in the foregoing examples, in certain embodiments, the carbocyclyl is either a monocyclic ring ("monocyclic carbocyclyl"), or comprises a fused, bridged or spirocyclic ring system, such as a bicyclic ring system ("bicyclic carbocyclyl"), and may be saturated or may be partially unsaturated. "Carbocyclyl" also includes a ring system in which the carbocyclic ring as defined above is fused to one or more aryl or heteroaryl groups, wherein the point of attachment is on the carbocyclic ring, and in this case, the number of carbons continues to represent the number of carbons in the carbocyclic ring system. Unless otherwise specified, each example of a carbocyclyl is independently optionally substituted, i.e., unsubstituted ("unsubstituted carbocyclyl") or substituted ("substituted carbocyclyl") with one or more substituents. In certain embodiments, a carbocyclyl is an unsubstituted C 3-10 In certain embodiments, a carbocyclyl group is a substituted C 3-10 Carbocyclic group.
[0036] In some embodiments, a "carbocyclyl" is a monocyclic saturated carbocyclyl ("C 3-10 In some embodiments, a cycloalkyl group has 3 to 8 ring carbon atoms (“C 3-8 In some embodiments, a cycloalkyl group has 3 to 6 ring carbon atoms (“C 3-6 In some embodiments, a cycloalkyl group has 5 to 6 ring carbon atoms (“C 5-6 In some embodiments, a cycloalkyl group has 5 to 10 ring carbon atoms (“C 5-10 (cycloalkyl) 5-6 Examples of cycloalkyl groups include cyclopentyl (C5) and cyclohexyl (C6). 3-6 Examples of the cycloalkyl group include the aforementioned C 5-6 Cycloalkyl and cyclopropyl (C3), cyclobutyl (C4), etc. 3-8 Examples of the cycloalkyl group include the aforementioned C 3-6 Cycloalkyl and cycloheptyl (C7), cyclooctyl (C8), etc. Unless otherwise specified, each instance of cycloalkyl is independently unsubstituted ("unsubstituted cycloalkyl") or substituted ("substituted cycloalkyl") with one or more substituents. In certain embodiments, cycloalkyl is unsubstituted C 3-10 In certain embodiments, the cycloalkyl group is a substituted C 3-10 Cycloalkyl.
[0037] "Heterocyclyl" or "heterocycle" refers to a radical of a 3-10 membered non-aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, sulfur, boron, phosphorus and silicon ("3-10 membered heterocyclyl"). In heterocyclyls containing one or more nitrogen atoms, the point of attachment can be a carbon atom or a nitrogen atom, as long as the valence state permits. The heterocyclyl is either a monocyclic ring ("monocyclic carbocyclyl"), or a fused, bridged or spirocyclic ring system, such as a bicyclic ring system ("bicyclic heterocyclyl"), and can be saturated or can be partially unsaturated. Heterocyclyl bicyclic ring systems can include one or more heteroatoms in one or both rings. "Heterocyclyl" also includes a ring system in which a heterocycle as defined above is fused to one or more carbocyclyls, wherein the point of attachment is on the carbocyclyl or heterocycle, or a ring system in which a heterocycle as defined above is fused to one or more aryl or heteroaryl groups, wherein the point of attachment is on the heterocycle, and in this case, the number of ring members continues to represent the number of ring members in the heterocyclic ring system. Unless otherwise specified, each instance of a heterocyclyl is independently optionally substituted, i.e., unsubstituted ("unsubstituted heterocyclyl") or substituted ("substituted heterocyclyl") with one or more substituents. In certain embodiments, a heterocyclyl is an unsubstituted 3-10 membered heterocyclyl. In certain embodiments, a heterocyclyl is a substituted 3-10 membered heterocyclyl.
[0038] In some embodiments, heterocyclyl is a 5-10 membered non-aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, sulfur, boron, phosphorus and silicon (“5-10 membered heterocyclyl”). In some embodiments, heterocyclyl is a 5-8 membered non-aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen and sulfur (“5-8 membered heterocyclyl”). In some embodiments, heterocyclyl is a 5-6 membered non-aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen and sulfur (“5-6 membered heterocyclyl”). In some embodiments, 5-6 membered heterocyclyl has 1-3 ring heteroatoms selected from nitrogen, oxygen and sulfur.
[0039] In some embodiments, the 5-6 membered heterocyclyl has 1-2 ring heteroatoms selected from nitrogen, oxygen, and sulfur.
[0040] In some embodiments, the 5-6 membered heterocyclyl has one ring heteroatom selected from nitrogen, oxygen, and sulfur.
[0041] Exemplary 3-membered heterocyclic groups containing one heteroatom include, but are not limited to, aziridine, oxirane, and thiirane. Exemplary 4-membered heterocyclic groups containing one heteroatom include, but are not limited to, azetidinyl, oxirane, and thiirane. Exemplary 5-membered heterocyclic groups containing one heteroatom include, but are not limited to, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothienyl, dihydrothienyl, pyrrolidinyl, dihydropyrrolyl, and pyrrolyl-2,5-dione. Exemplary 5-membered heterocyclic groups containing two heteroatoms include, but are not limited to, dioxolanyl, oxathiolanyl, dithiolanyl, and oxaziridine-2-one. Exemplary 5-membered heterocyclic groups containing three heteroatoms include, but are not limited to, triazacyclopentyl, oxadiazacyclopentyl, and thiazolinyl. Exemplary 6-membered heterocyclic groups containing one heteroatom include, but are not limited to, piperidinyl, tetrahydropyranyl, dihydropyridinyl, and thiacyclohexyl. Exemplary 6-membered heterocyclic groups containing two heteroatoms include, but are not limited to, piperazinyl, morpholinyl, dithiohexyl, and dioxanyl. Exemplary 6-membered heterocyclic groups containing two heteroatoms include, but are not limited to, triazine. Exemplary 7-membered heterocyclic groups containing one heteroatom include, but are not limited to, azepanyl, oxepinyl, and thioheptanyl. Exemplary 8-membered heterocyclic groups containing one heteroatom include, but are not limited to, azocyclooctanyl, oxepinyl, and thiocyclooctanyl. Exemplary 5-membered heterocyclic groups fused to a C6 aromatic ring (also referred to herein as 5,6-bicyclic heterocyclic rings) include, but are not limited to, indolinyl, isoindolyl, dihydrobenzofuranyl, dihydrobenzothienyl, benzoxazolinone, and the like. Exemplary 6-membered heterocyclic groups fused to an aromatic ring (also referred to herein as 6,6-bicyclic heterocyclic rings) include, but are not limited to, tetrahydroquinolinyl, tetrahydroisoquinolinyl, and the like.
[0042] "Aryl" refers to a monocyclic or polycyclic (e.g., bicyclic or tricyclic) 4n+2 aromatic ring system (e.g., having 6, 10, or 14 π electrons shared in the cyclic array) having 6-14 ring carbon atoms and zero heteroatoms ("C 6-14 In some embodiments, an aryl group has six ring carbon atoms (a "C6 aryl"; e.g., a phenyl group). In some embodiments, an aryl group has ten ring carbon atoms (a "C 10 In some embodiments, an aryl group has fourteen ring carbon atoms ("C 14 "Aryl"; e.g., anthracenyl). "Aryl" also includes ring systems in which an aryl ring as defined above is fused to one or more carbocyclic or heterocyclic groups, wherein the radical or point of attachment is on the aromatic ring, and in such cases, the number of carbon atoms continues to refer to the number of carbon atoms in the aromatic ring system. Unless otherwise specified, each instance of aryl is independently optionally substituted, i.e., unsubstituted ("unsubstituted aryl") or substituted ("substituted aryl") with one or more substituents. In certain embodiments, aryl is unsubstituted C6-14 In certain embodiments, aryl is substituted C 6-14 Aryl.
[0043] "Aralkyl" refers to an optionally substituted alkyl group substituted with an optionally substituted aryl group. In certain embodiments, the aralkyl group is an optionally substituted benzyl group. In certain embodiments, the aralkyl group is a benzyl group. In certain embodiments, the aralkyl group is an optionally substituted phenethyl group. In certain embodiments, the aralkyl group is a phenethyl group.
[0044] "Heteroaryl" refers to a radical of a 5-10 membered monocyclic or bicyclic 4n+2 aromatic ring system (e.g., having 6 or 10 π electrons shared in a cyclic array) having ring carbon atoms provided in the aromatic ring system and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen and sulfur ("5-10 membered heteroaryl"). In heteroaryl groups containing one or more nitrogen atoms, the point of attachment can be a carbon atom or a nitrogen atom, as long as the valence state permits. Heteroaryl bicyclic ring systems may include one or more heteroatoms in one or both rings. "Heteroaryl" also includes ring systems in which a heteroaryl ring as defined above is fused to one or more carbocyclic or heterocyclic groups, wherein the point of attachment is on the heteroaryl group, and in this case, the number of ring atoms continues to represent the number of ring atoms in the heteroaromatic ring system. "Heteroaryl" also includes ring systems in which a heteroaryl ring as defined above is fused to one or more aryl groups, wherein the point of attachment is on the aryl or heteroaryl group, and in this case the number of ring atoms refers to the number of ring atoms in the fused (aryl / heteroaryl) ring system. | The point of attachment for bicyclic heteroaryls in which one ring contains no heteroatoms (e.g., indolyl, quinolyl, carbazolyl, etc.) can be on either ring, i.e., either on the ring carrying the heteroatom (e.g., 2-indolyl) or on the ring containing no heteroatoms (e.g., 5-indolyl).
[0045] In some embodiments, heteroaryl is a 5-10 membered aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen and sulfur ("5-10 membered heteroaryl"). In some embodiments, heteroaryl is a 5-8 membered aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen and sulfur ("5-8 membered heteroaryl"). In some embodiments, heteroaryl is a 5-6 membered aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen and sulfur ("5-6 membered heteroaryl"). In some embodiments, 5-6 membered heteroaryl has 1-3 ring heteroatoms selected from nitrogen, oxygen and sulfur. In some embodiments, 5-6 membered heteroaryl has 1-2 ring heteroatoms selected from nitrogen, oxygen and sulfur. In some embodiments, the 5-6 membered heteroaryl has 1 ring heteroatom selected from nitrogen, oxygen and sulfur. Unless otherwise specified, each instance of heteroaryl is independently optionally substituted, i.e., unsubstituted ("unsubstituted heteroaryl") or substituted ("substituted heteroaryl") with one or more substituents. In certain embodiments, heteroaryl is an unsubstituted 5-14 membered heteroaryl. In certain embodiments, heteroaryl is a substituted 5-14 membered heteroaryl.
[0046] Exemplary 5-membered heteroaryl groups containing one heteroatom include, but are not limited to, pyrrolyl, furanyl, and thienyl. Exemplary 5-membered heteroaryl groups containing two heteroatoms include, but are not limited to, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, and isothiazolyl. Exemplary 5-membered heteroaryl groups containing three heteroatoms include, but are not limited to, triazolyl, oxadiazolyl, and thiadiazolyl. Exemplary 5-membered heteroaryl groups containing four heteroatoms include, but are not limited to, tetrazolyl. Exemplary 6-membered heteroaryl groups containing one heteroatom include, but are not limited to, pyridinyl. Exemplary 6-membered heteroaryl groups containing two heteroatoms include, but are not limited to, pyridazinyl, pyrimidinyl, and pyrazinyl. Exemplary 6-membered heteroaryl groups containing three or four heteroatoms include, but are not limited to, triazinyl and tetrazinyl, respectively. Exemplary 7-membered heteroaryl groups containing one heteroatom include, but are not limited to, azacycloheptatrienyl, oxacycloheptatrienyl, and thiacycloheptatrienyl. Exemplary 5,6-bicyclic heteroaryl groups include, but are not limited to, indolyl, isoindolyl, indazolyl, benzotriazolyl, benzothienyl, isobenzothienyl, benzofuranyl, benzisofuranyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzoxadiazolyl, benzothiazolyl, benzisothiazolyl, benzothiadiazolyl, indolizinyl, and purinyl. Exemplary 6,6-bicyclic heteroaryl groups include, but are not limited to, naphthyridinyl, pteridinyl, quinolyl, isoquinolyl, cinnolinyl, quinoxalinyl, phthalazinyl, and quinazolinyl.
[0047] "Heteroaralkyl" is a subset of alkyl and heteroaryl, and refers to an optionally substituted alkyl group substituted by an optionally substituted heteroaryl group.
[0048] "Unsaturated" or "partially unsaturated" refers to a group that contains at least one double or triple bond. "Partially unsaturated" ring systems are further intended to include rings with multiple sites of unsaturation, but are not intended to include aromatic groups (e.g., aryl or heteroaryl). Likewise, "saturated" refers to a group that does not contain double or triple bonds, i.e., contains all single bonds.
[0049] Alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl and heteroaryl groups as divalent linking groups are further indicated using the prefix "ene", for example, alkylene, alkenylene, alkynylene, carbocyclylene, heterocyclylene, arylene and heteroarylene.
[0050] Unless expressly stated otherwise, the atoms, moieties or groups described herein may be unsubstituted or substituted as far as valence permits. The term "optionally substituted" means substituted or unsubstituted.
[0051] The group may be optionally substituted unless otherwise expressly specified. The term "optionally substituted" refers to substituted or unsubstituted. In certain embodiments, alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl and heteroaryl are optionally substituted (e.g., "substituted" or "unsubstituted" alkyl, "substituted" or "unsubstituted" alkenyl, "substituted" or "unsubstituted" alkynyl, "substituted" or "unsubstituted" carbocyclyl, "substituted" or "unsubstituted" heterocyclyl, "substituted" or "unsubstituted" aryl, or "substituted" or "unsubstituted" heteroaryl). In general, the term "substituted", whether or not there is the term "optionally" in front, refers to at least one hydrogen present on a group (e.g., carbon or nitrogen atom) being replaced by a substituent that is allowed, such as a substituent that produces a stable compound after substitution, such as a compound that does not spontaneously undergo transformation (e.g., rearrangement, cyclization, elimination or other reactions). Unless otherwise stated, a "substituted" group has a substituent at one or more substitutable positions of the group, and when more than one position in any given structure is substituted, the substituent may be the same or different at each position. The term "substituted" is intended to include substitution with all permissible substituents of organic compounds, any substituent described herein that results in the formation of a stable compound. The present disclosure contemplates any and all such combinations to obtain a stable compound. For the purposes of the present disclosure, heteroatoms such as nitrogen may have hydrogen substituents and / or any suitable substituents described herein that satisfy the valence of the heteroatoms and result in the formation of a stable moiety. In certain embodiments, the substituent is a carbon atom substituent. In certain embodiments, the substituent is a nitrogen atom substituent. In certain embodiments, the substituent is an oxygen atom substituent. In certain embodiments, the substituent is a sulfur atom substituent.
[0052] Exemplary carbon atom substituents include halogen, -CN, -NO2, -N3, -SO2H, -SO3H, -OH, -OR aa 、-ON(R bb )2、-N(R bb )2、-N(R bb )3 + X - 、-N(OR cc )R bb , -SH, -SR aa 、-SSR cc 、-C(=O)R aa 、-CO2H、-CHO、-C(OR cc 2. -CO2R aa 、-OC(=O)R aa 、-OCO2R aa 、-C(=O)N(R bb )2, -OC(=O)N(R bb )2.-NR bb C(=O)R aa 、-NR bb CO2R aa 、-NR bb C(=O)N(R bb )2, -C(=NR bb )R aa 、-C(=NR bb )OR aa 、-OC(=NR bb )R aa 、-OC(=NR bb )OR aa 、-C(=NR bb )N(R bb )2, -OC(=NR bb )N(R bb )2.-NR bb C(=NR bb )N(R bb )2, -C(=O)NR bb S02R aa 、-NR bb S02R aa 、-SO2N(R bb 2. -SO2R aa 、-SO2OR aa 、-OSO2R aa 、-S(=O)R aa 、-OS(=O)R aa 、-Si(R aa)3.-OSi(R aa )3. -C(=S)N(R bb )2, -C(=O)SR aa 、-C(=S)SR aa 、-SC(=S)SR aa 、-SC(=O)SR aa 、-OC(=O)SR aa 、-SC(=O)OR aa 、-SC(=O)R aa 、-P(=O)2R aa 、-OP(=O)2R aa ,-P(=O)(R aa )2.-OP(=O)(R aa )2.-OP(=O)(OR cc )2、-P(=O)2N(R bb )2、-OP(=O)2N(R bb )2, -P(=O)(NR bb )2, -OP(=O)(NR bb )2.-NR bb P(=O)(OR cc )2.-NR bb P(=O)(NR bb )2. -P(R cc )2. -P(R cc )3.-OP(R cc )2.-OP(R cc )3. -B(R aa )2、-B(OR cc )2. -BR aa (OR cc ), C 1-10 Alkyl, C 1-10 Perhaloalkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-10 Carbocyclic group, 3-14 membered heterocyclic group, C 6-14 Aryl and 5-14 membered heteroaryl, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl and heteroaryl is independently substituted by 0, 1, 2, 3, 4 or 5 R dd or two geminal hydrogen atoms on a carbon atom are replaced by groups =O, =S, =NN(R bb )2, =NNR bb C(=O)R aa , =NNR bb C(=O)OR aa , =NNR bb S(=O)2Raa , =NR bb or = NOR cc replace;
[0053] R aa Each instance of is independently selected from C 1-10 Alkyl, C 1-10 Perhaloalkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-10 Carbocyclic group, 3-14 membered heterocyclic group, C 6-14 Aryl and 5-14 membered heteroaryl, or two R aa The groups are connected to form a 3-14 membered heterocyclic or 5-14 membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl and heteroaryl group is independently substituted by 0, 1, 2, 3, 4 or 5 R dd group substitution;
[0054] R bb Each instance of is independently selected from hydrogen, -OH, -OR aa 、-N(R cc )2, -CN, -C(=O)R aa 、-C(=O)N(R cc 2. -CO2R aa 、-SO2R aa 、-C(=NR cc )OR aa 、-C(=NR cc )N(R cc )2、-SO2N(R cc 2. -SO2R cc 、-SO2OR cc 、-SOR aa 、-C(=S)N(R cc )2, -C(=O)SR cc 、-C(=S)SR cc 、-P(=O)2R aa 、-P(=O)(R aa )2、-P(=O)2N(R cc )2, -P(=O)(NR cc 2. C 1-10 Alkyl, C 1-10 Perhaloalkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-10 Carbocyclic group, 3-14 membered heterocyclic group, C 6-14 Aryl and 5-14 membered heteroaryl, or two R bbThe groups are connected to form a 3-14 membered heterocyclic or 5-14 membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl and heteroaryl group is independently substituted by 0, 1, 2, 3, 4 or 5 R dd Group substitution;
[0055] R cc Each instance of is independently selected from C 1-10 Alkyl, C 1-10 Perhaloalkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-10 Carbocyclic group, 3-14 membered heterocyclic group, C 6-14 aryl, and 5-14 membered heteroaryl, or two R cc The groups are connected to form a 3-14 membered heterocyclic or 5-14 membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl and heteroaryl group is independently substituted by 0, 1, 2, 3, 4 or 5 R dd Group substitution;
[0056] R dd Each instance of is independently selected from halogen, -CN, -NO2, -N3, -SO2H, -SO3H, -OH, -OR ee 、-ON(R ff )2、-N(R ff )2、-N(R ff )3 + X - 、-N(OR ee )R ff , -SH, -SR ee 、-SSR ee 、-C(=O)R ee 、-CO2H、-CO2R ee 、-OC(=O)R ee 、-OCO2R ee 、-C(=O)N(R ff )2, -OC(=O)N(R ff )2.-NR ff C(=O)R ee 、-NR ff CO2R ee 、-NR ff C(=O)N(R ff )2, -C(=NR ff )OR ee 、-OC(=NR ff )R ee 、-OC(=NR ff )OR ee 、-C(=NR ff)N(R ff )2, -OC(=NR ff )N(R ff )2.-NR ff C(=NR ff )N(R ff )2.-NR ff S02R ee 、-SO2N(R ff 2. -SO2R ee 、-SO2OR ee 、-OSO2R ee 、-S(=O)R ee 、-Si(R ee )3.-OSi(R ee )3. -C(=S)N(R ff )2, -C(=O)SR ee 、-C(=S)SR ee 、-SC(=S)SR ee 、-P(=O)2R ee 、-P(=O)(R ee )2.-OP(=O)(R ee )2.-OP(=O)(OR ee 2. C 1-6 Alkyl, C 1-6 Perhaloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic group, 3-10 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl and heteroaryl is independently substituted by 0, 1, 2, 3, 4 or 5 R gg group substituted, or two geminal R dd Substituents may be linked to form =O or =S;
[0057] R ee Each instance of is independently selected from C 1-6 Alkyl, C 1-6 Perhaloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic group, C 6-10 aryl, 3-10 membered heterocyclyl and 3-10 membered heteroaryl, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl and heteroaryl is independently substituted by 0, 1, 2, 3, 4 or 5 R gg group substitution;
[0058] R ff Each instance of is independently selected from hydrogen, C1-6 Alkyl, C 1-6 Perhaloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic group, 3-10 membered heterocyclic group, C 6-10 Aryl, 5-10 membered heteroaryl, or two R ff The groups are connected to form a 3-14 membered heterocyclic or 5-14 membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl and heteroaryl group is independently substituted by 0, 1, 2, 3, 4 or 5 R gg Group substitution; and
[0059] R gg Each instance of is independently halogen, -CN, -NO2, -N3, -SO2H, -SO3H, -OH, -OC 1-6 Alkyl, -ON(C 1-6 Alkyl)2, -N(C 1-6 Alkyl)2, -N(C 1-6 Alkyl)3 + X - 、-NH(C 1-6 Alkyl)2 + X - 、-NH2(C 1-6 alkyl) + X - 、-NH3 + X - 、-N(OC 1-6 Alkyl)(C 1-6 Alkyl), -N(OH)(C 1-6 Alkyl), -NH(OH), -SH, -SC 1-6 Alkyl, -SS(C 1-6 alkyl), -C(=O)(C 1-6 alkyl), -CO2H, -CO2(C 1-6 alkyl), -OC(=O)(C 1-6 Alkyl), -OCO2(C 1-6 alkyl), -C(=O)NH2, -C(=O)N(C 1-6 alkyl)2, -OC(=O)NH(C 1-6 alkyl), -NHC(=O)(C 1-6 Alkyl), -N(C 1-6 alkyl)C(=O)(C 1-6 Alkyl), -NHCO2(C 1-6 alkyl), -NHC(=O)N(C 1-6 Alkyl)2, -NHC(=O)NH(C 1-6alkyl), -NHC(=O)NH2, -C(=NH)O(C 1-6 alkyl), -OC(=NH)(C 1-6 alkyl), -OC(=NH)OC 1-6 Alkyl, -C(=NH)N(C 1-6 Alkyl)2, -C(=NH)NH(C 1-6 alkyl), -C(=NH)NH2, -OC(=NH)N(C 1-6 Alkyl)2, -OC(NH)NH(C 1-6 alkyl), -OC(NH)NH2, -NHC(NH)N(C 1-6 Alkyl)2, -NHC(=NH)NH2, -NHSO2(C 1-6 Alkyl), -SO2N(C 1-6 Alkyl)2, -SO2NH(C 1-6 Alkyl), -SO2NH2, -SO2C 1-6 Alkyl, -SO2OC 1-6 Alkyl, -OSO2C 1-6 Alkyl, -SOC 1-6 Alkyl, -Si(C 1-6 Alkyl)3, -OSi(C 1-6 alkyl)3-C(=S)N(C 1-6 alkyl)2, C(=S)NH(C 1-6 alkyl), C(=S)NH2, -C(=O)S(C 1-6 Alkyl), -C(=S)SC 1-6 Alkyl, -SC(=S)SC 1-6 Alkyl, -P(=O)2(C 1-6 alkyl), -P(=O)(C 1-6 Alkyl)2, -OP(=O)(C 1-6 Alkyl)2, -OP(=O)(OC 1-6 Alkyl)2, C 1-6 Alkyl, C 1-6 Perhaloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Carbocyclic group, C 6-10 aryl, 3-10 membered heterocyclyl, 5-10 membered heteroaryl; or two geminal R gg Substituents may be linked to form =O or =S; where X - It is a counter ion.
[0060] "Counter ions" or "anionic counter ions" are negatively charged groups attached to a cationic quaternary amino group to maintain electrical neutrality. Exemplary counter ions include halides (e.g., F- , Cl - Br - ,I - )、NO3 - 、ClO4 - OH - 、H2PO4 - 、HSO4 - , sulfonate ions (e.g., methanesulfonate, trifluoromethanesulfonate, p-toluenesulfonate, benzenesulfonate, 10-camphorsulfonate, naphthalene-2-sulfonate, naphthalene-1-sulfonic acid-5-sulfonate, ethane-1-sulfonic acid-2-sulfonate, etc.) and carboxylate ions (e.g., acetate (acetate), propionate, benzoate, glycerate, lactate, tartrate, glycolate, etc.).
[0061] "Halo" or "halogen" refers to fluorine (fluoro, -F), chlorine (chloro, -Cl), bromine (bromo, -Br), or iodine (iodo, -I).
[0062] "Acyl" refers to a moiety selected from: -C(=O)R aa 、-CHO、-CO2R aa 、-C(=O)N(R bb )2, -C(=NR bb )R aa 、-C(=NR bb )OR aa 、-C(=NR bb )N(R bb )2, -C(=O)NR bb S02R aa 、-C(=S)N(R bb )2, -C(=O)SR aa or -C(=S)SR aa , where R aa and R bb As defined herein.
[0063] The nitrogen atoms may be substituted or unsubstituted, as valence permits, and include primary, secondary, tertiary, and quaternary nitrogen atoms. Exemplary nitrogen atom substituents include hydrogen, -OH, -OR aa 、-N(R cc )2, -CN, -C(=O)R aa 、-C(=O)N(R cc 2. -CO2R aa 、-SO2R aa 、-C(=NR bb )R aa 、-C(=NR cc )OR aa 、-C(=NRcc )N(R cc )2、-SO2N(R cc 2. -SO2R cc 、-SO2OR cc 、-SOR aa 、-C(=S)N(R cc )2, -C(=O)SR cc 、-C(=S)SR cc 、-P(=O)2R aa 、-P(=O)(R aa )2、-P(=O)2N(R cc )2, -P(=O)(NR cc 2. C 1-10 Alkyl, C 1-10 Perhaloalkyl, C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-10 Carbocyclic group, 3-14 membered heterocyclic group, C 6-14 aryl, and 5-14 membered heteroaryl, or two R cc The groups are connected to form a 3-14 membered heterocyclic or 5-14 membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl and heteroaryl group is independently substituted by 0, 1, 2, 3, 4 or 5 R dd substituted with a group, and wherein R aa , R bb , R cc and R dd As defined above.
[0064] In certain embodiments, the substituent present on the nitrogen atom is a nitrogen protecting group (also known as an amino protecting group). Nitrogen protecting groups include -OH, -OR aa 、-N(R cc )2, -C(=O)R aa 、-C(=O)N(R cc 2. -CO2R aa 、-SO2R aa 、-C(=NR cc )R aa 、-C(=NR cc )OR aa 、-C(=NR cc )N(R cc )2、-SO2N(R cc 2. -SO2R cc 、-SO2OR cc 、-SOR aa 、-C(=S)N(R cc )2, -C(=O)SRcc 、-C(=S)SR cc , C 1-10 Alkyl (e.g., aralkyl, heteroaralkyl), C 2-10 Alkenyl, C 2-10 Alkynyl, C 3-10 Carbocyclic group, 3-14 membered heterocyclic group, C 6-14 aryl and 5-14 membered heteroaryl, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aralkyl, aryl and heteroaryl is independently substituted by 0, 1, 2, 3, 4 or 5 R dd substituted with a group, and wherein R aa , R bb , R cc and R dd As defined herein. Nitrogen protecting groups are well known in the art and include those described in detail in Protecting Groups in Organic Synthesis, TW Greene and PGM Wuts, 3rd Edition, John Wiley & Sons, 1999, which is incorporated herein by reference.
[0065] For example, an amide group (e.g., -C(=O)R aa ) include formamide, acetamide, chloroacetamide, trichloroacetamide, trifluoroacetamide, phenylacetamide, 3-phenylpropionamide, picolinamide, 3-pyridinecarboxamide, N-benzoylphenylalanyl derivatives, benzamide, p-phenylbenzamide, o-nitrobenzylacetamide, o-nitrophenoxyacetamide, acetoacetamide, (N′-dithiobenzyloxyamido)acetamide, 3-(p-hydroxyphenyl)propionamide, 3-(o-nitrophenyl)propionamide, 2-methyl-2-(o-nitrophenoxy)propionamide, 2-methyl-2-(o-phenylazophenoxy)propionamide, 4-chlorobutanamide, 3-methyl-3-nitrobutanamide, o-nitrocinnamamide, N-acetylmethionine derivatives, o-nitrobenzamide and o-(benzoyloxymethyl)benzamide.
[0066] Such as carbamate groups (e.g., -C(=O)OR aa) includes: methyl carbamate, ethyl carbamate, 9-fluorenylmethyl carbamate (Fmoc), 9-(2-sulfo)fluorenylmethyl carbamate, 9-(2,7-dibromo)fluorenylmethyl carbamate, 2,7-di-tert-butyl-[9-(10,10-dioxo-10,10,10,10-tetrahydrothioxanthenyl)]methanol carbamate (DBD-Tmoc), 4-methoxybenzoylmethyl carbamate (Phenoc), 2,2,2-trichloroethyl carbamate (Troc), 2-trimethylsilylethyl carbamate (Teoc), 2-phenylethyl carbamate (hZ), 1-(1-adamantyl)-1-methylethyl carbamate Ester (Adpoc), carbamic acid-1,1-dimethyl-2-haloethyl ester, carbamic acid-1,1-dimethyl-2,2-dibromoethyl ester (DB-t-BOC), carbamic acid-1,1-dimethyl-2,2,2-trichloroethyl ester (TCBOC), carbamic acid-1-methyl-1-(4-biphenyl)ethyl ester (Bpoc), carbamic acid-1-(3,5-di-tert-butylphenyl)-1-methylethyl ester (t-Bumeoc), carbamic acid-2-(2′- and 4′-pyridyl)ethyl ester (Pyoc), carbamic acid-2-(N,N-dicyclohexylcarboxamido)ethyl ester, carbamic acid-tert-butyl ester (BOC or Boc), carbamic acid-1-adamantyl ester (Adoc), Vinyl carbamate (Voc), allyl carbamate (Alloc), 1-isopropyl allyl carbamate (Ipaoc), cinnamyl carbamate (Coc), 4-nitrocinnamyl carbamate (Noc), 8-quinolinyl carbamate, piperidinyl carbamate-N-hydroxypiperidinyl ester, alkyl dithiocarbamate, benzyl carbamate (Cbz), p-methoxybenzyl carbamate (Moz), p-nitrobenzyl carbamate, p-bromobenzyl carbamate, p-chlorobenzyl carbamate, 2,4-dichlorobenzyl carbamate, 4-methylsulfinylbenzyl carbamate (Msz), 9-anthryl methyl carbamate, diphenyl methyl carbamate, 2-methylthioethyl carbamate, -2-methylsulfonylethyl ester, carbamic acid-2-(p-toluenesulfonyl)ethyl ester, carbamic acid [2-(1,3-disulfide)]methyl ester (Dmoc), carbamic acid-4-methylthiophene ester (Mtpc), carbamic acid-2,4-dimethylthiophene ester (Bmpc), carbamic acid-2-phosphinoethyl ester (Peoc), carbamic acid-2-triphenylphosphinoisopropyl ester (Ppoc), carbamic acid-1,1-dimethyl-2-cyanoethyl ester, carbamic acid-m-chloro-p-acyloxybenzyl ester, carbamic acid-p-(dihydroxyboryl)benzyl ester, carbamic acid-5-benzisoxazolylmethyl ester, carbamic acid-2-(trifluoromethyl)-6-chromonylmethyl ester (Tcroc), carbamic acid-m-nitrophenyl ester, carbamic acid-3,5-dimethoxybenzyl ester, o-nitrobenzyl amino acid ester, 3,4-dimethoxy-6-nitrobenzyl carbamate, phenyl (o-nitrophenyl) methyl carbamate, tert-amyl carbamate, S-benzyl thiocarbamate, p-cyanobenzyl carbamate, cyclobutyl carbamate, cyclohexyl carbamate, cyclopentyl carbamate, cyclopropyl methyl carbamate, p-decyloxybenzyl carbamate, 2,2-dimethoxyacyl vinyl carbamate, o-(N,N-dimethylformamido)benzyl carbamate, 1,1-dimethyl-3-(N,N-dimethylformamido)propyl carbamate, 1,1-dimethylpropynyl carbamate, di(2-pyridyl)methyl carbamate, 2-furylmethyl carbamate, 2-iodocarbamate ethyl ester, isoborinyl carbamate, isobutyl carbamate, isonicotinoyl carbamate, p-(p'-methoxyphenylazo)benzyl carbamate, 1-methylcyclobutyl carbamate, 1-methylcyclohexyl carbamate, 1-methyl-1-cyclopropylmethyl carbamate, 1-methyl-1-(3,5-dimethoxyphenyl)ethyl carbamate, 1-methyl-1-(p-phenylazophenyl)ethyl carbamate, 1-methyl-1-phenylethyl carbamate, 1-methyl-1-(4-pyridyl)ethyl carbamate, phenyl carbamate, p-(phenylazo)benzyl carbamate, 2,4,6-tri-tert-butylphenyl carbamate, 4-(trimethylammonium)benzyl carbamate and 2,4,6-trimethylbenzyl carbamate.
[0067] Nitrogen protecting groups such as sulfonamide groups (e.g., -S(=O)2R aa ) include p-toluenesulfonamide (Ts), benzenesulfonamide, 2,3,6-trimethyl-4-methoxybenzenesulfonamide (Mtr), 2,4,6-trimethoxybenzenesulfonamide (Mtb), 2,6-dimethyl-4-methoxybenzenesulfonamide (Pme), 2,3,5,6-tetramethyl-4-methoxybenzenesulfonamide (Mte), 4-methoxybenzenesulfonamide (Mbs), 2,4,6-trimethylbenzenesulfonamide (Mts), 2,6-dimethoxy-4-methylbenzenesulfonamide (iMds), 2,2,5,7,8-pentamethylchroman-6-sulfonamide (Pmc), methanesulfonamide (Ms), β-trimethylsilylethanesulfonamide (SES), 9-anthracenesulfonamide, 4-(4,8-dimethoxynaphthylmethyl)benzenesulfonamide (DNMBS), benzylsulfonamide, trifluoromethylsulfonamide and phenacylmethylsulfonamide.
[0068] Other nitrogen protecting groups include phenothiazinyl-(10)-acyl derivatives, N′-toluenesulfonylaminoacyl derivatives, N′-phenylaminothioacyl derivatives, N-benzoylphenylalanyl derivatives, N-acetylmethionine derivatives, 4,5-diphenyl-3-oxazolin-2-one, N-phthalimide, N-dithiosuccinimide (Dts), N-2,3-diphenylmaleimide, N-2,5-dimethylpyrrole, N-1,1,4,4-tetramethyldisilazide adduct (STABASE), 5-substituted 1,3-dimethyl-1,3,5-triazacyclohexan-2-one, 5 -substituted 1,3-dibenzyl-1,3,5-triazacyclohexan-2-one, 1-substituted 3,5-dinitro-4-pyridone, N-methylamine, N-allylamine, N-[2-(trimethylsilyl)ethoxy]methylamine (SEM), N-3-acetoxypropylamine, N-(1-isopropyl-4-nitro-2-oxo-3-pyrrolin-3-yl)amine, quaternary ammonium salts, N-benzylamine, N-di(4-methoxyphenyl)methylamine, N-5-dibenzocycloheptylamine, N-triphenylmethylamine (Tr), N-[(4-methoxyphenyl)diphenylmethyl]amine (MMTr), N-9-phenylfluorenamine (PhF), N-2,7-di Chloro-9-fluorenylmethyleneamine, N-ferrocenylmethylamino (Fcm), N-2-methylpyridine amino N′-oxide, N-1,1-dimethylthiomethyleneamine, N-benzylideneamine, N-p-methoxybenzylideneamine, N-diphenylmethyleneamine, N-[(2-pyridyl)-trimethylbenzene]methyleneamine, N-(N′,N′-dimethylaminomethylene)amine, N,N′-isopropylidenediamine, N-p-nitrobenzylideneamine, N-salicylideneamine, N-5-chlorosalicylideneamine, N-(5-chloro-2-hydroxyphenyl)phenylmethyleneamine, N-cyclohexyleneamine, N-(5,5-dimethyl-3-oxo-1-cyclohexenyl)amine, N-borane derivatives, N-diphenylboronic acid derivatives, N-[phenyl(pentaacylchromium / tungsten)acyl]amine, N-copper chelates, N-zinc chelates, N-nitroamines, N-nitrosoamines, N-amine oxides, diphenylphosphinamide (Dpp), dimethylphosphinothioamide (Mpt), diphenylphosphinothioamide (Ppt), dialkylphosphoramidates, dibenzylphosphoramidates, diphenylphosphoramidates, benzenesulfenamide, o-nitrobenzenesulfenamide (Nps), 2,4-dinitrobenzenesulfenamide, pentachlorobenzenesulfenamide, 2-nitro-4-methoxybenzenesulfenamide, triphenylmethylsulfenamide and 3-nitropyridinesulfenamide (Npys).
[0069] Exemplary oxygen atom substituents include -R aa 、-C(=O)SR aa 、-C(=O)R aa 、-CO2R aa, -C(=O)N(R bb )2, -C(=NR bb )R aa , -C(=NR bb )OR aa , -C(=NR bb )N(R bb )2, -S(=O)R aa , -SO2R aa , -Si(R aa )3, -P(R cc )2, -P(R cc )3, -P(=O)2R aa , -P(=O)(R aa )2, -P(=O)(OR cc )2, -P(=O)2N(R bb )2 and -P(=O)(NR bb )2, where R aa , R bb and R ccAs defined herein.In certain embodiments, the oxygen atom substituent present on oxygen atom is oxygen protecting group (also referred to as hydroxy protecting group).Oxygen protecting group is well known in the art, and is included in Protecting Groups in Organic Synthesis, TW Greene and PGM Wuts, third edition, John Wiley & Sons, those described in detail in 1999, which are incorporated herein by reference.Exemplary oxygen protecting groups include methyl, tert-butyloxycarbonyl (BOC or Boc), methoxymethyl (MOM), methylthiomethyl (MTM), tert-butylthiomethyl, (phenyldimethylsilyl) methoxymethyl (SMOM), benzyloxymethyl (BOM), p-methoxybenzyloxymethyl (PMBM), (4-methoxyphenoxy) methyl (p-AOM), guaiacol methyl (GUM), tert-butoxymethyl, 4-pentenyloxymethyl (POM), siloxymethyl, 2-methoxyethoxymethyl (MEM), 2,2,2-trichloroethoxymethyl, bis (2-chloroethoxy) 1-[(2-chloro-4-methyl)phenyl]-4-methoxypiperidin-4-yl (CTMP), 1,4-dioxane-2-yl, tetrahydrofuranyl, tetrahydrothiofuranyl, 2-(trimethylsilyl)ethoxymethyl (SEMOR), tetrahydropyranyl (THP), 3-bromotetrahydropyranyl, tetrahydrothiopyranyl, 1-methoxycyclohexyl, 4-methoxytetrahydropyranyl (MTHP), 4-methoxytetrahydrothiopyranyl, 4-methoxytetrahydrothiopyranyl S,S-dioxide, 1-[(2-chloro-4-methyl)phenyl]-4-methoxypiperidin-4-yl (CTMP), 1,4-dioxane-2-yl, tetrahydrofuranyl, tetrahydrothiofuranyl, 2,3,3a,4,5,6,7,7a-octahydro-7,8,8 -trimethyl-4,7-dimethoxybenzofuran-2-yl, 1-ethoxyethyl, 1-(2-chloroethoxy)ethyl, 1-methyl-1-methoxyethyl, 1-methyl-1-benzyloxyethyl, 1-methyl-1-benzyloxy-2-fluoroethyl, 2,2,2-trichloroethyl, 2-trimethylsilylethyl, 2-(phenylhydrogen seleno)ethyl, tert-butyl, allyl, p-chlorophenyl, p-methoxyphenyl, 2,4-dinitrophenyl, benzyl (Bn), p-methoxybenzyl, 3,4-dimethoxybenzyl, o-nitrobenzyl, p-nitrobenzyl, p-halobenzyl, 2,6-dichlorobenzyl, p- Benzyl cyanide, p-phenylbenzyl, 2-methylpyridine, 4-methylpyridine, 3-methyl-2-methylpyridine N-oxide, diphenylmethyl, p,p′-dinitrobenzyl, 5-dibenzosuberyl, trityl, α-naphthyldiphenylmethyl, p-methoxyphenyldiphenylmethyl, di(p-methoxyphenyl)phenylmethyl, tri(p-methoxyphenyl)methyl, 4-(4'-bromophenacyloxyphenyl)diphenylmethyl, 4,4′,4″-tris(4,5-dichlorophthalimidophenyl)methyl, 4,4′,4″-tris(levulinyloxyphenyl)methyl, 4,4′,4″-Tris(benzoyloxyphenyl)methyl, 3-(imidazol-1-yl)bis(4′,4″-dimethoxyphenyl)methyl, 1,1-bis(4-methoxyphenyl)-1′-pyranylmethyl, 9-anthryl, 9-(9-phenyl)xanthenyl, 9-(9-phenyl-10-oxo)anthryl, 1,3-benzodithiofuran-2-yl, benzisothiazolyl S,S-dioxide, trimethylsilyl (TMS), triethylsilyl (TES), triisopropylsilyl (TIPS), dimethylisopropylsilyl (IPDMS), diethylisopropylsilyl (DEIPS), dimethyltert-hexylsilyl, tert-butyldimethylsilyl (TBDMS), tert-butyldiphenyl Silyl (TBDPS), tribenzylsilyl, tri-p-xylylsilyl, triphenylsilyl, diphenylmethylsilyl (DPMS), tert-butylmethoxyphenylsilyl (TBMPS), formate, benzoylformate, acetate, chloroacetate, dichloroacetate, trichloroacetate, trifluoroacetate, methoxyacetate, triphenylmethoxyacetate, phenoxyacetate, p-chlorophenoxyacetate, 3-phenylpropionate, 4-oxopentanoate (levulinic acid ester), 4,4-(ethylenedithio)pentanoate (levulinic acid dithioacetal), pivalate, adamantate, crotonate, 4-methoxycrotonate, benzoate, p-phenylbenzoate, 2,4,6-trimethylbenzoate, Alkyl methyl carbonate, 9-fluorenyl methyl carbonate (Fmoc), alkyl ethyl carbonate, alkyl 2,2,2-trichloroethyl carbonate (Troc), 2-(trimethylsilyl)ethyl carbonate (TMSEC), 2-(phenylsulfonyl)ethyl carbonate (Psec), 2-(triphenylphosphino)ethyl carbonate (Peoc), alkyl isobutyl carbonate, alkyl ethylene carbonate, alkyl allyl carbonate, alkyl p-nitrophenyl carbonate, alkyl benzyl carbonate, alkyl p-methoxybenzyl carbonate, alkyl 3,4-dimethoxybenzyl carbonate, alkyl o-nitrobenzyl carbonate, alkyl p-nitrobenzyl carbonate, alkyl S-benzyl thiocarbonate, 4-ethoxy-1-naphthyl carbonate, methyl dithiocarbonate, 2-iodobenzoate, 4-azidobutyrate, 4-nitro-4-methylvalerate, o-(dibromomethyl)benzoate, 2-formylbenzenesulfonate, 2-(methylthiomethoxy)ethyl, 4-(methylthiomethoxy)butyrate, 2-(methylthiomethoxymethyl)benzoate, 2,6-dichloro-4-methylphenoxyacetate, 2,6-dichloro-4-(1,1,3,3-tetramethylbutyl)phenoxyacetate, 2,4-bis(1,1-dimethylpropyl)phenoxyacetate, chlorodiphenylacetate, isobutyrate, monosuccinate, (E)-2-methyl-2-butenoate, o-(methoxyacyl)benzoate, α-naphthoate, nitrate, alkyl N,N,N',N'-tetramethylphosphorodiamidate (alkyl N,N,N',N′-tetramethylphosphorodiamidate), alkyl N-phenyl carbamate, borate, dimethylphosphinothioyl, alkyl 2,4-dinitrobenzenesulfonate, sulfate, mesylate, benzylsulfonate and tosylate (Ts).
[0070] Exemplary sulfur atom substituents include -R aa 、-C(=O)SR aa 、-C(=O)R aa 、-CO2R aa 、-C(=O)N(R bb )2, -C(=NR bb )R aa 、-C(=NR bb )OR aa 、-C(=NR bb )N(R bb )2, -S(=O)R aa 、-SO2R aa 、-Si(R aa )3. -P(R cc )2. -P(R cc )3, -P(=O)2R aa ,-P(=O)(R aa )2.-P(=O)(OR cc )2、-P(=O)2N(R bb )2 and -P(=O)(NR bb )2, where R aa , R bb and R cc As defined herein. In certain embodiments, the sulfur atom substituent present on the sulfur atom is a sulfur protecting group (also referred to as a thiol protecting group). Sulfur protecting groups are well known in the art and are included in those described in detail in Protecting Groups in Organic Synthesis, TW Greene and PGM Wuts, 3rd edition, John Wiley & Sons, 1999, which are incorporated herein by reference.
[0071] "Hydrocarbon chain" refers to a substituted or unsubstituted divalent alkyl, alkenyl or alkynyl group. A hydrocarbon chain includes (1) one or more carbon atom chains immediately between two groups of the hydrocarbon chain; (2) optionally, one or more hydrogen atoms on the carbon atom chain; and (3) optionally, one or more substituents on the carbon atom chain ("non-chain substituents", which are not hydrogen). The carbon atom chain consists of continuously connected carbon atoms ("chain atoms" or "carbon units") and does not include hydrogen atoms or heteroatoms. However, the non-chain substituents of the hydrocarbon chain can include any atom, including hydrogen atoms, carbon atoms and heteroatoms. For example, the hydrocarbon chain -C A H(C B H2C C H3)-includes a chain atom C A , C A A hydrogen atom on the B H2C C H3) The term “C x A "hydrocarbon chain" is a hydrocarbon chain that includes x number of chain atoms between two groups of the hydrocarbon chain, where x is a positive integer. If there is more than one possible value for x, the smallest possible value of x is used to define the hydrocarbon chain. For example, -CH(C2H5)- is a C1 hydrocarbon chain, is a C3 hydrocarbon chain. When a range of values is used, the meaning of the range is as described herein. For example, C 3-10 A hydrocarbon chain refers to a hydrocarbon chain in which the shortest chain of carbon atoms immediately between two groups of the hydrocarbon chain has 3, 4, 5, 6, 7, 8, 9, or 10 chain atoms. The hydrocarbon chain may be saturated (e.g., -(CH4-)). The hydrocarbon chain may also be unsaturated and include one or more C=C and / or C°C bonds at any position of the hydrocarbon chain. For example, -CH=CH-CH2-, -CH2-C°C-CH2-, and -C°C-CH=CH- are all examples of unsubstituted unsaturated hydrocarbon chains. In certain embodiments, the hydrocarbon chain is unsubstituted (e.g., -C°C- or -CH4-). In certain embodiments, the hydrocarbon chain is substituted (e.g., -CH(C2H5)- and -CF2-). Any two substituents on the hydrocarbon chain may be connected to form an optionally substituted carbocyclic group, an optionally substituted heterocyclic group, an optionally substituted aryl group, or an optionally substituted heteroaryl ring. For example, as well as are all examples of hydrocarbon chains. In contrast, in certain embodiments, It is not within the scope of the hydrocarbon chain described herein. X When a hydrocarbon chain atom is replaced by a heteroatom, the resulting group is called a C X Hydrocarbon chain, with C x-1 This is in contrast to a hydrocarbon chain in which chain atoms are replaced by heteroatoms. For example, It is a C3 hydrocarbon chain in which one of the chain atoms is replaced by an oxygen atom.
[0072] The term "leaving group" is given its usual meaning in synthetic organic chemistry to refer to an atom or group that can be displaced by a nucleophile. Examples of suitable leaving groups include halogen (e.g., F, Cl, Br, or I (iodine)), alkoxycarbonyloxy, aryloxycarbonyloxy, alkanesulfonyloxy, arenesulfonyloxy, alkyl-carbonyloxy (e.g., acetoxy), arylcarbonyloxy, aryloxy, methoxy, N,O-dimethylhydroxyamino, pixyl, and haloformate. In some cases, the leaving group is a sulfonate, such as tosylate (-OTs), mesylate (-OMs), bromobenzenesulfonyloxy (bromobenzenesulfonate, -OBs), -OS(=O)2(CF3CF3(perfluorobutylsulfonate, -ONf) or triflate (-OTf). In some cases, the leaving group is bromobenzenesulfonate, such as bromobenzenesulfonyloxy. In some cases, the leaving group is a nitrobenzenesulfonate, such as 2-nitrobenzenesulfonyloxy. The leaving group can also be a phosphine oxide (e.g., formed during a Mitsunobu reaction) or an internal leaving group, such as an epoxide or a cyclic sulfate. Other non-limiting examples of leaving groups are water, ammonia, alcohols, ether moieties, thioether moieties, zinc halides, magnesium moieties, diazonium salts, and copper moieties.
[0073] The term "pharmaceutically acceptable salt" refers to salts that are suitable for use in contact with tissues of humans and lower animals without undue toxicity, irritation, allergic reactions, etc., and that are matched with a reasonable benefit / risk ratio within the scope of sound medical judgment. Pharmaceutically acceptable salts are well known in the art. For example, Berge et al. describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66, 1-19, which are incorporated herein by reference. Pharmaceutically acceptable salts of the compounds described herein include salts derived from suitable inorganic and organic acids and bases. Examples of pharmaceutically acceptable non-toxic acid addition salts are salts of amino groups formed with inorganic acids (such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid) or with organic acids (such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid), or by using other methods known in the art (such as ion exchange) to form amino salts. Other pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxyethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylacidate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate and the like. Salts derived from suitable bases include alkali metal, alkaline earth metal, ammonium and N + (C 1-4 Alkyl)4 - Salts. Representative alkali metal or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, etc. Other pharmaceutically acceptable salts include (when appropriate) non-toxic ammonium, quaternary ammonium and amine cations formed using counterions, such as halides, hydroxides, carboxylates, sulfates, phosphates, nitrates, lower alkyl sulfonates and aryl sulfonates.
[0074] The term "solvate" refers to a compound form that is usually combined with a solvent by a solvolysis reaction. This physical combination may include hydrogen bonds. Conventional solvents include water, methanol, ethanol, acetic acid, DMSO, THF, ether, etc. The compounds described herein can be prepared as crystalline forms and can be solvated. Suitable solvates include pharmaceutically acceptable solvates, and also include stoichiometric solvates and non-stoichiometric solvates. In some cases, for example, when one or more solvent molecules are incorporated into the crystal lattice of the crystalline solid, the solvate can be separated. "Solvate" includes both solution phases and separable solvates. Representative solvates include hydrates, ethanolates and methanolates.
[0075] The term "hydrate" refers to a compound combined with water. Generally, the number of water molecules contained in the hydrate of a compound is proportional to the number of compound molecules in the hydrate. Therefore, the hydrate of a compound can be represented, for example, by the general formula R·xH2O, where R is a compound and x is a number greater than 0. A given compound can form more than one type of hydrate, for example, a monohydrate (x is 1), a lower hydrate (x is a number greater than 0 and less than 1, such as a hemihydrate (R·0.5H2O)) and a polyhydrate (x is a number greater than 1, such as a dihydrate (R·2H2O) and a hexahydrate (R·6H2O)).
[0076] The term "tautomer" or "tautomeric" refers to two or more interchangeable compounds resulting from at least one formal migration of a hydrogen atom and at least one change in valence (e.g., a single bond to a double bond, a triple bond to a single bond, or vice versa). The exact ratio of tautomers depends on several factors, including temperature, solvent, and pH. Tautomerization (i.e., a reaction that provides a tautomeric pair) can be catalyzed by an acid or a base. Exemplary tautomerizations include keto-enol, amide-imide, lactam-lactim, enamine-imine, and tautomerization of one enamine to another enamine.
[0077] It is also understood that compounds that have the same molecular formula but differ in the nature or sequence of bonding of their atoms or the arrangement of their atoms in space are termed "isomers." Isomers that differ in the arrangement of their atoms in space are termed "stereoisomers."
[0078] Stereoisomers that are not mirror images of one another are called "diastereomers," while stereoisomers whose mirror images are not superimposable are called "enantiomers." When a compound has an asymmetric center, for example, when it is attached to four different groups, a pair of enantiomers may exist. Enantiomers can be characterized by the absolute configuration of their asymmetric center and described by Cahn and Prelog's rules of R- and S-order, or by the way the molecule rotates the plane of polarized light and named as right- or left-handed (i.e., (+) or (-)-isomers, respectively). Chiral compounds can exist as a single enantiomer or as a mixture thereof. A mixture containing equal proportions of enantiomers is called a "racemic mixture."
[0079] The term "polymorph" refers to the crystalline form of a compound (or its salt, hydrate or solvate) in a specific crystal packing arrangement. All polymorphs have the same elemental composition. Different crystalline forms usually have different X-ray diffraction patterns, infrared spectra, melting points, density, hardness, crystal shapes, optical and electrical properties, stability and solubility. Recrystallization solvents, crystallization rates, storage temperatures and other factors may lead to one crystal form being dominant. Various polymorphs can be prepared by crystallization of a compound under different conditions.
[0080] The term "co-crystal" refers to a crystal structure composed of at least two components. In certain embodiments, a co-crystal may comprise a compound of the present disclosure and one or more other components, including atoms, ions, molecules, or solvent molecules. In certain embodiments, a co-crystal may comprise a compound of the present disclosure and one or more components related to the compound, including an isomer, tautomer, salt, solvate, hydrate, synthetic precursor, synthetic derivative, fragment, or impurity of the compound.
[0081] The term "isotopically labeled derivative" or "isotopically labeled" refers to a compound in which one or more atoms in a compound (or the associated ions or molecules of a salt, hydrate, or solvate) have been replaced by an isotope of the same element. For a specified element or position in a molecule, all atoms of the element in the molecule or all atoms at the position in the sample will be isotopically enriched or the isotope will be present in a higher percentage relative to an unlabeled variant. In certain embodiments, the enriched isotope will be a stable isotope. In certain embodiments, the enriched isotope will be an unstable or radioactive isotope (e.g., a radionuclide). In certain embodiments, the enriched isotope can be detected by a measurement technique including nuclear magnetic resonance, mass spectrometry, infrared spectroscopy, or a technique for measuring radioactive decay.
[0082] The term "prodrug" refers to a compound having a cleavable group and becoming a compound described herein by solvent decomposition or under physiological conditions, which has in vivo pharmaceutical activity. Such examples include choline ester derivatives and analogs, N-alkyl morpholine esters and analogs. Other derivatives of the compounds described herein are active in their acid and acid derivative forms, but generally provide advantages of solubility, tissue compatibility or delayed release in mammalian organisms in acid-sensitive forms (see, Bundgard, H., Design of Prodrugs, pages 7-9, 21-24, Elsevier, Amsterdam 1985). Prodrugs include acid derivatives well known to practitioners in the art, for example, esters prepared by reacting the parent acid with a suitable alcohol, or amides prepared by reacting the parent acid compound with a substituted or unsubstituted amine, or anhydrides, or mixed anhydrides. Simple aliphatic or aromatic esters, amides and anhydrides derived from acidic groups on the compounds described herein are specific prodrugs. In some cases, it is desirable to prepare a double ester type prodrug, such as an (acyloxy)alkyl ester or a ((alkoxycarbonyl)oxy)alkyl ester. The C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, aryl, C6-C8 12 Substituted aryl and C7-C 12 Aryl alkyl esters are preferred.
[0083] The term "inhibit" or "inhibitor" refers to the ability of a compound to reduce, slow, stop or prevent a particular biological process (eg, the activity of a cyclin-dependent kinase) in a cell relative to the vehicle.
[0084] When a compound, pharmaceutical composition, method, use or kit is referred to as "selectively", "specifically" or "competitively" binding to a first protein or first chromatin, the compound, pharmaceutical composition, method, use or kit binds to the first protein or first chromatin with a higher binding affinity (e.g., not less than about 2 times, not less than about 5 times, not less than about 10 times, not less than about 30 times, not less than about 100 times, not less than about 1000 times, or not less than about 10,000 times) than it binds to a second protein or second chromatin that is different from the first protein and the first chromatin. When a compound, pharmaceutical composition, method, use or kit is referred to as "selectively", "specifically" or "competitively" modulating (e.g., increasing or inhibiting) the activity of a cyclin-dependent kinase, the compound, pharmaceutical composition, method, use or kit modulates the activity of the cyclin-dependent kinase to a greater extent (e.g., not less than about 2-fold, not less than about 5-fold, not less than about 10-fold, not less than about 30-fold, not less than about 100-fold, not less than about 1000-fold, or not less than about 10,000-fold) as compared to the activity of at least one protein other than the cyclin-dependent kinase.
[0085] The term "abnormal activity" refers to an activity that deviates from normal activity, that is, abnormal activity. The term "increased activity" refers to an activity that is higher than normal activity.
[0086] The terms "composition" and "formulation" are used interchangeably.
[0087] A "subject" to which administration is intended refers to a human (i.e., a male or female of any age group, e.g., a child subject (e.g., an infant, child, or adolescent) or an adult subject (e.g., a young, middle-aged, or elderly)) or a non-human animal. In certain embodiments, the non-human animal is a mammal (e.g., a primate (e.g., a cynomolgus monkey or a rhesus monkey), a commercially relevant mammal (e.g., a cow, pig, horse, sheep, goat, cat, or dog), or a bird (e.g., a commercially relevant bird, such as a chicken, duck, goose, or turkey)). In certain embodiments, the non-human animal is a fish, a reptile, or an amphibian. The non-human animal can be male or female at any stage of development. The non-human animal can be a transgenic animal or a genetically engineered animal. "Patient" refers to a human subject in need of treatment for a disease. A subject may also be a plant. In certain embodiments, the plant is a terrestrial plant. In certain embodiments, the plant is a non-vascular terrestrial plant. In certain embodiments, the plant is a vascular terrestrial plant. In certain embodiments, the plant is a seed plant. In certain embodiments, the plant is a cultivated plant. In certain embodiments, the plant is a dicot. In certain embodiments, the plant is a monocot. In certain embodiments, the plant is a flowering plant. In some embodiments, the plant is a cereal, for example, corn, wheat, rice, oats, barley, rye, or millet. In some embodiments, the plant is a leguminous plant, for example, a leguminous plant, such as a soybean plant. In some embodiments, the plant is a tree or a shrub.
[0088] The term "biological sample" refers to any sample including tissue samples (such as tissue sections and needle biopsies of a tissue); cell samples (e.g., cell smears (such as Papanicolaou smears (Pap) or blood smears) or cell samples obtained by microdissection); samples of whole organisms (such as samples of yeast or bacteria); or cell fractions, fragments or organelles (such as obtained by lysing cells and separating their components by centrifugation or other methods). Other examples of biological samples include blood, serum, urine, semen, feces, cerebrospinal fluid, interstitial fluid, mucus, tears, sweat, pus, biopsy tissue (e.g., obtained by surgical biopsy or needle biopsy), nipple aspirates, milk, vaginal fluid, saliva, swabs (such as buccal swabs), or any material containing biomolecules derived from another biological sample.
[0089] The terms "administering," "applying," or "administering" refer to implanting, absorbing, ingesting, injecting, inhaling, or otherwise introducing a compound described herein or a composition thereof into or on a subject.
[0090] The terms "treat," "treat," and "treat" refer to reversing, alleviating, delaying the onset of, or inhibiting the progression of a disease described herein. In some embodiments, treatment may be given after one or more signs or symptoms of the disease have developed or have been observed. In other embodiments, treatment may be given in the absence of signs or symptoms of the disease. For example, susceptible subjects may be treated before symptoms develop (e.g., based on a history of symptoms and / or in view of exposure to a pathogen). Treatment may also be continued after symptoms disappear, for example, to delay or prevent recurrence.
[0091] The terms "condition," "disease," and "disorder" are used interchangeably.
[0092] An "effective amount" of a compound described herein refers to an amount sufficient to cause a desired biological response (i.e., to treat the condition). As will be appreciated by those of ordinary skill in the art, the effective amount of a compound described herein may vary according to factors such as the desired biological endpoint, the pharmacokinetics of the compound, the condition being treated, the mode of administration, and the age and health of the subject. In certain embodiments, the effective amount is a therapeutically effective amount. In certain embodiments, the effective amount is a prophylactically effective amount. In certain embodiments, the effective amount is the amount of a single dose of a compound described herein. In certain embodiments, the effective amount is the combined amount of multiple doses of a compound described herein.
[0093] A "therapeutically effective amount" of a compound described herein is an amount sufficient to provide a therapeutic benefit in treating a condition or to delay or minimize one or more symptoms associated with the condition. A therapeutically effective amount of a compound refers to an amount of a therapeutic agent, alone or in combination with other treatments, that provides a therapeutic benefit in treating the condition. The term "therapeutically effective amount" can include an amount that improves overall treatment, reduces or avoids symptoms, signs, or causes of a condition, and / or enhances the therapeutic efficacy of another therapeutic agent.
[0094] A "prophylactically effective amount" of a compound described herein is an amount sufficient to prevent a condition, or one or more symptoms associated with the condition, or to prevent its recurrence. A prophylactically effective amount of a compound refers to an amount of a therapeutic agent, alone or in combination with other treatments, that provides a prophylactic benefit in preventing the condition. The term "prophylactically effective amount" may include an amount that improves overall prevention or enhances the prophylactic efficacy of another prophylactic agent.
[0095] "Proliferative disease" refers to a disease that occurs due to abnormal growth or expansion caused by cell proliferation (Walker, Cambridge Dictionary of Biology; Cambridge University Press: Cambridge, UK, 1990). Proliferative diseases may be associated with: 1) pathological proliferation of normally quiescent cells; 2) pathological migration of cells from their normal location (e.g., metastasis of neoplastic cells); 3) pathological expression of proteolytic enzymes such as matrix metalloproteinases (e.g., collagenases, gelatinases, and elastases); or 4) pathological angiogenesis in proliferative retinopathy and tumor metastasis. Exemplary proliferative diseases include cancer (i.e., "malignancies"), benign neoplasms, diseases associated with angiogenesis, inflammatory diseases, and autoimmune diseases.
[0096] The term "angiogenesis" refers to the physiological process by which new blood vessels are formed from pre-existing blood vessels. Angiogenesis is different from vasculogenesis, which is the de novo formation of endothelial cells from mesodermal cell precursors. The first blood vessels during embryonic development are formed by angiogenesis, after which angiogenesis is the main cause of blood vessel growth during normal or abnormal development. Angiogenesis is an important process in growth and development, wound healing, and granulation tissue formation. However, angiogenesis is also a basic step in the transformation of tumors from a benign state to a malignant state, resulting in the use of angiogenesis inhibitors in cancer treatment. Angiogenesis can be chemically stimulated by angiogenesis proteins such as growth factors (e.g., VEGF). "Pathological angiogenesis" refers to abnormal (e.g., excessive or insufficient) angiogenesis that is equivalent to a disease and / or disease-related.
[0097] The terms "vegetation" and "tumor" are used interchangeably herein and refer to an abnormal mass of tissue in which the growth of the mass exceeds the growth of normal tissue and is not coordinated as the growth of normal tissue. Vegetation or tumor may be "benign" or "malignant", depending on the following characteristics: degree of cell differentiation (including morphology and function), growth rate, local invasion and metastasis. "Benign neoplasms" are usually well differentiated, characterized in that the growth rate is slower than that of malignant tumors, and are still confined to the primary site. In addition, benign neoplasms do not have the ability to infiltrate, invade or metastasize to distant sites. Typical benign neoplasms include lipomas, chondromas, adenomas, soft droops, senile hemangiomas, seborrheic keratosis, freckles and sebaceous hyperplasia. In some cases, some "benign" tumors may later develop into malignant tumors, which may be due to additional genetic changes in a subpopulation of the neoplastic cells of the tumor, and these tumors are referred to as "precancerous tumors". An exemplary pre-malignant tumor is a teratoma. In contrast, "malignant tumors" are usually poorly differentiated (anaplastic), and are characterized in that they grow rapidly while being accompanied by the gradual infiltration, invasion and destruction of surrounding tissues. In addition, malignant tumors often have the ability to metastasize to distant sites. The term "metastasis" refers to the spread or migration of cancer cells from an initial or primary tumor to another organ or tissue, and can often be identified by the presence of "secondary tumors" or "secondary cell masses" of the tissue type of the initial or primary tumor rather than the tissue type of the organ or tissue where the secondary (metastatic) tumor is located. For example, prostate cancer that has migrated to the bone is called metastatic prostate cancer and includes cancerous prostate cancer cells growing in bone tissue.
[0098] The term "cancer" refers to a class of diseases characterized by the development of abnormal cells that proliferate uncontrollably and have the ability to infiltrate and destroy normal body tissues. See, e.g., Stedman's Medical Dictionary, 25th ed.; Hensyl, ed.; Williams & Wilkins: Philadelphia, 1990. Exemplary cancers include hematological malignancies. Additional exemplary cancers include acoustic neuroma; adenocarcinoma; adrenal cancer; anal cancer; angiosarcoma (e.g., lymphangiosarcoma, lymphangioendothelial sarcoma, angiosarcoma); appendix cancer; benign monoclonal gammopathy; bile duct cancer (e.g., cholangiocarcinoma); bladder cancer; breast cancer (e.g., breast adenocarcinoma, breast papillary carcinoma, breast cancer, medullary breast cancer, triple negative breast cancer (TNBC)); brain cancer (e.g., meningioma, glioblastoma, glioma (e.g., astrocytoma, oligodendroglioma, medulloblastoma); bronchial carcinoma; carcinoid tumor; cervical cancer (e.g., cervical adenocarcinoma); choriocarcinoma; chordoma; cranial Pharyngioma; colorectal cancer (e.g., colon cancer, rectal cancer, colorectal adenocarcinoma); connective tissue cancer; epithelial cancer; ependymoma; endothelial sarcoma (e.g., Kaposi sarcoma, multiple idiopathic hemorrhagic sarcomas); endometrial cancer (e.g., uterine cancer, uterine sarcoma); esophageal cancer (e.g., esophageal adenocarcinoma, Barrett's adenocarcinoma); Ewing sarcoma; eye cancer (e.g., intraocular melanoma, retinoblastoma); common eosinophilia; gallbladder cancer; gastric cancer (e.g., gastric adenocarcinoma); gastrointestinal stromal tumors (GIST); germ cell cancer; head and neck cancer (e.g., head and neck squamous cell carcinoma, oral cancer (e.g., oral squamous cell carcinoma), laryngeal cancer (e.g., laryngeal cancer, pharyngeal cancer, nasopharyngeal cancer, oropharyngeal cancer); heavy chain disease (e.g., alpha chain disease, gamma chain disease, mu chain disease; hemangioblastoma; hypopharyngeal cancer; inflammatory myofibroblastic tumor; immune cell amyloidosis; kidney cancer (e.g., Wilms tumor also known as Wilms tumor, renal cell carcinoma); liver cancer (e.g., hepatocellular carcinoma (HCC), malignant liver cancer); lung cancer (e.g., bronchogenic carcinoma, small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), lung adenocarcinoma); leiomyosarcoma (LMS); mastocytosis (e.g., systemic mastocytosis); muscle cancer; myelodysplastic syndrome (MDS); mesothelioma; myeloproliferative disorders (MPDs) (e.g., polycythemia vera (PV), essential thrombocythemia (ET), idiopathic myeloid metaplasia (AMM), also known as myelofibrosis (MF), chronic idiopathic myelofibrosis, chronic myeloid leukemia (CML), chronic neutrophilic leukemia (CNL), hypereosinophilic syndrome (HES)); neuroblastoma; neurofibromas (e.g., neurofibromatosis (NF) type 1 or 2, schwannomatosis);Neuroendocrine cancer (e.g., gastroenteropancreatic neuroendocrine tumor (GEP-NET), carcinoid); osteosarcoma (e.g., bone cancer); ovarian cancer (e.g., cystadenocarcinoma, ovarian embryonal carcinoma, ovarian adenocarcinoma); papillary adenocarcinoma; pancreatic cancer (e.g., pancreatic adenocarcinoma, intraductal papillary mucinous neoplasm (IPMN), islet cell tumor); penile cancer (e.g., Paget's disease of the penis and scrotum); pinealoma; primitive neuroectodermal tumor; plasma cell tumor; paraneoplastic syndrome; intraepithelial neoplasia; prostate cancer (e.g., prostate adenocarcinoma); rectal cancer; rhabdomyosarcoma; salivary gland cancer; skin cancer (e.g., squamous cell carcinoma); (SCC), keratoacanthoma (KA), melanoma, basal cell carcinoma (BCC)); small bowel cancer (e.g., appendix cancer); soft tissue sarcomas (e.g., malignant fibrous histiocytoma (MFH), liposarcoma, malignant peripheral nerve sheath tumor (MPNST), chondrosarcoma, fibrosarcoma, myxosarcoma); sebaceous gland carcinoma; small bowel cancer; sweat gland carcinoma; synovioma; testicular cancer (e.g., seminoma, testicular embryonal carcinoma); thyroid cancer (e.g., papillary thyroid carcinoma, papillary thyroid carcinoma (PTC), medullary thyroid cancer), urethral cancer, vaginal cancer, and vulvar cancer (e.g., vulvar Paget's disease).
[0099] The term "hematologic malignancy" refers to a tumor that affects the blood, bone marrow, and / or lymph nodes. Exemplary hematologic malignancies include leukemias, such as acute lymphocytic leukemia (ALL) (e.g., B-cell ALL, T-cell ALL), acute myeloid leukemia (AML) (e.g., B-cell AML, T-cell AML), chronic myeloid leukemia (CML) (e.g., B-cell CML, T-cell CML), chronic lymphocytic leukemia (CLL) (e.g., B-cell CLL, T-cell CLL); lymphomas, such as Hodgkin lymphoma (HL) (e.g., B-cell HL, T-cell HL) and non-Hodgkin lymphoma (NH L) (e.g., B-cell NHL, such as diffuse large cell lymphoma (DLCL) (e.g., diffuse large B-cell lymphoma (DLBCL, e.g., activated B-cell (ABC) DLBCL (ABC-DLBCL)), follicular lymphoma, chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), mantle cell lymphoma (MCL), marginal zone B-cell lymphoma (e.g., mucosa-associated lymphoid tissue (MALT) lymphoma, nodal marginal zone B-cell lymphoma, splenic marginal zone B-cell lymphoma), primary mediastinal B-cell lymphoma, Burkitt lymphoma, macroglobulinemia (WM, lymphoplasmacytic lymphoma), hairy cell leukemia (HCL), immunoblastic large cell lymphoma, precursor B lymphoblastic lymphoma, central nervous system (CNS) lymphomas (e.g., primary CNS lymphoma and secondary CNS lymphoma); and T-cell NHL, such as precursor T-lymphocytic lymphoma / leukemia, peripheral T-cell lymphoma (PTCL) (e.g., cutaneous T-cell lymphoma (CTCL) (e.g., mycosis fungoides, Sezary syndrome, angioimmunoblastic T-cell lymphoma, extranodal natural killer T-cell lymphoma, enteropathy-type T-cell lymphoma, subcutaneous panniculitis-like T-cell lymphoma, and anaplastic large cell lymphoma); immune privileged sites (immune privileged sites); site of the disease (e.g., brain, eye, placental, fetal, testicular); a mixture of one or more leukemia / lymphomas as described above; myelodysplasia; and multiple myeloma (MM).
[0100] The term "inflammatory disease" refers to a disease caused by, derived from, or resulting in inflammation. The term "inflammatory disease" may also refer to an inflammatory response that causes an overreaction of macrophages, granulocytes, and / or T lymphocytes, resulting in abnormal tissue damage and / or cell death. Inflammatory diseases may be acute or chronic inflammatory conditions, and may be caused by infectious or non-infectious causes. Inflammatory diseases include, but are not limited to, atherosclerosis, arteriosclerosis, autoimmune disorders, multiple sclerosis, systemic lupus erythematosus, polymyalgia rheumatica (PMR), gouty arthritis, degenerative arthritis, tendinitis, bursitis, psoriasis, cystic fibrosis, arthritis, rheumatoid arthritis, inflammatory arthritis, Sjögren's syndrome, giant cell arteritis, progressive systemic sclerosis (scleroderma), ankylosing spondylitis, polymyositis, dermatomyositis, pemphigus, pemphigoid, diabetes (e.g., type I), myasthenia gravis, Hashimoto's thyroiditis, Graves' disease, Goodpasture's disease , mixed connective tissue disease, sclerosing cholangitis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, pernicious anemia, inflammatory skin diseases, usual interstitial pneumonia (UIP), asbestosis, silicosis, bronchiectasis, berylliosis, talcosis, pneumoconiosis, sarcoidosis, desquamative interstitial pneumonia, lymphointerstitial pneumonia, giant cell interstitial pneumonia, cellular interstitial pneumonia, extrinsic allergic alveolitis, Wegener's granulomatosis and related forms of vasculitis (temporal arteritis and polyarteritis nodosa), inflammatory skin diseases, hepatitis, delayed hypersensitivity reactions (e.g., poison ivy dermatitis), pneumonia, respiratory tract inflammation, adults Respiratory distress syndrome (ARDS), encephalitis, immediate hypersensitivity reaction, asthma, hay fever, allergy, acute allergic reaction, rheumatic fever, glomerulonephritis, pyelonephritis, cellulitis, cystitis, chronic cholecystitis, ischemia (ischemic injury), reperfusion injury, allograft rejection, host graft rejection, appendicitis, arteritis, blepharitis, bronchiolitis, bronchitis, cervicitis, cholangitis, chorioamnionitis, conjunctivitis, lacrimal gland inflammation, dermatomyositis, endocarditis, endometritis, enteritis, enterocolitis, epicondylitis, epididymitis, fasciitis, fibrositis, gastritis, gastroenteritis, Gingivitis, ileitis, iritis, laryngitis, myelitis, myocarditis, nephritis, omphalitis, oophoritis, orchitis, osteitis, otitis, pancreatitis, mumps, pericarditis, pharyngitis, pleurisy, phlebitis, pneumonia, proctitis, prostatitis, rhinitis, salpingitis, sinusitis, stomatitis, synovitis, orchitis, tonsillitis, urethritis, cystitis, uveitis, vaginitis, vasculitis, vulvitis, vulvovaginitis, vasculitis, chronic bronchitis, osteomyelitis optic neuritis, temporal arteritis, transverse myelitis, necrotizing fasciitis, and necrotizing enterocolitis.
[0101] An "autoimmune disease" is a disease caused by an abnormal immune response to substances and tissues that are normally present in the body. In other words, the immune system mistakes a part of the body for a pathogen and attacks its own cells. This may be localized to certain organs (e.g., in autoimmune thyroiditis) or involve specific tissues in different parts (e.g., Goodpasture's disease, which may affect the basement membranes of the lungs and kidneys). Autoimmune diseases are often treated with immunosuppression, i.e., drugs that reduce the immune response. Exemplary autoimmune diseases include glomerulonephritis, Goodpasture syndrome, necrotizing vasculitis, lymphadenitis, periarteritis nodosa, systemic lupus erythematosus, rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus, psoriasis, ulcerative colitis, systemic sclerosis, dermatomyositis / polymyositis, antiphospholipid antibody syndrome, scleroderma, pemphigus vulgaris, ANCA-associated vasculitis (e.g., Wegener's granulomatosis, microscopic polyangiitis), uveitis, Sjögren's syndrome, Crohn's disease, Reiter's syndrome, ankylosing spondylitis, Lyme's disease, Guillain-Barré syndrome, Hashimoto's thyroiditis, and cardiomyopathy.
[0102] The term "kinase" refers to an enzyme that transfers a phosphate group from a high energy donor molecule (such as ATP) to a specific substrate, a process called phosphorylation. Kinases are part of a large family of phosphotransferases. The largest class of kinases are protein kinases, which act on and modify the activity of specific proteins. Kinases are widely used in cells to transmit signals and control complex processes. Various other kinases act on small molecules such as lipids, carbohydrates, amino acids and nucleotides, either for signal transmission or to activate their metabolic pathways. Kinases are usually named after their substrates. More than 500 different protein kinases have been identified in humans. Exemplary human protein kinases include: AAK1, ABL, ACK, ACTR2, ACTR2B, AKT1, AKT2, AKT3, ALK, ALK1, ALK2, ALK4, ALK7, AMPKa1, AMPKa2, ANKRD3, ANPa, ANPb, ARAF, ARAFps, ARG, AurA, AurAps1, AurAps2, AurB, AurBps1, AurC, AXL, BARK1, BARK2, BIKE, BLK, BMPR1A, BMPR1A ps1, BMPR1Aps2, BMPR1B, BMPR2, BMX, BRAF, BRAFps, BRK, BRSK1, BRSK2, BTK, BUB1, BUBR1, CaMK1a, CaMK1b, CaMK1d, CaMK1 g, CaMK2a, CaMK2b, CaMK2d, CaMK2g, CaMK4, CaMKK1, CaMKK2, caMLCK, CASK, CCK4, CCRK, CDC2, CDC7, CDK10, CDK11, CDK2, C DK3, CDK4, CDK4ps, CDK5, CDK5ps, CDK6, CDK7, CDK7ps, CDK8, CDK8ps, CDK9, CDKL1, CDKL2, CDKL3, CDKL4, CDKL5, CGDps, CH ED, CHK1, CHK2, CHK2ps1, CHK2ps2, CK1a, CK1a2, CK1aps1, CK1aps2, CK1aps3, CK1d, CK1e, CK1g1, CK1g2, CK1g2ps, CK1g3, CK2a1, CK2a1-rs, CK2a2, CLIK1, CLIK1L, CLK1, CLK2, CLK2ps, CLK3, CLK3ps, CLK4, COT, CRIK, CRK7, CSK, CTK, CYGD, CYGF, DAPK1, DAPK2, DAPK3, DCAMKL1, DCAMKL2, DCAMKL3, DDR1, DDR2, DLK, DMPK1, DMPK2, DRAK1, DRAK2, DYRK1A, DYRK1B, DYRK2,DYRK3、DYRK4、EGFR、EphA1、EphA10、EphA2、EphA3、EphA4、EphA5、EphA6、EphA7、EphA8、EphB1、EphB2、EphB3、EphB4、EphB6、Erk1、Erk2、Erk3、Eph3 Erk3ps2、Erk3ps3、Erk3ps4、Erk4、Erk5、Erk7、FAK、FER、FERps、FES、FGFR1、FGFR2、FGFR3、FGFR4、FGR、FLT1、FLT1ps、FLT3、FLT4、FMS、FRK、Fused、FYN、 GAK、GCK、GCN2、GCN22、GPRK4、GPRK5、GPRK6、GPRK6ps、GPRK7、GSK3A、GSK3B、Haspin、HCK、HER2 / ErbB2、HER3 / ErbB3、HER4 / ErbB4、HH498、HIPK1、HIPK2 HIPK3、HIPK4、HPK1、HRI、HRIps、HSER、HUNK、ICK、IGF1R、IKKa、IKKb、IKKe、ILK、INSR、IRAK1、IRAK2、IRAK3、IRAK4、IRE1、IRE2、IRR、ITK、JAK1、JAK2、JA K3、JNK1、JNK2、JNK3、KDR、KHS1、KHS2、KIS、KIT、KSGCps、KSR1、KSR2、LATS1、LATS2、LCK、LIMK1、LIMK2、LIMK2ps、LKB1、LMR1、LMR2、LMR3、LOK、LRRK1、LR RK2、LTK、LYN、LZK、MAK、MAP2K1、MAP2K1ps、MAP2K2、MAP2K2ps、MAP2K3、MAP2K4、MAP2K5、MAP2K6、MAP2K7、MAP3K1、MAP3K2、MAP3K3、MAP3K4、MAP3K5、MAP 3K6、MAP3K7、MAP3K8、MAPKAPK2、MAPKAPK3、MAPKAPK5、MAPKAPKps1、MARK1、MARK2、MARK3、MARK4、MARKps01、MARKps02、MARKps03、MARKps04、MARKps05、 MARKps07、MARKps08、MARKps09、MARKps10、MARKps11、MARKps12、MARKps13、MARKps15、MARKps16、MARKps17、MARKps18、MARKps19、MARKps20、MARKps21、MARKps22、MARKps23、MARKps24、MARKps25、MARKps26、MARKps27、MARKps28 MARKps29、MARKps30、MAST1、MAST2、MAST3、MAST4、MASTL、MELK、MER、MET、 MISR2、MLK1、MLK2、MLK3、MLK4、MLKL、MNK1、MNK1ps、MNK2、MOK、MOS、MPSK1、 MPSK1ps、MRCKa、MRCKb、MRCKps、MSK1、MSK12、MSK2、MSK22、MSSK1、MST1、MST 2、MST3、MST3ps、MST4、MUSK、MYO3A、MYO3B、MYT1、NDR1、NDR2、NEK1、NEK10、 NEK11、NEK2、NEK2ps1、NEK2ps2、NEK2ps3、NEK3、NEK4、NEK4ps、NEK5、NEK6、 NEK7、NEK8、NEK9、NIK、NIM1、NLK、NRBP1、NRBP2、NuaK1、NuaK2、Obscn、Obsc n2、OSR1、p38a、p38b、p38d、p38g、p70S6K、p70S6Kb、p70S6Kps1、p70S6Kps2、 PAK1、PAK2、PAK2ps、PAK3、PAK4、PAK5、PAK6、PAKK、PBK、PCTAIRE1、PCTAIRE 2、PCTAIRE3、PDGFRa、PDGFRb、PDK1、PEK、PFTAIRE1、PFTAIRE2、PHKg1、PHKg 1ps1、PHKg1ps2、PHKg1ps3、PHKg2、PIK3R4、PIM1、PIM2、PIM3、PINK1、PITSL RE、PKACa、PKACb、PKACg、PKCa、PKCb、PKCd、PKCe、PKCg、PKCh、PKCi、PKCips、 PKCt、PKCz、PKD1、PKD2、PKD3、PKG1、PKG2、PKN1、PKN2、PKN3、PKR、PLK1、PLK 1ps1、PLK1ps2、PLK2、PLK3、PLK4、PRKX、PRKXps、PRKY、PRP4、PRP4ps、PRPK、 PSKH1、PSKH1ps、PSKH2、PYK2、QIK、QSK、RAF1、RAF1ps、RET、RHOK、RIPK1、RI PK2、RIPK3、RNAseL、ROCK1、ROCK2、RON、ROR1、ROR2、ROS、RSK1、RSK12、RSK2、RSK22, RSK3, RSK32, RSK4, RSK42, RSKL1, RSKL2, RYK, RYKps, SAKps, SBK, SCYL1, SCYL2, SCYL2ps, SCYL3, SGK, SgK050ps. SgK069, SgK071, SgK085, SgK110, SgK196, SGK2, SgK223, Sg K269, SgK288, SGK3, SgK307, SgK384ps, SgK396, SgK424, SgK 493, SgK494, SgK495, SgK496, SIK(free,SIK1), SIK, skMLCK. SLK, Slob, smMLCK, SNRK, SPEG, SPEG2, SRC, SRM, SRPK1, SRPK 2, SRPK2ps, SSTK, STK33, STK33ps, STLK3, STLK5, STLK6, STLK6ps1, STLK6-rs, SuRTK106, SYK, TAK1, TAO1, TAO2, TAO3, TB CK, TBK1, TEC, TESK1, TSK2, TGFbR1, TGFbR2, TIE1, TIE2, TLK1, TLK1ps, TLK2, TLK2ps1, TLK2ps2, TNK1, Trad, Trb1, Trb 2, Trb3, Trio, TRKA, TRKB, TRKC, TSSK1, TSSK2, TSSK3, TSSK4, TSSKps1, TSSKps2, TTBK1, TTBK2, TTK, TTN, TXK, TYK2, TYK2 2, TYRO3, TYRO3ps, ULK1, ULK2, ULK3, ULK4, VACAMKL, VRK1, VRK2, VRK3, VRK3ps, Wee1, Wee1B, Wee1Bps, Wee1ps1, Wee1ps 2, Wnk1, Wnk2, Wnk3, Wnk4, YANK1, YANK2, YANK3, YES, YESps. YSK1, ZAK, ZAP70, ZC1 / HGK, ZC2 / TNIK, ZC3 / MINK, and ZC4 / NRK.
[0103] The term "Src family kinase" refers to a family of non-receptor tyrosine protein kinases that includes the following nine members: the SrcA subfamily, including c-Src (proto-oncogene tyrosine protein kinase Src), YES (proto-oncogene tyrosine protein kinase YES), FYN (proto-oncogene tyrosine protein kinase FYN) and FGR (Gardner-Rasheed feline sarcoma virus (v-FGR) oncogene homolog); the SrcB subfamily, including LCK (lymphocyte-specific protein tyrosine kinase), HCK (tyrosine protein kinase HCK, hematopoietic cell kinase), BLK (tyrosine protein kinase BLK) and LYN (tyrosine protein kinase LYN); and FRK (Fyn-related kinase).
[0104] The term "CDK" refers to cyclin-dependent kinases. CDK binds to cyclin (e.g., cyclin H), which is a regulatory protein. CDK phosphorylates its substrate at serine and threonine. The consensus sequence of the phosphorylation site in the amino acid sequence of the CDK substrate is [S / T*]PX[K / R] (SEQ ID NO: 1), wherein S / T* is phosphorylated serine or threonine, P is proline, X is any amino acid, K is lysine, and R is arginine. CDK includes CDK1, CDK2, CDK3, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, CDK10, CDK11, CDK12, CDK13, CDK14, CDK15, CDK16, CDK17, CDK18, CDK19, and CDK20.
[0105] "CDK7" or "cyclin-dependent kinase 7" is a CDK wherein the substrate is Cyclin H, MAT1 (e.g., MNAT1), or Cyclin H and MAT1. CDK7 is alternatively referred to as CAK1, HCAK, MO15, STK1, CDKN7, and p39MO15. Non-limiting examples of nucleotide and protein sequences of human CDK7 are described in GenBank Accession No. NP_001790, which is incorporated herein by reference. The amino acid sequence of this CDK7 is as follows:
[0106] MALDVKSRAKRYEKLDFLGEGQFATVYKARDKNTNQIVAIKKIKLGHRSEAKDGINRTALREIKLLQELSHPNIIGLLDAFGHKSNISLVFDFMETDLEVIIKDNSLVLTPSHIKAYMLMTLQGLEYLHQHWILHRDLKPNNLLLDENGVLKLADFGLAKSFGSPNRAYTHQVVT RWYRAPELLFGARMYGVGVDMWAVGCILAELLLRVPFLPGDSDLDQLTRIFETLGTPTEEQWPDMCSLPDYVTFKSFPGIPLHHIFSAAGDDLLDLIQGLFLFNPCARITATQALKMKYFSNRPGPTPGCQLPRPNCPVETLKEQSNPALAIKRKRTEALEQGGLPKKLIF(SEQ ID NO:2). BRIEF DESCRIPTION OF THE DRAWINGS
[0107] The accompanying drawings, which are incorporated in and constitute a part of this specification, illustrate several embodiments of the present disclosure and, together with the description, serve to explain the principles of the present disclosure.
[0108] Figure 1 Exemplary results of pull down assays of compounds 205, 200 and 207 at 1 and 2.5 μM are shown. Experimental details are described elsewhere. Immunoblotting with cyclin H identified CDK7-cyclin H complexes (CDK7), while immunoblotting with cyclin K identified CDK12-cyclin K and CDK13-cyclin K complexes.
[0109] Figure 2 Exemplary results of pull-down experiments are shown for compounds 200, 201 and 206 at 1 and 2.5 μM. Experimental details are described elsewhere. Immunoblotting with cyclin H identified CDK7-cyclin H complexes (CDK7), while immunoblotting with cyclin K identified CDK12-cyclin K and CDK13-cyclin K complexes.
[0110] Figure 3Exemplary results of pull-down experiments with compounds 202 and 203 at 1 μM are shown. Experimental details are described elsewhere. Immunoblotting with cyclin H identified CDK7-cyclin H complexes (CDK7), while immunoblotting with cyclin K identified CDK12-cyclin K and CDK13-cyclin K complexes.
[0111] Figure 4 Exemplary results of pull-down experiments at 1 μM for compounds 200 and 204 are shown. Experimental details are described elsewhere. Immunoblotting with cyclin H identified CDK7-cyclin H complexes (CDK7), while immunoblotting with cyclin K identified CDK12-cyclin K and CDK13-cyclin K complexes.
[0112] Figure 5 Exemplary results of pull-down experiments with compounds 207, 208 and 209 at 1 and 2.5 μM are shown. Experimental details are described elsewhere. Immunoblotting with cyclin H identified CDK7-cyclin H complexes (CDK7), while immunoblotting with cyclin K identified CDK12-cyclin K and CDK13-cyclin K complexes.
[0113] Figure 6 Exemplary results of pull-down experiments with compounds 065 and 079 at 1 μM are shown. Experimental details are described elsewhere. Immunoblotting with cyclin H identified CDK7-cyclin H complexes (CDK7), while immunoblotting with cyclin K identified CDK12-cyclin K and CDK13-cyclin K complexes. DETAILED DESCRIPTION
[0114] Kinases are implicated in a range of diseases. Specifically, CDKs are key regulators of the cell cycle. Their sequential activation and inactivation drives the cycle forward. The activity of CDKs is regulated by multiple mechanisms, such as positive and negative phosphorylation, binding to regulatory proteins such as cyclins, and CDK inhibitors. CDK7 plays an important role in the regulation of RNA polymerase II-mediated transcription of protein-coding genes. Disruption of CDK7 signaling may lead to transcriptional defects. The lack of selective inhibitors for CDK7 has hampered studies of the transcriptional and functional consequences of acute and long-term inhibition of CDK7 activity under normal and pathological conditions.
[0115] The present disclosure provides, in one aspect, compounds of formula (I) and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, cocrystals, tautomers, stereoisomers, isotope-labeled derivatives or prodrugs thereof. The compounds of the present disclosure can inhibit the activity of kinases. In certain embodiments, the kinase is CDK. In certain embodiments, the kinase is CDK7. In certain embodiments, the kinase is CDK2, CDK9 or CDK12. The compounds of the present disclosure can selectively inhibit the activity of a certain kinase (e.g., CDK7) relative to other kinases (e.g., CDK2, CDK9, CDK12). Pharmaceutical compositions, kits, methods of use and uses relating to the compounds of the present disclosure are also provided. The compounds, pharmaceutical compositions, kits, methods of use and uses of the present disclosure can be used to inhibit kinase activity, inhibit cell growth and / or induce apoptosis. The compounds, pharmaceutical compositions, kits, methods of use and uses of the present disclosure can also be used to treat diseases and / or prevent diseases. In certain embodiments, the disease is a proliferative disease (eg, cancer, benign neoplasms, pathological angiogenesis, inflammatory disease, autoinflammatory disease, autoimmune disease) or cystic fibrosis.
[0116] Compound
[0117] In one aspect, the present disclosure provides compounds of formula (I):
[0118]
[0119] or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, cocrystal, tautomer, stereoisomer, isotope-labeled derivative or prodrug thereof, wherein:
[0120] Ring A is a carbocyclyl, heterocyclyl, aryl or heteroaryl group;
[0121] R 1 For the formula:
[0122]
[0123]
[0124] in:
[0125] L 3 is a bond or substituted or unsubstituted C 1-4 A hydrocarbon chain, optionally wherein one or more carbon units of the hydrocarbon chain are independently -C=O-, -O-, -S-, -NR L3a -、-NR L3a C(=O)-, -C(=O)NR L3a -, -SC(=O)-, -C(=O)S-, -OC(=O)-, -C(=O)O-, -NRL3a C(=S)-、-C(=S)NR L3a -、Anti-CR L3b =CR L3b -、Shun-CR L3b =CR L3b -, -C℃-, -S(=O)-, -S(=O)O-, -OS(=O)-, -S(=O)NR L3a -、-NR L3a S(=O)-, -S(=O)2-, -S(=O)2O-, -OS(=O)2-, -S(=O)2NR L3a -or-NR L3a S(=O)2-substituted, where R L3a is hydrogen, substituted or unsubstituted acyl, substituted or unsubstituted C 1-6 alkyl or a nitrogen protecting group, and wherein R L3b Each instance of is independently hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, or two R L3b Connected to form a substituted or unsubstituted carbocyclic group or a substituted or unsubstituted heterocyclic group;
[0126] L 4 is a bond or a substituted or unsubstituted branched or unbranched C 1-6 hydrocarbon chain;
[0127] R E1 , R E2 and R E3 Each of the above is independently hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -CN, -CH2OR EE 、-CH2N(R EE )2, -CH2SR EE 、-OR EE 、-N(R EE )2、-Si(R EE )3 or -SR EE , where R EE Each instance of is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, or two R EE Connected to form a substituted or unsubstituted heterocyclic group;
[0128] or R E1 and R E3 , or R E2 and R E3 , or R E1 and R E2 Connected to form a substituted or unsubstituted carbocyclic group or a substituted or unsubstituted heterocyclic group;
[0129] R E4 is a leaving group;
[0130] R E5 It is a halogen;
[0131] R E6 is hydrogen, substituted or unsubstituted C 1-6 Alkyl or nitrogen protecting groups;
[0132] Each instance of Y is independently O, S or NR E7 , where R E7 is hydrogen, substituted or unsubstituted C 1-6 Alkyl or nitrogen protecting groups;
[0133] a is 1 or 2; and
[0134] Each instance of z is independently 0, 1, 2, 3, 4, 5 or 6, as valency permits;
[0135] m is 0 or 1;
[0136] R 2 Each instance of is independently halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -OR a , –N(R a 2. –SR a , –CN, –SCN, –C(=NR a )R a , –C(=NR a )OR a , –C(=NR a )N(R a )2. –C(=O)R a 、–C(=O)OR a , –C(=O)N(R a )2, –NO2, –NR a C(=O)R a ,–NR a C(=O)OR a ,–NR a C(=O)N(R a)2. –OC(=O)R a 、–OC(=O)OR a or –OC(=O)N(R a )2;
[0137] n is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11, as long as the valence permits;
[0138] L is a single bond or -C(=O)-;
[0139] R 3 is hydrogen, substituted or unsubstituted acyl, substituted or unsubstituted alkyl, or a nitrogen protecting group;
[0140] R 4 is hydrogen, substituted or unsubstituted acyl, substituted or unsubstituted alkyl, or a nitrogen protecting group;
[0141] R 5a and R 5b Each of the above is independently hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -OR a , –N(R a 2. –SR a , –CN, –SCN, –C(=NR a )R a , –C(=NR a )OR a , –C(=NR a )N(R a )2. –C(=O)R a 、–C(=O)OR a , –C(=O)N(R a )2, –NO2, –NR a C(=O)R a ,–NR a C(=O)OR a ,–NR a C(=O)N(R a )2. –OC(=O)R a 、–OC(=O)OR a or –OC(=O)N(R a )2, or R 5a and R 5b Connected to form a substituted or unsubstituted carbocyclic group or a substituted or unsubstituted heterocyclic group;
[0142] R 6 and R 7Each instance of is independently hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -OR a , –N(R a 2. –SR a , –CN, –SCN, –C(=NR a )R a , –C(=NR a )OR a , –C(=NR a )N(R a )2. –C(=O)R a 、–C(=O)OR a , –C(=O)N(R a )2, –NO2, –NR a C(=O)R a ,–NR a C(=O)OR a ,–NR a C(=O)N(R a )2. –OC(=O)R a 、–OC(=O)OR a or –OC(=O)N(R a )2, or R 6 and R 7 Connected to form a substituted or unsubstituted carbocyclic group or a substituted or unsubstituted heterocyclic group;
[0143] R 8 is hydrogen, substituted or unsubstituted acyl, substituted or unsubstituted alkyl, or a nitrogen protecting group;
[0144] R 9 and R 10 Each instance of is independently hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -OR a , –N(R a 2. –SR a , –CN, –SCN, –C(=NR a )R a , –C(=NR a )OR a , –C(=NR a )N(R a )2. –C(=O)R a 、–C(=O)ORa , –C(=O)N(R a )2, –NO2, –NR a C(=O)R a ,–NR a C(=O)OR a ,–NR a C(=O)N(R a )2. –OC(=O)R a 、–OC(=O)OR a or –OC(=O)N(R a )2, or R 9 and R 10 Connected to form a substituted or unsubstituted carbocyclic group or a substituted or unsubstituted heterocyclic group;
[0145] p is 0, 1, 2, 3 or 4;
[0146] Ring D is a carbocyclic group or a heterocyclic group;
[0147] R 11 Each instance of is independently halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted aryl, substituted or unsubstituted heteroaryl, -OR a , –N(R a 2. –SR a , –CN, –SCN, –C(=NR a )R a , –C(=NR a )OR a , –C(=NR a )N(R a )2. –C(=O)R a 、–C(=O)OR a , –C(=O)N(R a )2, –NO2, –NR a C(=O)R a ,–NR a C(=O)OR a ,–NR a C(=O)N(R a )2. –OC(=O)R a 、–OC(=O)OR a 、–OC(=O)N(R a )2, or a nitrogen protecting group attached to a nitrogen atom;
[0148] q is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11, as valency permits; and
[0149] R a Each instance of is independently hydrogen, substituted or unsubstituted acyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, a nitrogen protecting group attached to a nitrogen atom, an oxygen protecting group attached to an oxygen atom, or a sulfur protecting group attached to a sulfur atom, or R a Two instances of are linked to form a substituted or unsubstituted heterocyclyl or a substituted or unsubstituted heteroaryl;
[0150] The prerequisite is that the compound is not of the following formula:
[0151]
[0152] Formula (I) includes the ring In certain embodiments, ring A is a carbocyclyl. In certain embodiments, ring A is a 3-7 membered monocyclic carbocyclyl containing 0, 1 or 2 double bonds in a carbocyclic ring system, as long as valence permits. In certain embodiments, ring A is a 5-13 membered bicyclic carbocyclyl containing 0, 1, 2 or 3 double bonds in a carbocyclic ring system, as long as valence permits. In certain embodiments, ring A is a cyclopropyl, cyclopentyl, cyclohexyl or cycloheptyl. In certain embodiments, ring A is a cyclobutyl. In certain embodiments, ring A is not a cyclobutyl.
[0153] In certain embodiments, ring A is a heterocyclyl. In certain embodiments, ring A is a 3-7 membered monocyclic heterocyclyl. In certain embodiments, ring A is an oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl, or piperazinyl. In certain embodiments, ring A is a 5-13 membered bicyclic heterocyclyl. In certain embodiments, ring A is a heterocyclyl, wherein the heteroatoms in the heterocyclic ring system are oxygen and / or nitrogen. In certain embodiments, ring A is a heterocyclyl, wherein the heteroatoms in the heterocyclic ring system are oxygen. In certain embodiments, ring A is a heterocyclyl, wherein the heteroatoms in the heterocyclic ring system are nitrogen.
[0154] In certain embodiments, Ring A is aryl. In certain embodiments, Ring A is phenyl. In certain embodiments, Ring A is naphthyl.
[0155] In certain embodiments, Ring A is a heteroaryl. In certain embodiments, Ring A is a 5-membered or 6-membered monocyclic heteroaryl. In certain embodiments, Ring A is furanyl, thienyl, pyrrolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, or isothiazolyl. In certain embodiments, Ring A is pyridinyl. In certain embodiments, Ring A is wherein the point of attachment is connected to L. In certain embodiments, Ring A is wherein the point of attachment is connected to L. In certain embodiments, Ring A is pyrimidinyl. In certain embodiments, Ring A is wherein the point of attachment is connected to L. In certain embodiments, Ring A is wherein the point of attachment is connected to L. In certain embodiments, Ring A is wherein the point of attachment is connected to L. In certain embodiments, ring A is pyrazinyl or pyridazinyl. In certain embodiments, ring A is a 9-membered or 10-membered bicyclic (e.g., 5,6-fused, 6,5-fused, or 6,6-fused) heteroaryl. In certain embodiments, when ring A is a 9-membered or 10-membered bicyclic heteroaryl, the monocyclic ring connected to L is a monocyclic heteroaryl. In certain embodiments, when ring A is a 9-membered or 10-membered bicyclic heteroaryl, the monocyclic ring connected to L is a phenyl. In certain embodiments, ring A is benzofuranyl, aza-benzofuranyl, diaza-benzofuranyl, benzothiophenyl, aza-benzothiophenyl, diaza-benzothiophenyl, indolyl, aza-indolyl, diaza-indolyl, isoindolyl, aza-isoindolyl, diaza-isoindolyl, benzoxazolyl, aza-benzoxazolyl, diaza-benzoxazolyl, benzothiazolyl, aza-benzothiazolyl, diaza-benzothiazolyl, benzimidazolyl, aza-benzimidazolyl, or diaza-benzimidazolyl. In certain embodiments, ring A is thieno[2,3-d]pyrimidinyl or thieno[3,2-d]pyrimidinyl. In certain embodiments, ring A is wherein the point of attachment is connected to L. In certain embodiments, Ring A is wherein the point of attachment is connected to L. In certain embodiments, Ring A is isoquinolinyl. In certain embodiments, Ring A is wherein the point of attachment is attached to L. In certain embodiments, Ring A is aza-isoquinolyl, diaza-isoquinolyl, quinolyl, aza-quinolyl, or diaza-quinolyl.
[0156] Ring A may include a substituent R 1 In certain embodiments, yes (For example, ). In certain embodiments, yes (For example, ). In certain embodiments, yes In certain embodiments, yes (For example, ). In certain embodiments, yes (For example, ). In certain embodiments, yes (For example, ), (For example, ), (For example, ),or (For example, ). In certain embodiments, yes (For example, ). In certain embodiments, yes (For example, ), (For example, ), (For example, ), (For example, ),or (For example, ). In certain embodiments, yes In certain embodiments, yes (For example, ). In certain embodiments, yes (For example, ). In certain embodiments, yes (For example, ). In certain embodiments, yes (For example, ). In certain embodiments, yes (For example, ), (For example, ), (For example, ), (For example, ),or (For example, ). In certain embodiments, yes (For example, ), (For example, ),or (For example, ).
[0157] In certain embodiments, yes In certain embodiments, yes (For example, ). In certain embodiments, yes In certain embodiments, yes (For example, ), (For example, ),or (For example, ). In certain embodiments, yes In certain embodiments, yes (For example, ). In certain embodiments, yes In certain embodiments, yes (For example, ). In certain embodiments, yes (For example, ). In certain embodiments, yes (For example, ), (For example, ), (For example, ),or (For example, ).
[0158] In certain embodiments, R 1 In certain embodiments, R 1 In some embodiments, the electrophilic part or the Michael acceptor part reacts with the cysteine residue of the kinase (e.g., CDK (e.g., CDK7)). In some embodiments, the electrophilic part or the Michael acceptor part can react with the residue Cys312 of CDK7. In some embodiments, the compounds of the present disclosure can covalently or irreversibly bind to kinases. In some embodiments, the compounds of the present disclosure can covalently or irreversibly bind to CDK7. In some embodiments, the compounds of the present disclosure can non-covalently or reversibly bind to kinases. The non-covalent or reversible binding to kinases can involve non-covalent interactions (e.g., electrostatic interactions, hydrophobic interactions, hydrogen bonds, van der Waals interactions, π-p stacking, or a combination thereof).
[0159] In certain embodiments, R 1 Formula (i-1): In certain embodiments, R 1 For the formula: and m is 1. In certain embodiments, R 1 Formula (i-2): In certain embodiments, R 1 Formula (i-3): In certain embodiments, R 1 Formula (i-4): In certain embodiments, R 1 Formula (i-5): In certain embodiments, R 1 Formula (i-6): In certain embodiments, R 1 Formula (i-7): In certain embodiments, R 1 Formula (i-8): In certain embodiments, R 1 Formula (i-9): In certain embodiments, R 1 Formula (i-10): In certain embodiments, R 1 Formula (i-11): In certain embodiments, R 1 Formula (i-12): In certain embodiments, R 1 Formula (i-13): In certain embodiments, R 1 Formula (i-14): In certain embodiments, R 1 Formula (i-15): In certain embodiments, R 1 Formula (i-16): In certain embodiments, R 1 Formula (i-17): In certain embodiments, R 1 Formula (i-18): In certain embodiments, R 1 Formula (i-19): In certain embodiments, R 1 Formula (i-20): In certain embodiments, R 1Formula (i-21): In certain embodiments, R 1 Formula (i-22): In certain embodiments, R 1 Formula (i-23): In certain embodiments, R 1 Formula (i-24): In certain embodiments, R 1 Formula (i-25): In certain embodiments, R 1 Formula (i-26): In certain embodiments, R 1 Formula (i-27): In certain embodiments, R 1 Formula (i-28): In certain embodiments, R 1 Formula (i-29): In certain embodiments, R 1 Formula (i-30): In certain embodiments, R 1 Formula (i-31): In certain embodiments, R 1 Formula (i-32): In certain embodiments, R 1 Formula (i-33): In certain embodiments, R 1 Formula (i-34): In certain embodiments, R 1 Formula (i-35): In certain embodiments, R 1 Formula (i-36): In certain embodiments, R 1 Formula (i-37): In certain embodiments, R 1 Formula (i-38): In certain embodiments, R 1 Formula (i-39): In certain embodiments, R 1 Formula (i-40): In certain embodiments, R 1 Formula (i-41): In certain embodiments, R 1 Formula (i-42): In certain embodiments, R 1 Formula (i-1a): In certain embodiments, R 1 Formula (i-1b): In certain embodiments, R 1 Formula (i-1c): In certain embodiments, R 1 Formula (i-1d): In certain embodiments, R 1 Formula (i-1e): In certain embodiments, R 1 Formula (i-1f): In certain embodiments, R 1 Formula (i-1g): In certain embodiments, R 1 yes In certain embodiments, R 1 yes In certain embodiments, R 1 yes In certain embodiments, R 1 Formula (i-1g): (For example, In certain embodiments, R 1 yes In certain embodiments, R 1 yes In certain embodiments, R 1 yes (For example, In certain embodiments, R 1 yes (For example, In certain embodiments, R 1 For the formula: and m is 1. In certain embodiments, R 1 For the formula: In certain embodiments, R 1 For the formula: (For example, In certain embodiments, R 1 For the formula: (For example, In certain embodiments, R 1 For the formula: (For example, In certain embodiments, R 1Not any of the formulas (i-35) to (i-42).
[0160] In certain embodiments, L 3 Yes key. 3 is an optionally substituted C 1-4 In certain embodiments, L 3 is an optionally substituted C 1-4 In certain embodiments, L 3 is unsubstituted C 1-4 In certain embodiments, L 3 is an optionally substituted C 2-4 In certain embodiments, L 3 is an optionally substituted C 2-4 In certain embodiments, L 3 is an optionally substituted C 1-4 A hydrocarbon chain, wherein one or more carbon units of the hydrocarbon chain are independently replaced by -C(=O)-, -O-, -S-, -NR L3a -、-NR L3a C(=O)-, -C(=O)NR L3a -, -SC(=O)-, -C(=O)S-, -OC(=O)-, -C(=O)O-, -NR L3a C(=S)-、-C(=S)NR L3a -, trans-CR L3b =CR L3b -、cis-CR L3b =CR L3b -, -C℃-, -S(=O)-, -S(=O)O-, -OS(=O)-, -S(=O)NR L3a -、-NR L3a S(=O)-, -S(=O)2-, -S(=O)2O-, -OS(=O)2-, -S(=O)2NR L3a -or-NR L3a In certain embodiments, L 3 is an optionally substituted C 1-4 A hydrocarbon chain wherein one carbon unit of the hydrocarbon chain is replaced by -NR L3a - (e.g., -NH-) substitution. In certain embodiments, L 3 Formula: -(CH2) 1-4 -NR L3a -(e.g., -(CH2) 1-4 -NH-) or -NR L3a -CH2) 1-4- (e.g., -NH-CH2) 1-4 -). In certain embodiments, L 3 For-NR L3a -. In certain embodiments, L 3 For-NR L3a (C=O)-. In certain embodiments, L 3 -(C=O)NR L3a -. In certain embodiments, L 3 In certain embodiments, L 3 In certain embodiments, L 3 is -NH(C=O)-. In certain embodiments, L 3 is -(C=O)NH-. In certain embodiments, L 3 In certain embodiments, L 3 For -S-.
[0161] In certain embodiments, R L3a is hydrogen. In certain embodiments, R L3a is a substituted or unsubstituted acyl group (e.g., -C(=O)R a 、–C(=O)OR a , –C(=O)N(R a )2). In certain embodiments, R L3a is an optionally substituted C 1-6 In certain embodiments, R L3a is a nitrogen protecting group (eg, Bn, BOC, Cbz, Fmoc, trifluoroacetyl, triphenylmethyl, acetyl, Ts).
[0162] When formula (I) includes two or more instances of a moiety, unless otherwise specified, any two instances of the moiety may be the same or different from each other.
[0163] In certain embodiments, R L3b At least one example of is hydrogen. In certain embodiments, R L3b Each instance of is hydrogen. In certain embodiments, R L3b At least one example of is -Cl, -Br or -I. In certain embodiments, R L3b Each instance of is -Cl, -Br or -I. In certain embodiments, R L3b At least one example of is -F. In certain embodiments, R L3b Each instance of is -F. In certain embodiments, R L3bAt least one example of is optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl. In certain embodiments, R L3b At least one example of is optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl. In certain embodiments, two R L3b The groups are linked to form an optionally substituted carbocyclic ring. L3b The groups are linked to form an optionally substituted heterocyclic ring.
[0164] In certain embodiments, L 4 In certain embodiments, L 4 is an optionally substituted C 1-6 In certain embodiments, L 4 is an optionally substituted C 1-3 In certain embodiments, L 4 is -CH2-. In certain embodiments, L 4 is -(CH2)2-. In certain embodiments, L 4 It is –(CH2)3–.
[0165] In certain embodiments, R E1 is hydrogen. In certain embodiments, R E1 is -Cl, -Br or -I. In certain embodiments, R E1 In certain embodiments, R E1 is an optionally substituted alkyl group (e.g., a substituted or unsubstituted C 1-6 In certain embodiments, R E1 is optionally substituted alkenyl or optionally substituted alkynyl. In certain embodiments, R E1 is an optionally substituted carbocyclyl, an optionally substituted heterocyclyl, an optionally substituted aryl, or an optionally substituted heteroaryl. In certain embodiments, R E1 -CN, -CH2OR EE 、-CH2N(R EE )2, -CH2SR EE 、-OR EE 、-N(R EE )2、-Si(R EE )3 or -SR EE In certain embodiments, R E1 Yes -CH2N(R EE )2. In certain embodiments, R E1 is -CH2N(optionally substituted alkyl)2 (e.g., -CH2N(CH3)2). In certain embodiments, R E1 In certain embodiments, RE1 Not –OH, –SH, –NHR EE Or -NH2.
[0166] In certain embodiments, R E2 is hydrogen. In certain embodiments, R E2 is -Cl, -Br or -I. In certain embodiments, R E2 In certain embodiments, R E2 is an optionally substituted alkyl group (e.g., a substituted or unsubstituted C 1-6 In certain embodiments, R E2 is optionally substituted alkenyl or optionally substituted alkynyl. In certain embodiments, R E2 is an optionally substituted carbocyclyl, an optionally substituted heterocyclyl, an optionally substituted aryl, or an optionally substituted heteroaryl. In certain embodiments, R E2 -CN, -CH2OR EE 、-CH2N(R EE )2, -CH2SR EE 、-OR EE 、-N(R EE )2、-Si(R EE )3 or -SR EE In certain embodiments, R E2 Yes -CH2N(R EE )2. In certain embodiments, R E2 is -CH2N(optionally substituted alkyl)2 (e.g., -CH2N(CH3)2). In certain embodiments, R E2 In certain embodiments, R E2 Not –OH, –SH, –NHR EE Or -NH2.
[0167] In certain embodiments, R E3 is hydrogen. In certain embodiments, R E3 is -Cl, -Br or -I. In certain embodiments, R E3 In certain embodiments, R E3 is an optionally substituted alkyl group (e.g., a substituted or unsubstituted C 1-6 In certain embodiments, R E3 is optionally substituted alkenyl or optionally substituted alkynyl. In certain embodiments, R E3 is an optionally substituted carbocyclyl, an optionally substituted heterocyclyl, an optionally substituted aryl, or an optionally substituted heteroaryl. In certain embodiments, R E3 -CN, -CH2OR EE 、-CH2N(REE )2, -CH2SR EE 、-OR EE 、-N(R EE )2、-Si(R EE )3 or -SR EE In certain embodiments, R E3 Yes -CH2N(R EE )2. In certain embodiments, R E3 is -CH2N(optionally substituted alkyl)2 (e.g., -CH2N(CH3)2). In certain embodiments, R E3 In certain embodiments, R E3 Not –OH, –SH, –NHR EE Or -NH2.
[0168] In certain embodiments, R E1 and R E3 are connected to form an optionally substituted carbocyclic ring. E1 and R E3 In certain embodiments, R E2 and R E3 are connected to form an optionally substituted carbocyclic ring. E2 and R E3 In certain embodiments, R E1 and R E2 are connected to form an optionally substituted carbocyclic ring. E1 and R E2 Joining to form an optionally substituted heterocyclic ring.
[0169] In certain embodiments, R EE At least one example of is hydrogen. In certain embodiments, R EE Each instance of is hydrogen. In certain embodiments, R EE Each instance of is not hydrogen. In certain embodiments, R EE At least one example is an optionally substituted alkyl group (eg, a substituted or unsubstituted C 1-6 In certain embodiments, R EE At least one instance of unsubstituted C 1-3 In certain embodiments, R EE Each instance of is optionally substituted alkyl. EE Each instance of is unsubstituted C 1-3 In certain embodiments, R EEAt least one example of is optionally substituted alkenyl or optionally substituted alkynyl. In certain embodiments, R EE At least one example of is optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl. In certain embodiments, two R EE In certain embodiments, R EE Each instance of is independently hydrogen or substituted or unsubstituted alkyl, or two R EE are connected to form a substituted or unsubstituted heterocyclic group; and m is 1.
[0170] In certain embodiments, R E4 is -Cl, -Br or -I. In certain embodiments, R E4 In certain embodiments, R E4 Yes-OS(=O)R E4a or -OS(=O)2R E4a , where R E4a is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl. In certain embodiments, R E4 Yes-OR E4a In certain embodiments, R E4 is -OMS, -OTf, -OTs, -OBs or 2-nitrobenzenesulfonyloxy. In certain embodiments, R E4 is -OMe, -OCF3 or -OPh. In certain embodiments, R E4 Yes-OC(=O)R E4a In certain embodiments, R E4 is -OC(=O)Me, -OC(=O)CF3, -OC(=O)Ph or -OC(=O)Cl. In certain embodiments, R E4 Yes-OC(=O)OR E4a In certain embodiments, R E4 It is -OC(=O)OMe or -OC(=O)O(t-Bu).
[0171] In certain embodiments, R E5 is -Cl, -Br or -I. In certain embodiments, R E5 Yes -F.
[0172] In certain embodiments, R E6 is hydrogen. In certain embodiments, R E6is a substituted or unsubstituted C1-C6 alkyl group (eg, Me). E6 is a nitrogen protecting group (eg, Bn, BOC, Cbz, Fmoc, trifluoroacetyl, triphenylmethyl, acetyl, Ts).
[0173] In certain embodiments, a is 1. In certain embodiments, a is 2.
[0174] In certain embodiments, at least one instance of z is 0. In certain embodiments, at least one instance of z is 1. In certain embodiments, at least one instance of z is 2. In certain embodiments, at least one instance of z is 3, 4, 5, or 6.
[0175] In certain embodiments, at least one instance of Y is O. In certain embodiments, every instance of Y is O. In certain embodiments, at least one instance of Y is S. In certain embodiments, at least one instance of Y is NR E7 In certain embodiments, at least one instance of Y is NH.
[0176] In certain embodiments, R E7 is hydrogen. In certain embodiments, R E7 is a substituted or unsubstituted C1-C6 alkyl group (eg, Me). E7 is a nitrogen protecting group (eg, Bn, BOC, Cbz, Fmoc, trifluoroacetyl, triphenylmethyl, acetyl, Ts).
[0177] In certain embodiments, m is 0. In certain embodiments, m is 1.
[0178] In certain embodiments, R 2 At least one example of is halogen (e.g., F, Cl, Br, I). In certain embodiments, R 2 At least one instance of is substituted alkyl (eg, alkyl substituted with one or more halogen instances (eg, F)). In certain embodiments, R 2 In certain embodiments, R 2 At least one instance of unsubstituted C 1-6 In certain embodiments, R 2 At least one example of is Me. In certain embodiments, R 2 At least one example of is Et, Pr or Bu. In certain embodiments, R 2 At least one instance of a substituted C 1-6 In certain embodiments, R 2At least one example of is substituted methyl (e.g., -CF3, -CF2H, -CFH2). In certain embodiments, R 2 At least one example of is substituted ethyl, substituted propyl or substituted butyl. In certain embodiments, R 2 At least one example of is substituted or unsubstituted alkenyl. In certain embodiments, R 2 At least one example is a substituted or unsubstituted C 2-6 In certain embodiments, R 2 At least one example of is substituted or unsubstituted alkynyl. 2 At least one example is a substituted or unsubstituted C 2-6 In certain embodiments, R 2 At least one example of is a substituted or unsubstituted carbocyclyl (e.g., a substituted or unsubstituted 3-7 membered monocyclic carbocyclyl containing 0, 1 or 2 double bonds in the carbocyclic ring system, as long as the valence state permits). In certain embodiments, R 2 At least one example of is substituted or unsubstituted cyclopropyl, substituted or unsubstituted cyclobutyl, substituted or unsubstituted cyclopentyl, substituted or unsubstituted cyclohexyl or substituted or unsubstituted cycloheptyl. In certain embodiments, R 2 At least one example of is a substituted or unsubstituted heterocyclyl (e.g., a substituted or unsubstituted 3-7 membered monocyclic heterocyclyl). In certain embodiments, R 2 At least one example of is substituted or unsubstituted oxetanyl, substituted or unsubstituted tetrahydrofuranyl, substituted or unsubstituted tetrahydropyranyl, substituted or unsubstituted azetidinyl, substituted or unsubstituted pyrrolidinyl, substituted or unsubstituted piperidinyl, substituted or unsubstituted morpholinyl or substituted or unsubstituted piperazinyl. In certain embodiments, R 2 At least one example of is substituted or unsubstituted aryl. In certain embodiments, R 2 At least one example of is substituted or unsubstituted phenyl. In certain embodiments, R 2 At least one example of is substituted or unsubstituted naphthyl. In certain embodiments, R 2 At least one example of is substituted or unsubstituted heteroaryl. In certain embodiments, R 2 At least one example of is a substituted or unsubstituted 5-6 membered monocyclic heteroaryl. In certain embodiments, R 2At least one example of is substituted or unsubstituted furanyl, substituted or unsubstituted thienyl, substituted or unsubstituted pyrrolyl, substituted or unsubstituted imidazolyl, substituted or unsubstituted oxazolyl, substituted or unsubstituted isoxazolyl, substituted or unsubstituted thiazolyl or substituted or unsubstituted isothiazolyl. In certain embodiments, R 2 At least one example of is substituted or unsubstituted pyridyl, substituted or unsubstituted pyrazinyl, substituted or unsubstituted pyrimidinyl or substituted or unsubstituted pyridazinyl. In certain embodiments, R 2 At least one example is a substituted or unsubstituted 9-10 membered bicyclic heteroaryl. In certain embodiments, R 2 At least one instance of –OR a (e.g., -OH, -O(substituted or unsubstituted C 1-6 In certain embodiments, R 2 At least one example of is -OMe. In certain embodiments, R 2 At least one instance of –SR a (e.g., -SH, -S(substituted or unsubstituted C 1-6 In certain embodiments, R 2 At least one instance of –N(R a )2(e.g., -NH2, -NH(substituted or unsubstituted C 1-6 alkyl) (e.g., –NHMe) or -N (substituted or unsubstituted C 1-6 Alkyl)-(substituted or unsubstituted C 1-6 In certain embodiments, R 2 At least one example of is -CN or -SCN. In certain embodiments, R 2 At least one example of is -NO2. In certain embodiments, R 2 At least one instance of –C(=NR a )R a , –C(=NR a )OR a or –C(=NR a )N(R a )2. In certain embodiments, R 2 At least one instance of -C(=O)R a(eg, -C(=O)(substituted or unsubstituted alkyl) (eg, -C(=O)Me) or -C(=O)(substituted or unsubstituted phenyl)). In certain embodiments, R 2 At least one example of -C(=O)OR a (eg, -C(=O)OH, -C(=O)O(substituted or unsubstituted alkyl) (eg, -C(=O)OMe) or -C(=O)O(substituted or unsubstituted phenyl)). In certain embodiments, R 2 At least one example is -C(=O)N(R a )2 (e.g., -C(=O)NH2, -C(=O)NH(substituted or unsubstituted alkyl) (e.g., -C(=O)NHMe), -C(=O)NH(substituted or unsubstituted phenyl), -C(=O)N(substituted or unsubstituted alkyl)-(substituted or unsubstituted alkyl) or -C(=O)N(substituted or unsubstituted phenyl)-(substituted or unsubstituted alkyl)). In certain embodiments, R 2 At least one instance of –NR a C(=O)R a (e.g., –NHC(=O)(substituted or unsubstituted C 1-6 In certain embodiments, R 2 At least one instance of –NR a C(=O)OR a In certain embodiments, R 2 At least one instance of –NR a C(=O)N(R a )2 (e.g., -NHC(=O)NH2, -NHC(=O)NH (substituted or unsubstituted C 1-6 In certain embodiments, R 2 At least one example of -OC(=O)R a (eg, -OC(=O)(substituted or unsubstituted alkyl) or -OC(=O)(substituted or unsubstituted phenyl)), -OC(=O)OR a (e.g., -OC(=O)O(substituted or unsubstituted alkyl) or -OC(=O)O(substituted or unsubstituted phenyl)), or -OC(=O)N(R a)2 (e.g., -OC(=O)NH2, -OC(=O)NH(substituted or unsubstituted alkyl), -OC(=O)NH(substituted or unsubstituted phenyl), -OC(=O)N(substituted or unsubstituted alkyl)-(substituted or unsubstituted alkyl), or -OC(=O)N((substituted or unsubstituted phenyl)-(substituted or unsubstituted alkyl)).
[0179] In certain embodiments, n is 0. In certain embodiments, n is 1. In certain embodiments, n is 2. In certain embodiments, n is 3, 4, 5, or 6.
[0180] In certain embodiments, R 2 At least one example is halogen, substituted or unsubstituted alkyl, -OR a , –N(R a 2. –SR a , –CN, –SCN, –C(=NR a )R a , –C(=NR a )OR a , –C(=NR a )N(R a )2. –C(=O)R a 、–C(=O)OR a , –C(=O)N(R a )2, –NO2, –NR a C(=O)R a ,–NR a C(=O)OR a ,–NR a C(=O)N(R a )2. –OC(=O)R a 、–OC(=O)OR a or –OC(=O)N(R a )2; and n is 1 or 2, as long as the valence state permits.
[0181] In certain embodiments, L is a single bond. In certain embodiments, L is -C(=O)-.
[0182] Formula (I) includes R 3 As a substituent on a nitrogen atom. In certain embodiments, R 3 is hydrogen. In certain embodiments, R 3 is a substituted or unsubstituted acyl group (e.g., -C(=O)R a 、–C(=O)OR a , –C(=O)N(R a )2). In certain embodiments, R 3is a substituted or unsubstituted alkyl group (e.g., a substituted or unsubstituted C 1-6 In certain embodiments, R 3 is Me. In certain embodiments, R 3 is Et, Pr, Bu, substituted methyl, substituted ethyl, substituted propyl or substituted butyl. In certain embodiments, R 3 is a nitrogen protecting group (eg, Bn, BOC, Cbz, Fmoc, trifluoroacetyl, triphenylmethyl, acetyl, Ts).
[0183] Formula (I) includes the ring Ring B is a heteroaryl ring. Formula (I) also includes ring Ring B and ring C are fused to form a double ring In certain embodiments, yes (For example, ). In certain embodiments, yes (For example, In certain embodiments, when R 4 When it is hydrogen, Also includes another tautomeric form
[0184] Formula (I) includes the substituent R on the nitrogen atom of ring B 4 In certain embodiments, R 4 is hydrogen. In certain embodiments, R 4 is a substituted or unsubstituted acyl group (e.g., -C(=O)R a 、–C(=O)OR a , –C(=O)N(R a )2). In certain embodiments, R 4 is a substituted or unsubstituted alkyl group (e.g., a substituted or unsubstituted C 1-6 In certain embodiments, R 4 is Me. In certain embodiments, R 4 is Et, Pr, Bu, substituted methyl, substituted ethyl, substituted propyl or substituted butyl. In certain embodiments, R 4 is a nitrogen protecting group (eg, Bn, BOC, Cbz, Fmoc, trifluoroacetyl, triphenylmethyl, acetyl, Ts).
[0185] Formula (I) includes a substituent R on a carbon atom of ring C 5a and R 5b .
[0186] In certain embodiments, R 5ais hydrogen. In certain embodiments, R 5a is a halogen (e.g., F, Cl, Br, I). In certain embodiments, R 5a is substituted alkyl (eg, alkyl substituted with one or more halogen atoms (eg, F)). In certain embodiments, R 5a is unsubstituted alkyl. In certain embodiments, R 5a is unsubstituted C 1-6 In certain embodiments, R 5a is Me. In certain embodiments, R 5a is Et, Pr or Bu. In certain embodiments, R 5a is replaced by C 1-6 In certain embodiments, R 5a is a substituted methyl group (e.g., -CF3, -CF2H, -CFH2). In certain embodiments, R 5a is substituted ethyl, substituted propyl or substituted butyl. In certain embodiments, R 5a is a substituted or unsubstituted alkenyl. In certain embodiments, R 5a At least one example is a substituted or unsubstituted C 2-6 In certain embodiments, R 5a is a substituted or unsubstituted alkynyl. 5a is substituted or unsubstituted C 2-6 In certain embodiments, R 5a is a substituted or unsubstituted carbocyclyl (e.g., a substituted or unsubstituted 3-7 membered monocyclic carbocyclyl containing 0, 1 or 2 double bonds in the carbocyclic ring system, as long as the valence state permits). 5a is substituted or unsubstituted cyclopropyl, substituted or unsubstituted cyclobutyl, substituted or unsubstituted cyclopentyl, substituted or unsubstituted cyclohexyl or substituted or unsubstituted cycloheptyl. In certain embodiments, R 5a is a substituted or unsubstituted heterocyclyl (eg, a substituted or unsubstituted 3-7 membered monocyclic heterocyclyl). 5a is substituted or unsubstituted oxetanyl, substituted or unsubstituted tetrahydrofuranyl, substituted or unsubstituted tetrahydropyranyl, substituted or unsubstituted azetidinyl, substituted or unsubstituted pyrrolidinyl, substituted or unsubstituted piperidinyl, substituted or unsubstituted morpholinyl or substituted or unsubstituted piperazinyl. In certain embodiments, R 5a is a substituted or unsubstituted aryl group. In certain embodiments, R 5a is substituted or unsubstituted phenyl. In certain embodiments, R5a is substituted or unsubstituted naphthyl. In certain embodiments, R 5a is a substituted or unsubstituted heteroaryl. In certain embodiments, R 5a is a substituted or unsubstituted 5-6 membered monocyclic heteroaryl. 5a is substituted or unsubstituted furanyl, substituted or unsubstituted thienyl, substituted or unsubstituted pyrrolyl, substituted or unsubstituted imidazolyl, substituted or unsubstituted oxazolyl, substituted or unsubstituted isoxazolyl, substituted or unsubstituted thiazolyl or substituted or unsubstituted isothiazolyl. In certain embodiments, R 5a is substituted or unsubstituted pyridinyl, substituted or unsubstituted pyrazinyl, substituted or unsubstituted pyrimidinyl or substituted or unsubstituted pyridazinyl. In certain embodiments, R 5a is a substituted or unsubstituted 9-10 membered bicyclic heteroaryl. 5a Yes – OR a (e.g., -OH, -O(substituted or unsubstituted C 1-6 In certain embodiments, R 5a is -OMe. In certain embodiments, R 5a Yes – SR a (e.g., -SH, -S(substituted or unsubstituted C 1-6 In certain embodiments, R 5a Yes – N(R a )2(e.g., -NH2, -NH(substituted or unsubstituted C 1-6 alkyl) (e.g., –NHMe) or -N (substituted or unsubstituted C 1-6 Alkyl)-(substituted or unsubstituted C 1-6 In certain embodiments, R 5a In certain embodiments, R 5a is -NO2. In certain embodiments, R 5a Yes – C(=NR a )R a , –C(=NR a )OR a or –C(=NR a )N(R a )2. In certain embodiments, R 5aYes – C(=O)R a (eg, -C(=O)(substituted or unsubstituted alkyl) (eg, -C(=O)Me) or -C(=O)(substituted or unsubstituted phenyl)). In certain embodiments, R 5a Yes – C(=O)OR a (eg, -C(=O)OH, -C(=O)O(substituted or unsubstituted alkyl) (eg, -C(=O)OMe) or -C(=O)O(substituted or unsubstituted phenyl)). In certain embodiments, R 5a Yes – C(=O)N(R a )2 (e.g., -C(=O)NH2, -C(=O)NH(substituted or unsubstituted alkyl) (e.g., -C(=O)NHMe), -C(=O)NH(substituted or unsubstituted phenyl), -C(=O)N(substituted or unsubstituted alkyl)-(substituted or unsubstituted alkyl) or -C(=O)N(substituted or unsubstituted phenyl)-(substituted or unsubstituted alkyl)). In certain embodiments, R 5a Yes – NR a C(=O)R a (e.g., –NHC(=O)(substituted or unsubstituted C 1-6 In certain embodiments, R 5a Yes – NR a C(=O)OR a In certain embodiments, R 5a Yes – NR a C(=O)N(R a )2 (e.g., -NHC(=O)NH2, -NHC(=O)NH (substituted or unsubstituted C 1-6 In certain embodiments, R 5a Yes-OC(=O)R a (eg, -OC(=O)(substituted or unsubstituted alkyl) or -OC(=O)(substituted or unsubstituted phenyl)), -OC(=O)OR a (e.g., -OC(=O)O(substituted or unsubstituted alkyl) or -OC(=O)O(substituted or unsubstituted phenyl)), or -OC(=O)N(R a )2 (e.g., -OC(=O)NH2, -OC(=O)NH(substituted or unsubstituted alkyl), -OC(=O)NH(substituted or unsubstituted phenyl), -OC(=O)N(substituted or unsubstituted alkyl)-(substituted or unsubstituted alkyl), or -OC(=O)N((substituted or unsubstituted phenyl)-(substituted or unsubstituted alkyl)).
[0187] In certain embodiments, R 5b is hydrogen. In certain embodiments, R 5b is a halogen (e.g., F, Cl, Br, I). In certain embodiments, R 5b is substituted alkyl (eg, alkyl substituted with one or more halogen atoms (eg, F)). In certain embodiments, R 5b is unsubstituted alkyl. In certain embodiments, R 5b is unsubstituted C 1-6 In certain embodiments, R 5b is Me. In certain embodiments, R 5b is Et, Pr or Bu. In certain embodiments, R 5b is replaced by C 1-6 In certain embodiments, R 5b is a substituted methyl group (e.g., -CF3, -CF2H, -CFH2). In certain embodiments, R 5b is substituted ethyl, substituted propyl or substituted butyl. In certain embodiments, R 5b is a substituted or unsubstituted alkenyl. In certain embodiments, R 5b is substituted or unsubstituted C 2-6 In certain embodiments, R 5b is a substituted or unsubstituted alkynyl. 5b is substituted or unsubstituted C 2-6 In certain embodiments, R 5b is a substituted or unsubstituted carbocyclyl (e.g., a substituted or unsubstituted 3-7 membered monocyclic carbocyclyl containing 0, 1 or 2 double bonds in the carbocyclic ring system, as long as the valence state permits). 5b is substituted or unsubstituted cyclopropyl, substituted or unsubstituted cyclobutyl, substituted or unsubstituted cyclopentyl, substituted or unsubstituted cyclohexyl or substituted or unsubstituted cycloheptyl. In certain embodiments, R 5b is a substituted or unsubstituted heterocyclyl (eg, a substituted or unsubstituted 3-7 membered monocyclic heterocyclyl). 5b is substituted or unsubstituted oxetanyl, substituted or unsubstituted tetrahydrofuranyl, substituted or unsubstituted tetrahydropyranyl, substituted or unsubstituted azetidinyl, substituted or unsubstituted pyrrolidinyl, substituted or unsubstituted piperidinyl, substituted or unsubstituted morpholinyl or substituted or unsubstituted piperazinyl. In certain embodiments, R 5bis a substituted or unsubstituted aryl group. In certain embodiments, R 5b is substituted or unsubstituted phenyl. In certain embodiments, R 5b is substituted or unsubstituted naphthyl. In certain embodiments, R 5b is a substituted or unsubstituted heteroaryl. In certain embodiments, R 5b is a substituted or unsubstituted 5-6 membered monocyclic heteroaryl. 5b is substituted or unsubstituted furanyl, substituted or unsubstituted thienyl, substituted or unsubstituted pyrrolyl, substituted or unsubstituted imidazolyl, substituted or unsubstituted oxazolyl, substituted or unsubstituted isoxazolyl, substituted or unsubstituted thiazolyl or substituted or unsubstituted isothiazolyl. In certain embodiments, R 5b is substituted or unsubstituted pyridinyl, substituted or unsubstituted pyrazinyl, substituted or unsubstituted pyrimidinyl or substituted or unsubstituted pyridazinyl. In certain embodiments, R 5b is a substituted or unsubstituted 9-10 membered bicyclic heteroaryl. 5b Yes – OR a (e.g., -OH, -O(substituted or unsubstituted C 1-6 In certain embodiments, R 5b is -OMe. In certain embodiments, R 5b Yes – SR a (e.g., -SH, -S(substituted or unsubstituted C 1-6 In certain embodiments, R 5b Yes – N(R a )2(e.g., -NH2, -NH(substituted or unsubstituted C 1-6 alkyl) (e.g., –NHMe) or -N (substituted or unsubstituted C 1-6 Alkyl)-(substituted or unsubstituted C 1-6 In certain embodiments, R 5b In certain embodiments, R 5b is -NO2. In certain embodiments, R 5b Yes – C(=NR a )R a , –C(=NR a )OR a or –C(=NRa )N(R a )2. In certain embodiments, R 5b Yes – C(=O)OR a (eg, —C(═O)(substituted or unsubstituted alkyl) (eg, —C(═O)OMe) or —C(═O)(substituted or unsubstituted phenyl)). In certain embodiments, R 5b Yes – C(=O)OR a (eg, -C(=O)OH, -C(=O)O(substituted or unsubstituted alkyl) (eg, -C(=O)OMe) or -C(=O)O(substituted or unsubstituted phenyl)). In certain embodiments, R 5b Yes – C(=O)N(R a )2 (e.g., -C(=O)NH2, -C(=O)NH(substituted or unsubstituted alkyl) (e.g., -C(=O)NHMe), -C(=O)NH(substituted or unsubstituted phenyl), -C(=O)N(substituted or unsubstituted alkyl)-(substituted or unsubstituted alkyl) or -C(=O)N(substituted or unsubstituted phenyl)-(substituted or unsubstituted alkyl)). In certain embodiments, R 5b Yes – NR a C(=O)R a (e.g., –NHC(=O)(substituted or unsubstituted C 1-6 In certain embodiments, R 5b Yes – NR a C(=O)OR a In certain embodiments, R 5b Yes – NR a C(=O)N(R a )2 (e.g., -NHC(=O)NH2, -NHC(=O)NH (substituted or unsubstituted C 1-6 In certain embodiments, R 5b Yes-OC(=O)R a (eg, -OC(=O)(substituted or unsubstituted alkyl) or -OC(=O)(substituted or unsubstituted phenyl)), -OC(=O)OR a (e.g., -OC(=O)O(substituted or unsubstituted alkyl) or -OC(=O)O(substituted or unsubstituted phenyl)), or -OC(=O)N(R a)2 (e.g., -OC(=O)NH2, -OC(=O)NH(substituted or unsubstituted alkyl), -OC(=O)NH(substituted or unsubstituted phenyl), -OC(=O)N(substituted or unsubstituted alkyl)-(substituted or unsubstituted alkyl), or -OC(=O)N((substituted or unsubstituted phenyl)-(substituted or unsubstituted alkyl)).
[0188] In certain embodiments, R 5a and R 5b In certain embodiments, R 5a and R 5b Each is hydrogen. In certain embodiments, R 5a and R 5b Each is a substituted or unsubstituted alkyl. In certain embodiments, R 5a and R 5b Each is Me. In certain embodiments, R 5a and R 5b In certain embodiments, R 5a is hydrogen, and R 5b is substituted or unsubstituted alkyl (e.g., Me). 5b is hydrogen, and R 5a is a substituted or unsubstituted alkyl group (eg, Me).
[0189] In certain embodiments, R 5a and R 5b are connected to form a substituted or unsubstituted carbocyclic group. 5a and R 5b are connected to form an optionally substituted C3-C6 monocyclic carbocyclic group (e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl). In certain embodiments, R 5a and R 5b are connected to form a substituted or unsubstituted heterocyclic group. 5a and R 5b The groups are linked to form an optionally substituted monocyclic 3-7 membered heterocyclic group (eg, piperidinyl, piperazinyl, morpholinyl, pyrrolidinyl).
[0190] Formula (I) includes substituents R on the carbon atoms of ring C 6 and R 7 In certain embodiments, R 6 is hydrogen. In certain embodiments, R 6 is a halogen (e.g., F, Cl, Br, I). In certain embodiments, R 6 is substituted or unsubstituted C 1-3 In certain embodiments, R6 is substituted alkyl (eg, alkyl substituted with one or more halogen atoms (eg, F)). In certain embodiments, R 6 is unsubstituted alkyl. In certain embodiments, R 6 is unsubstituted C 1-6 In certain embodiments, R 6 is Me. In certain embodiments, R 6 is Et, Pr or Bu. In certain embodiments, R 6 is a substituted methyl group (e.g., -CF3, -CF2H, -CFH2). In certain embodiments, R 6 is substituted ethyl, substituted propyl or substituted butyl. In certain embodiments, R 6 is hydrogen, halogen, or substituted or unsubstituted alkyl. 6 is a substituted or unsubstituted alkenyl. In certain embodiments, R 6 is substituted or unsubstituted C 2-6 In certain embodiments, R 6 is a substituted or unsubstituted alkynyl. 6 is substituted or unsubstituted C 2-6 In certain embodiments, R 6 is a substituted or unsubstituted carbocyclyl (e.g., a substituted or unsubstituted 3-7 membered monocyclic carbocyclyl containing 0, 1 or 2 double bonds in the carbocyclic ring system, as long as the valence state permits). 6 is substituted or unsubstituted cyclopropyl, substituted or unsubstituted cyclobutyl, substituted or unsubstituted cyclopentyl, substituted or unsubstituted cyclohexyl or substituted or unsubstituted cycloheptyl. In certain embodiments, R 6 is a substituted or unsubstituted heterocyclyl (eg, a substituted or unsubstituted 3-7 membered monocyclic heterocyclyl). 6 is substituted or unsubstituted oxetanyl, substituted or unsubstituted tetrahydrofuranyl, substituted or unsubstituted tetrahydropyranyl, substituted or unsubstituted azetidinyl, substituted or unsubstituted pyrrolidinyl, substituted or unsubstituted piperidinyl, substituted or unsubstituted morpholinyl or substituted or unsubstituted piperazinyl. In certain embodiments, R 6 is a substituted or unsubstituted aryl group. In certain embodiments, R 6 is substituted or unsubstituted phenyl. In certain embodiments, R 6 is substituted or unsubstituted naphthyl. In certain embodiments, R 6 is a substituted or unsubstituted heteroaryl. In certain embodiments, R6 is a substituted or unsubstituted 5-6 membered monocyclic heteroaryl. 6 is substituted or unsubstituted furanyl, substituted or unsubstituted thienyl, substituted or unsubstituted pyrrolyl, substituted or unsubstituted imidazolyl, substituted or unsubstituted oxazolyl, substituted or unsubstituted isoxazolyl, substituted or unsubstituted thiazolyl or substituted or unsubstituted isothiazolyl. In certain embodiments, R 6 is substituted or unsubstituted pyridinyl, substituted or unsubstituted pyrazinyl, substituted or unsubstituted pyrimidinyl or substituted or unsubstituted pyridazinyl. In certain embodiments, R 6 is a substituted or unsubstituted 9-10 membered bicyclic heteroaryl. 6 Yes – OR a (e.g., -OH, -O(substituted or unsubstituted C 1-6 In certain embodiments, R 6 is -OMe. In certain embodiments, R 6 Yes – SR a (e.g., -SH, -S(substituted or unsubstituted C 1-6 In certain embodiments, R 6 Yes – N(R a )2(e.g., -NH2, -NH(substituted or unsubstituted C 1-6 alkyl) (e.g., –NHMe) or -N (substituted or unsubstituted C 1-6 Alkyl)-(substituted or unsubstituted C 1-6 In certain embodiments, R 6 In certain embodiments, R 6 is -NO2. In certain embodiments, R 6 Yes – C(=NR a )R a , –C(=NR a )OR a or –C(=NR a )N(R a )2. In certain embodiments, R 6 Yes – C(=O)OR a(eg, —C(═O)(substituted or unsubstituted alkyl) (eg, —C(═O)OMe) or —C(═O)O(substituted or unsubstituted phenyl)). In certain embodiments, R 6 Yes – C(=O)OR a (eg, -C(=O)OH, -C(=O)O(substituted or unsubstituted alkyl) (eg, -C(=O)OMe) or -C(=O)O(substituted or unsubstituted phenyl)). In certain embodiments, R 6 Yes – C(=O)N(R a )2 (e.g., -C(=O)NH2, -C(=O)NH(substituted or unsubstituted alkyl) (e.g., -C(=O)NHMe), -C(=O)NH(substituted or unsubstituted phenyl), -C(=O)N(substituted or unsubstituted alkyl)-(substituted or unsubstituted alkyl) or -C(=O)N(substituted or unsubstituted phenyl)-(substituted or unsubstituted alkyl)). In certain embodiments, R 6 Yes – NR a C(=O)R a (e.g., –NHC(=O)(substituted or unsubstituted C 1-6 In certain embodiments, R 6 Yes – NR a C(=O)OR a In certain embodiments, R 6 Yes – NR a C(=O)N(R a )2 (e.g., -NHC(=O)NH2, -NHC(=O)NH (substituted or unsubstituted C 1-6 In certain embodiments, R 6 Yes-OC(=O)R a (eg, -OC(=O)(substituted or unsubstituted alkyl) or -OC(=O)(substituted or unsubstituted phenyl)), -OC(=O)OR a (e.g., -OC(=O)O(substituted or unsubstituted alkyl) or -OC(=O)O(substituted or unsubstituted phenyl)), or -OC(=O)N(R a )2 (e.g., -OC(=O)NH2, -OC(=O)NH(substituted or unsubstituted alkyl), -OC(=O)NH(substituted or unsubstituted phenyl), -OC(=O)N(substituted or unsubstituted alkyl)-(substituted or unsubstituted alkyl), or -OC(=O)N((substituted or unsubstituted phenyl)-(substituted or unsubstituted alkyl)).
[0191] In certain embodiments, R 7 is hydrogen. In certain embodiments, R 7 is a halogen (e.g., F, Cl, Br, I). In certain embodiments, R 7 is substituted or unsubstituted C 1-3 In certain embodiments, R 7 is substituted alkyl (eg, alkyl substituted with one or more halogen atoms (eg, F)). In certain embodiments, R 7 is unsubstituted alkyl. In certain embodiments, R 7 is unsubstituted C 1-6 In certain embodiments, R 7 is Me. In certain embodiments, R 7 is Et, Pr or Bu. In certain embodiments, R 7 is replaced by C 1-6 In certain embodiments, R 7 is a substituted methyl group (e.g., -CF3, -CF2H, -CFH2). In certain embodiments, R 7 is substituted ethyl, substituted propyl or substituted butyl. In certain embodiments, R 7 is hydrogen, halogen, or substituted or unsubstituted alkyl. 7 is a substituted or unsubstituted alkenyl. In certain embodiments, R 7 is substituted or unsubstituted C 2-6 In certain embodiments, R 7 is a substituted or unsubstituted alkynyl. 7 is substituted or unsubstituted C 2-6 In certain embodiments, R 7 is a substituted or unsubstituted carbocyclyl (e.g., a substituted or unsubstituted 3-7 membered monocyclic carbocyclyl containing 0, 1 or 2 double bonds in the carbocyclic ring system, as long as the valence state permits). 7 is substituted or unsubstituted cyclopropyl, substituted or unsubstituted cyclobutyl, substituted or unsubstituted cyclopentyl, substituted or unsubstituted cyclohexyl or substituted or unsubstituted cycloheptyl. In certain embodiments, R 7 is a substituted or unsubstituted heterocyclyl (eg, a substituted or unsubstituted 3-7 membered monocyclic heterocyclyl). 7is substituted or unsubstituted oxetanyl, substituted or unsubstituted tetrahydrofuranyl, substituted or unsubstituted tetrahydropyranyl, substituted or unsubstituted azetidinyl, substituted or unsubstituted pyrrolidinyl, substituted or unsubstituted piperidinyl, substituted or unsubstituted morpholinyl or substituted or unsubstituted piperazinyl. In certain embodiments, R 7 is a substituted or unsubstituted aryl group. In certain embodiments, R 7 is substituted or unsubstituted phenyl. In certain embodiments, R 7 is substituted or unsubstituted naphthyl. In certain embodiments, R 7 is a substituted or unsubstituted heteroaryl. In certain embodiments, R 7 is a substituted or unsubstituted 5-6 membered monocyclic heteroaryl. 7 is substituted or unsubstituted furanyl, substituted or unsubstituted thienyl, substituted or unsubstituted pyrrolyl, substituted or unsubstituted imidazolyl, substituted or unsubstituted oxazolyl, substituted or unsubstituted isoxazolyl, substituted or unsubstituted thiazolyl or substituted or unsubstituted isothiazolyl. In certain embodiments, R 7 is substituted or unsubstituted pyridinyl, substituted or unsubstituted pyrazinyl, substituted or unsubstituted pyrimidinyl or substituted or unsubstituted pyridazinyl. In certain embodiments, R 7 is a substituted or unsubstituted 9-10 membered bicyclic heteroaryl. 7 Yes – OR a (e.g., -OH, -O(substituted or unsubstituted C 1-6 In certain embodiments, R 7 is -OMe. In certain embodiments, R 7 Yes – SR a (e.g., -SH, -S(substituted or unsubstituted C 1-6 In certain embodiments, R 7 Yes – N(R a )2(e.g., -NH2, -NH(substituted or unsubstituted C 1-6 alkyl) (e.g., –NHMe) or -N (substituted or unsubstituted C 1-6 Alkyl)-(substituted or unsubstituted C 1-6 In certain embodiments, R 7 In certain embodiments, R7 is -NO2. In certain embodiments, R 7 Yes – C(=NR a )R a , –C(=NR a )OR a or –C(=NR a )N(R a )2. In certain embodiments, R 7 Yes – C(=O)OR a (eg, —C(═O)(substituted or unsubstituted alkyl) (eg, —C(═O)OMe) or —C(═O)O(substituted or unsubstituted phenyl)). In certain embodiments, R 7 Yes – C(=O)OR a (eg, -C(=O)OH, -C(=O)O(substituted or unsubstituted alkyl) (eg, -C(=O)OMe) or -C(=O)O(substituted or unsubstituted phenyl)). In certain embodiments, R 7 Yes – C(=O)N(R a )2 (e.g., -C(=O)NH2, -C(=O)NH(substituted or unsubstituted alkyl) (e.g., -C(=O)NHMe), -C(=O)NH(substituted or unsubstituted phenyl), -C(=O)N(substituted or unsubstituted alkyl)-(substituted or unsubstituted alkyl) or -C(=O)N(substituted or unsubstituted phenyl)-(substituted or unsubstituted alkyl)). In certain embodiments, R 7 Yes – NR a C(=O)R a (e.g., –NHC(=O)(substituted or unsubstituted C 1-6 In certain embodiments, R 7 Yes – NR a C(=O)OR a In certain embodiments, R 7 Yes – NR a C(=O)N(R a )2 (e.g., -NHC(=O)NH2, -NHC(=O)NH (substituted or unsubstituted C 1-6 In certain embodiments, R 7 Yes-OC(=O)R a (eg, -OC(=O)(substituted or unsubstituted alkyl) or -OC(=O)(substituted or unsubstituted phenyl)), -OC(=O)OR a(e.g., -OC(=O)O(substituted or unsubstituted alkyl) or -OC(=O)O(substituted or unsubstituted phenyl)), or -OC(=O)N(R a )2 (e.g., -OC(=O)NH2, -OC(=O)NH(substituted or unsubstituted alkyl), -OC(=O)NH(substituted or unsubstituted phenyl), -OC(=O)N(substituted or unsubstituted alkyl)-(substituted or unsubstituted alkyl), or -OC(=O)N((substituted or unsubstituted phenyl)-(substituted or unsubstituted alkyl)).
[0192] In certain embodiments, R 6 and R 7 In certain embodiments, R 6 and R 7 Each is hydrogen. In certain embodiments, R 6 and R 7 Each is a substituted or unsubstituted alkyl. In certain embodiments, R 6 and R 7 Each is Me. In certain embodiments, R 6 and R 7 In certain embodiments, R 6 is hydrogen, and R 7 is substituted or unsubstituted alkyl (e.g., Me). 7 is hydrogen, and R 6 is a substituted or unsubstituted alkyl group (eg, Me).
[0193] In certain embodiments, R 6 and R 7 are connected to form a substituted or unsubstituted carbocyclic group. 6 and R 7 In certain embodiments, R 6 and R 7 There is no connection to form an unsubstituted cyclopropyl. In certain embodiments, R 6 and R 7 There is no connection to form a substituted or unsubstituted cyclopropyl. In certain embodiments, R 6 and R 7 are connected to form a substituted or unsubstituted carbocyclic group. 6 and R 7 are connected to form a substituted or unsubstituted heterocyclic group. 6 and R 7The groups are linked to form an optionally substituted monocyclic 3-7 membered heterocyclic group (eg, piperidinyl, piperazinyl, morpholinyl, pyrrolidinyl).
[0194] Formula (I) includes R 8 In certain embodiments, R 8 is hydrogen. In certain embodiments, R 8 is a substituted or unsubstituted acyl group (e.g., -C(=O)R a 、–C(=O)OR a , –C(=O)N(R a )2). In certain embodiments, R 8 is a substituted or unsubstituted alkyl group (e.g., a substituted or unsubstituted C 1-6 In certain embodiments, R 8 is Me. In certain embodiments, R 8 is Et, Pr, Bu, substituted methyl, substituted ethyl, substituted propyl or substituted butyl. In certain embodiments, R 8 is a nitrogen protecting group (eg, Bn, BOC, Cbz, Fmoc, trifluoroacetyl, triphenylmethyl, acetyl, Ts).
[0195] In certain embodiments, R 9 At least one example of is hydrogen. In certain embodiments, R 9 Each instance of is hydrogen. In certain embodiments, R 9 At least one example of is halogen (e.g., F, Cl, Br, I). In certain embodiments, R 9 At least one example is a substituted or unsubstituted C 1-3 In certain embodiments, R 9 At least one instance of is substituted alkyl (eg, alkyl substituted with one or more halogen instances (eg, F)). In certain embodiments, R 9 At least one instance of a )2 substituted alkyl. In certain embodiments, R 9 At least one example is –(CH2) 1-3 -N(substituted or unsubstituted alkyl)2 (eg, -CH2-N(substituted or unsubstituted alkyl)2). In certain embodiments, R 9 At least one example of is -CH2-N(CH3)2. In certain embodiments, R 9 In certain embodiments, R 9 At least one instance of unsubstituted C 1-6 In certain embodiments, R9 At least one example of is Me. In certain embodiments, R 9 At least one example of is Et, Pr or Bu. In certain embodiments, R 9 At least one instance of a substituted C 1-6 In certain embodiments, R 9 At least one example of is substituted methyl (e.g., -CF3, -CF2H, -CFH2). In certain embodiments, R 9 At least one example of is substituted ethyl, substituted propyl or substituted butyl. In certain embodiments, R 9 At least one example of is hydrogen, halogen, or substituted or unsubstituted alkyl. In certain embodiments, R 9 At least one example of is substituted or unsubstituted alkenyl. In certain embodiments, R 9 At least one example is a substituted or unsubstituted C 2-6 In certain embodiments, R 9 At least one example of is substituted or unsubstituted alkynyl. 9 At least one example is a substituted or unsubstituted C 2-6 In certain embodiments, R 9 At least one example of is a substituted or unsubstituted carbocyclyl (e.g., a substituted or unsubstituted 3-7 membered monocyclic carbocyclyl containing 0, 1 or 2 double bonds in the carbocyclic ring system, as long as the valence state permits). In certain embodiments, R 9 At least one example of is substituted or unsubstituted cyclopropyl, substituted or unsubstituted cyclobutyl, substituted or unsubstituted cyclopentyl, substituted or unsubstituted cyclohexyl or substituted or unsubstituted cycloheptyl. In certain embodiments, R 9 At least one example of is a substituted or unsubstituted heterocyclyl (e.g., a substituted or unsubstituted 3-7 membered monocyclic heterocyclyl). In certain embodiments, R 9 At least one example of is substituted or unsubstituted oxetanyl, substituted or unsubstituted tetrahydrofuranyl, substituted or unsubstituted tetrahydropyranyl, substituted or unsubstituted azetidinyl, substituted or unsubstituted pyrrolidinyl, substituted or unsubstituted piperidinyl, substituted or unsubstituted morpholinyl or substituted or unsubstituted piperazinyl. In certain embodiments, R 9 At least one example of is substituted or unsubstituted aryl. In certain embodiments, R 9 At least one example of is substituted or unsubstituted phenyl. In certain embodiments, R 9 At least one example of is substituted or unsubstituted naphthyl. In certain embodiments, R9 At least one example of is substituted or unsubstituted heteroaryl. In certain embodiments, R 9 At least one example of is a substituted or unsubstituted 5-6 membered monocyclic heteroaryl. In certain embodiments, R 9 At least one example of is substituted or unsubstituted furanyl, substituted or unsubstituted thienyl, substituted or unsubstituted pyrrolyl, substituted or unsubstituted imidazolyl, substituted or unsubstituted oxazolyl, substituted or unsubstituted isoxazolyl, substituted or unsubstituted thiazolyl or substituted or unsubstituted isothiazolyl. In certain embodiments, R 9 At least one example of is substituted or unsubstituted pyridyl, substituted or unsubstituted pyrazinyl, substituted or unsubstituted pyrimidinyl or substituted or unsubstituted pyridazinyl. In certain embodiments, R 9 At least one example is a substituted or unsubstituted 9-10 membered bicyclic heteroaryl. In certain embodiments, R 9 At least one instance of –OR a (e.g., -OH, -O(substituted or unsubstituted C 1-6 In certain embodiments, R 9 At least one example of is -OMe. In certain embodiments, R 9 At least one instance of –SR a (e.g., -SH, -S(substituted or unsubstituted C 1-6 In certain embodiments, R 9 At least one instance of –N(R a )2(e.g., -NH2, -NH(substituted or unsubstituted C 1-6 alkyl) (e.g., –NHMe) or -N (substituted or unsubstituted C 1-6 Alkyl)-(substituted or unsubstituted C 1-6 In certain embodiments, R 9 At least one example of is -CN or -SCN. In certain embodiments, R 9 At least one example of is -NO2. In certain embodiments, R 9 At least one instance of –C(=NR a )R a , –C(=NR a )OR a or –C(=NR a)N(R a )2. In certain embodiments, R 9 At least one example of -C(=O)OR a (eg, —C(═O)(substituted or unsubstituted alkyl) (eg, —C(═O)OMe) or —C(═O)(substituted or unsubstituted phenyl)). In certain embodiments, R 9 At least one example of -C(=O)OR a (eg, -C(=O)OH, -C(=O)O(substituted or unsubstituted alkyl) (eg, -C(=O)OMe) or -C(=O)O(substituted or unsubstituted phenyl)). In certain embodiments, R 9 At least one example is -C(=O)N(R a )2 (e.g., -C(=O)NH2, -C(=O)NH(substituted or unsubstituted alkyl) (e.g., -C(=O)NHMe), -C(=O)NH(substituted or unsubstituted phenyl), -C(=O)N(substituted or unsubstituted alkyl)-(substituted or unsubstituted alkyl) or -C(=O)N(substituted or unsubstituted phenyl)-(substituted or unsubstituted alkyl)). In certain embodiments, R 9 At least one instance of –NR a C(=O)R a (e.g., –NHC(=O)(substituted or unsubstituted C 1-6 In certain embodiments, R 9 At least one instance of –NR a C(=O)OR a In certain embodiments, R 9 At least one instance of –NR a C(=O)N(R a )2 (e.g., -NHC(=O)NH2, -NHC(=O)NH (substituted or unsubstituted C 1-6 In certain embodiments, R 9 At least one example of -OC(=O)R a (eg, -OC(=O)(substituted or unsubstituted alkyl) or -OC(=O)(substituted or unsubstituted phenyl)), -OC(=O)OR a (e.g., -OC(=O)O(substituted or unsubstituted alkyl) or -OC(=O)O(substituted or unsubstituted phenyl)), or -OC(=O)N(R a)2 (e.g., -OC(=O)NH2, -OC(=O)NH(substituted or unsubstituted alkyl), -OC(=O)NH(substituted or unsubstituted phenyl), -OC(=O)N(substituted or unsubstituted alkyl)-(substituted or unsubstituted alkyl), or -OC(=O)N((substituted or unsubstituted phenyl)-(substituted or unsubstituted alkyl)).
[0196] In certain embodiments, R 10 At least one example of is hydrogen. In certain embodiments, R 10 Each instance of is hydrogen. In certain embodiments, R 10 At least one example of is halogen (e.g., F, Cl, Br, I). In certain embodiments, R 10 At least one example is a substituted or unsubstituted C 1-3 In certain embodiments, R 10 At least one instance of is substituted alkyl (eg, alkyl substituted with one or more halogen instances (eg, F)). In certain embodiments, R 10 At least one instance of a )2 substituted alkyl. In certain embodiments, R 10 At least one example is –(CH2) 1-3 -N(substituted or unsubstituted alkyl)2 (eg, -CH2-N(substituted or unsubstituted alkyl)2). In certain embodiments, R 10 At least one example of is -CH2-N(CH3)2. In certain embodiments, R 10 In certain embodiments, R 10 At least one instance of unsubstituted C 1-6 In certain embodiments, R 10 At least one example of is Me. In certain embodiments, R 10 At least one example of is Et, Pr or Bu. In certain embodiments, R 10 At least one instance of a substituted C 1-6 In certain embodiments, R 10 At least one example of is substituted methyl (e.g., -CF3, -CF2H, -CFH2). In certain embodiments, R 10 At least one example of is substituted ethyl, substituted propyl or substituted butyl. In certain embodiments, R 10 At least one example of is hydrogen, halogen, or substituted or unsubstituted alkyl. In certain embodiments, R 10 At least one example of is substituted or unsubstituted alkenyl. In certain embodiments, R10 At least one example is a substituted or unsubstituted C 2-6 In certain embodiments, R 10 At least one example of is substituted or unsubstituted alkynyl. 10 At least one example is a substituted or unsubstituted C 2-6 In certain embodiments, R 10 At least one example of is a substituted or unsubstituted carbocyclyl (e.g., a substituted or unsubstituted 3-7 membered monocyclic carbocyclyl containing 0, 1 or 2 double bonds in the carbocyclic ring system, as long as the valence state permits). In certain embodiments, R 10 At least one example of is substituted or unsubstituted cyclopropyl, substituted or unsubstituted cyclobutyl, substituted or unsubstituted cyclopentyl, substituted or unsubstituted cyclohexyl or substituted or unsubstituted cycloheptyl. In certain embodiments, R 10 At least one example of is a substituted or unsubstituted heterocyclyl (e.g., a substituted or unsubstituted 3-7 membered monocyclic heterocyclyl). In certain embodiments, R 10 At least one example of is substituted or unsubstituted oxetanyl, substituted or unsubstituted tetrahydrofuranyl, substituted or unsubstituted tetrahydropyranyl, substituted or unsubstituted azetidinyl, substituted or unsubstituted pyrrolidinyl, substituted or unsubstituted piperidinyl, substituted or unsubstituted morpholinyl or substituted or unsubstituted piperazinyl. In certain embodiments, R 10 At least one example of is substituted or unsubstituted aryl. In certain embodiments, R 10 At least one example of is substituted or unsubstituted phenyl. In certain embodiments, R 10 At least one example of is substituted or unsubstituted naphthyl. In certain embodiments, R 10 At least one example of is substituted or unsubstituted heteroaryl. In certain embodiments, R 10 At least one example of is a substituted or unsubstituted 5-6 membered monocyclic heteroaryl. In certain embodiments, R 10 At least one example of is substituted or unsubstituted furanyl, substituted or unsubstituted thienyl, substituted or unsubstituted pyrrolyl, substituted or unsubstituted imidazolyl, substituted or unsubstituted oxazolyl, substituted or unsubstituted isoxazolyl, substituted or unsubstituted thiazolyl or substituted or unsubstituted isothiazolyl. In certain embodiments, R 10 At least one example of is substituted or unsubstituted pyridyl, substituted or unsubstituted pyrazinyl, substituted or unsubstituted pyrimidinyl or substituted or unsubstituted pyridazinyl. In certain embodiments, R 10At least one example is a substituted or unsubstituted 9-10 membered bicyclic heteroaryl. In certain embodiments, R 10 At least one instance of –OR a (e.g., -OH, -O(substituted or unsubstituted C 1-6 In certain embodiments, R 10 At least one example of is -OMe. In certain embodiments, R 10 At least one instance of –SR a (e.g., -SH, -S(substituted or unsubstituted C 1-6 In certain embodiments, R 10 At least one instance of –N(R a )2(e.g., -NH2, -NH(substituted or unsubstituted C 1-6 alkyl) (e.g., –NHMe) or -N (substituted or unsubstituted C 1-6 Alkyl)-(substituted or unsubstituted C 1-6 In certain embodiments, R 10 At least one example of is -CN or -SCN. In certain embodiments, R 10 At least one example of is -NO2. In certain embodiments, R 10 At least one instance of –C(=NR a )R a , –C(=NR a )OR a or –C(=NR a )N(R a )2. In certain embodiments, R 10 At least one example of -C(=O)OR a (eg, —C(═O)(substituted or unsubstituted alkyl) (eg, —C(═O)OMe) or —C(═O)O(substituted or unsubstituted phenyl)). In certain embodiments, R 10 At least one example of -C(=O)OR a (eg, -C(=O)OH, -C(=O)O(substituted or unsubstituted alkyl) (eg, -C(=O)OMe) or -C(=O)O(substituted or unsubstituted phenyl)). In certain embodiments, R 10 At least one example is -C(=O)N(Ra )2 (e.g., -C(=O)NH2, -C(=O)NH(substituted or unsubstituted alkyl) (e.g., -C(=O)NHMe), -C(=O)NH(substituted or unsubstituted phenyl), -C(=O)N(substituted or unsubstituted alkyl)-(substituted or unsubstituted alkyl) or -C(=O)N(substituted or unsubstituted phenyl)-(substituted or unsubstituted alkyl)). In certain embodiments, R 10 At least one instance of –NR a C(=O)R a (e.g., –NHC(=O)(substituted or unsubstituted C 1-6 In certain embodiments, R 10 At least one instance of –NR a C(=O)OR a In certain embodiments, R 10 At least one instance of –NR a C(=O)N(R a )2 (e.g., -NHC(=O)NH2, -NHC(=O)NH (substituted or unsubstituted C 1-6 In certain embodiments, R 10 At least one example of -OC(=O)R a (eg, -OC(=O)(substituted or unsubstituted alkyl) or -OC(=O)(substituted or unsubstituted phenyl)), -OC(=O)OR a (e.g., -OC(=O)O(substituted or unsubstituted alkyl) or -OC(=O)O(substituted or unsubstituted phenyl)), or -OC(=O)N(R a )2 (e.g., -OC(=O)NH2, -OC(=O)NH(substituted or unsubstituted alkyl), -OC(=O)NH(substituted or unsubstituted phenyl), -OC(=O)N(substituted or unsubstituted alkyl)-(substituted or unsubstituted alkyl), or -OC(=O)N((substituted or unsubstituted phenyl)-(substituted or unsubstituted alkyl)).
[0197] In certain embodiments, -C(R 9 )(R 10 )- is not -CH(Ph)-. In certain embodiments, -C(R 9 )(R 10 )- is not -CH(substituted or unsubstituted phenyl)-. In certain embodiments, R 9 and R 10In certain embodiments, R 9 and R 10 The examples are all substituted or unsubstituted phenyl.
[0198] In certain embodiments, At least one instance of wherein bond a is connected to ring D. In certain embodiments, At least one instance of wherein bond a is connected to ring D. In certain embodiments, At least one instance of wherein bond a is connected to ring D. In certain embodiments, At least one instance of Wherein bond a is connected to ring D.
[0199] In certain embodiments, yes wherein bond a is attached to the ring. In certain embodiments, yes wherein bond a is connected to ring D. In certain embodiments, yes wherein bond a is connected to ring D. In certain embodiments, yes wherein bond a is connected to ring D. In certain embodiments, yes Wherein bond a is connected to ring D.
[0200] R 12 Each instance of is independently hydrogen, substituted or unsubstituted acyl, substituted or unsubstituted alkyl, substituted or unsubstituted phenyl, or a nitrogen protecting group, or two R 12 In certain embodiments, R 12 At least one example of is hydrogen. In certain embodiments, R 12 Each instance of is hydrogen. In certain embodiments, R 12 In certain embodiments, R 12 At least one example is a substituted or unsubstituted acyl group (eg, -C(=O)R a 、–C(=O)OR a , –C(=O)N(R a )2). In certain embodiments, R 12 At least one example is a substituted or unsubstituted alkyl group (e.g., a substituted or unsubstituted C1-6 In certain embodiments, R 12 Each instance of is substituted or unsubstituted alkyl. In certain embodiments, R 12 At least one example of is Me. In certain embodiments, R 12 Each instance of is Me. In certain embodiments, R 12 At least one example of is Et, Pr, Bu, substituted methyl, substituted ethyl, substituted propyl or substituted butyl. In certain embodiments, R 12 An example of is hydrogen, and R 12 Another example is a substituted or unsubstituted alkyl group (e.g., a substituted or unsubstituted C 1-6 In certain embodiments, R 12 An example of is hydrogen, and R 12 Another example of is Me. In certain embodiments, R 12 At least one example of is substituted or unsubstituted phenyl. In certain embodiments, R 12 At least one example of is a nitrogen protecting group (e.g., Bn, BOC, Cbz, Fmoc, trifluoroacetyl, triphenylmethyl, acetyl, Ts). In certain embodiments, both R 12 In certain embodiments, two R 12 In certain embodiments, two R 12 The groups are linked to form a substituted or unsubstituted heteroaryl group (eg, a substituted or unsubstituted 5-6 membered monocyclic heteroaryl group comprising at least one nitrogen atom in the heteroaryl ring system).
[0201] In certain embodiments, R 9 and R 10 are connected to form a substituted or unsubstituted carbocyclic group. 9 and R 10 In certain embodiments, R 9 and R 10 There is no connection to form an unsubstituted cyclopropyl. In certain embodiments, R 9 and R 10 There is no connection to form a substituted or unsubstituted cyclopropyl. In certain embodiments, R 9 and R 10are connected to form a substituted or unsubstituted carbocyclic group. 9 and R 10 are connected to form a substituted or unsubstituted heterocyclic group. 9 and R 10 The groups are linked to form an optionally substituted C3-C9 monocyclic heterocyclic group (eg, piperidinyl, piperazinyl, morpholinyl, pyrrolidinyl).
[0202] In certain embodiments, p is 0. In certain embodiments, p is 1. In certain embodiments, p is 2. In certain embodiments, p is 3. In certain embodiments, p is 4.
[0203] Formula (I) includes the ring In certain embodiments, ring D is a carbocyclyl. In certain embodiments, ring D is a 3-7 membered monocyclic carbocyclyl containing 0, 1 or 2 double bonds in the carbocyclic ring system, as long as the valence state permits. In certain embodiments, ring D is cyclopropyl, cyclopentyl, cyclohexyl or cycloheptyl. In certain embodiments, ring D is cyclopropyl. In certain embodiments, yes (For example, ). In certain embodiments, yes (For example, In certain embodiments, ring D is a 5-13 membered bicyclic carbocyclyl containing 0, 1, 2 or 3 double bonds in the carbocyclic ring system, as long as valence permits. In certain embodiments, ring D is a 3-7 membered monocyclic carbocyclyl fused to a phenyl, wherein the 3-7 membered monocyclic carbocyclyl contains 0 or 1 double bonds in the unfused portion of the carbocyclic ring system, as long as valence permits.
[0204] In certain embodiments, ring D is a heterocyclyl. In certain embodiments, ring D is a 3-7 membered monocyclic heterocyclyl. In certain embodiments, ring D is a 5 or 6 membered monocyclic heterocyclyl. In certain embodiments, each heteroatom in the heterocyclic ring system of ring D is oxygen. In certain embodiments, each heteroatom in the heterocyclic ring system of ring D is nitrogen. In certain embodiments, ring D is oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl or piperazinyl. In certain embodiments, ring D is tetrahydropyranyl. In certain embodiments, yes (For example, ). In certain embodiments, Ring D is tetrahydrofuranyl. In certain embodiments, yes (For example, ). In certain embodiments, Ring D is piperazinyl. In certain embodiments, yes In certain embodiments, Ring D is morpholinyl. In certain embodiments, yes In certain embodiments, Ring D is piperidinyl. In certain embodiments, yes In certain embodiments, yes In certain embodiments, yes (For example, In certain embodiments, ring D is a 5-13 membered bicyclic heterocyclyl. In certain embodiments, ring D is a 3-7 membered monocyclic heterocyclyl fused to a phenyl group. In certain embodiments, yes (For example, ). In certain embodiments, yes (For example, ). In certain embodiments, yes (For example, ).
[0205] In certain embodiments, In certain embodiments, no In certain embodiments, In certain embodiments, no In certain embodiments, when p is 0, ring D does not include one or more nitrogen atoms in the ring system. In certain embodiments, when p is 2, ring D is not pyrrolidinyl. In certain embodiments, when p is 2, ring D is not morpholinyl. In certain embodiments, when p is 1, ring D is not cyclohexyl.
[0206] Ring D may include one or more substituents R 11 . R 11 R may be attached to any atom of the carbocyclic or heterocyclic ring system of ring D (e.g., a monocyclic or bicyclic ring system) as long as valence permits. 11 At least one example of is halogen (e.g., F, Cl, Br, I). In certain embodiments, R 11 At least one example is a substituted or unsubstituted C 1-3 In certain embodiments, R 11 At least one instance of is substituted alkyl (eg, alkyl substituted with one or more halogen instances (eg, F)). In certain embodiments, R 11At least one instance of a )2 substituted alkyl. In certain embodiments, R 11 At least one example is –(CH2) 1-3 -N(substituted or unsubstituted alkyl)2 (eg, -CH2-N(substituted or unsubstituted alkyl)2). In certain embodiments, R 11 At least one example of is -CH2-N(CH3)2. In certain embodiments, R 11 In certain embodiments, R 11 At least one instance of unsubstituted C 1-6 In certain embodiments, R 11 At least one example of is Me. In certain embodiments, R 11 At least one example of is Et, Pr or Bu. In certain embodiments, R 11 At least one instance of a substituted C 1-6 In certain embodiments, R 11 At least one example of is substituted methyl (e.g., -CF3, -CF2H, -CFH2). In certain embodiments, R 11 At least one example of is substituted ethyl, substituted propyl or substituted butyl. In certain embodiments, R 11 At least one example of is hydrogen, halogen, or substituted or unsubstituted alkyl. In certain embodiments, R 11 At least one example of is substituted or unsubstituted alkenyl. In certain embodiments, R 11 At least one example is a substituted or unsubstituted C 2-6 In certain embodiments, R 11 At least one example of is substituted or unsubstituted alkynyl. 11 At least one example is a substituted or unsubstituted C 2-6 In certain embodiments, R 11 At least one example of is a substituted or unsubstituted carbocyclyl (e.g., a substituted or unsubstituted 3-7 membered monocyclic carbocyclyl containing 0, 1 or 2 double bonds in the carbocyclic ring system, as long as the valence state permits). In certain embodiments, R 11 At least one example of is substituted or unsubstituted cyclopropyl, substituted or unsubstituted cyclobutyl, substituted or unsubstituted cyclopentyl, substituted or unsubstituted cyclohexyl or substituted or unsubstituted cycloheptyl. In certain embodiments, R 11At least one example of is a substituted or unsubstituted heterocyclyl (e.g., a substituted or unsubstituted 3-7 membered monocyclic heterocyclyl). In certain embodiments, R 11 At least one example of is substituted or unsubstituted oxetanyl, substituted or unsubstituted tetrahydrofuranyl, substituted or unsubstituted tetrahydropyranyl, substituted or unsubstituted azetidinyl, substituted or unsubstituted pyrrolidinyl, substituted or unsubstituted piperidinyl, substituted or unsubstituted morpholinyl or substituted or unsubstituted piperazinyl. In certain embodiments, R 11 At least one example of is substituted or unsubstituted aryl. In certain embodiments, R 11 At least one example of is substituted or unsubstituted phenyl. In certain embodiments, R 11 At least one example of is substituted or unsubstituted naphthyl. In certain embodiments, R 11 At least one example of is substituted or unsubstituted heteroaryl. In certain embodiments, R 11 At least one example of is a substituted or unsubstituted 5-6 membered monocyclic heteroaryl. In certain embodiments, R 11 At least one example of is substituted or unsubstituted furanyl, substituted or unsubstituted thienyl, substituted or unsubstituted pyrrolyl, substituted or unsubstituted imidazolyl, substituted or unsubstituted oxazolyl, substituted or unsubstituted isoxazolyl, substituted or unsubstituted thiazolyl or substituted or unsubstituted isothiazolyl. In certain embodiments, R 11 At least one example of is substituted or unsubstituted pyridyl, substituted or unsubstituted pyrazinyl, substituted or unsubstituted pyrimidinyl or substituted or unsubstituted pyridazinyl. In certain embodiments, R 11 At least one example of is a substituted or unsubstituted 9-11 membered bicyclic heteroaryl. In certain embodiments, R 11 At least one instance of –OR a (e.g., -OH, -O(substituted or unsubstituted C 1-6 In certain embodiments, R 11 At least one example of is -OMe. In certain embodiments, R 11 At least one instance of –SR a (e.g., -SH, -S (substituted or unsubstituted d C 1-6 In certain embodiments, R 11 At least one instance of –N(R a)2(e.g., -NH2, -NH(substituted or unsubstituted C 1-6 alkyl) (e.g., –NHMe) or -N (substituted or unsubstituted C 1-6 Alkyl)-(substituted or unsubstituted C 1-6 In certain embodiments, R 11 At least one example of is -CN or -SCN. In certain embodiments, R 11 At least one example of is -NO2. In certain embodiments, R 11 At least one instance of –C(=NR a )R a , –C(=NR a )OR a or –C(=NR a )N(R a )2. In certain embodiments, R 11 At least one example of -C(=O)OR a (eg, —C(═O)(substituted or unsubstituted alkyl) (eg, —C(═O)OMe) or —C(═O)(substituted or unsubstituted phenyl)). In certain embodiments, R 11 At least one example of -C(=O)OR a (eg, -C(=O)OH, -C(=O)O(substituted or unsubstituted alkyl) (eg, -C(=O)OMe) or -C(=O)O(substituted or unsubstituted phenyl)). In certain embodiments, R 11 At least one example is -C(=O)N(R a )2 (e.g., -C(=O)NH2, -C(=O)NH(substituted or unsubstituted alkyl) (e.g., -C(=O)NHMe), -C(=O)NH(substituted or unsubstituted phenyl), -C(=O)N(substituted or unsubstituted alkyl)-(substituted or unsubstituted alkyl) or -C(=O)N(substituted or unsubstituted phenyl)-(substituted or unsubstituted alkyl)). In certain embodiments, R 11 At least one instance of –NR a C(=O)R a (e.g., –NHC(=O)(substituted or unsubstituted C 1-6 In certain embodiments, R 11 At least one instance of –NR a C(=O)OR a In certain embodiments, R 11 At least one instance of –NR aC(=O)N(R a )2 (e.g., -NHC(=O)NH2, -NHC(=O)NH (substituted or unsubstituted C 1-6 In certain embodiments, R 11 At least one example of -OC(=O)R a (eg, -OC(=O)(substituted or unsubstituted alkyl) or -OC(=O)(substituted or unsubstituted phenyl)), -OC(=O)OR a (e.g., -OC(=O)O(substituted or unsubstituted alkyl) or -OC(=O)O(substituted or unsubstituted phenyl)), or -OC(=O)N(R a )2 (e.g., -OC(=O)NH2, -OC(=O)NH(substituted or unsubstituted alkyl), -OC(=O)NH(substituted or unsubstituted phenyl), -OC(=O)N(substituted or unsubstituted alkyl)-(substituted or unsubstituted alkyl), or -OC(=O)N((substituted or unsubstituted phenyl)-(substituted or unsubstituted alkyl)). In certain embodiments, R 11 At least one example of is a nitrogen protecting group (eg, Bn, BOC, Cbz, Fmoc, trifluoroacetyl, triphenylmethyl, acetyl, Ts).
[0207] In certain embodiments, q is 0. In certain embodiments, q is 1. In certain embodiments, q is 2. In certain embodiments, q is 3, 4, 5, 6, 7, 8, 9, 10, or 11.
[0208] In certain embodiments, R a At least one example of is hydrogen. In certain embodiments, R a Each instance of is hydrogen. In certain embodiments, R a At least one instance of is not hydrogen. In certain embodiments, R a In certain embodiments, R a At least one instance of is substituted alkyl (eg, alkyl substituted with one or more halogen instances (eg, F)). In certain embodiments, R a In certain embodiments, R a At least one instance of unsubstituted C 1-6 In certain embodiments, R a At least one example of is Me. In certain embodiments, R a At least one example of is Et, Pr or Bu. In certain embodiments, R a At least one instance of a substituted C1-6 In certain embodiments, R a At least one example of is substituted methyl. In certain embodiments, R a At least one example of is substituted ethyl, substituted propyl or substituted butyl. In certain embodiments, R a At least one example of is substituted or unsubstituted alkenyl. In certain embodiments, R a At least one example is a substituted or unsubstituted C 2-6 In certain embodiments, R a At least one example of is substituted or unsubstituted alkynyl. a At least one example is a substituted or unsubstituted C 2-6 In certain embodiments, R a At least one example of is a substituted or unsubstituted carbocyclyl (e.g., a substituted or unsubstituted 3-7 membered monocyclic carbocyclyl containing 0, 1 or 2 double bonds in the carbocyclic ring system, as long as the valence state permits). In certain embodiments, R a At least one example of is substituted or unsubstituted cyclopropyl, substituted or unsubstituted cyclobutyl, substituted or unsubstituted cyclopentyl, substituted or unsubstituted cyclohexyl or substituted or unsubstituted cycloheptyl. In certain embodiments, R a At least one example of is a substituted or unsubstituted heterocyclyl (e.g., a substituted or unsubstituted 3-7 membered monocyclic heterocyclyl). In certain embodiments, R a At least one example of is substituted or unsubstituted oxetanyl, substituted or unsubstituted tetrahydrofuranyl, substituted or unsubstituted tetrahydropyranyl, substituted or unsubstituted azetidinyl, substituted or unsubstituted pyrrolidinyl, substituted or unsubstituted piperidinyl, substituted or unsubstituted morpholinyl or substituted or unsubstituted piperazinyl. In certain embodiments, R a At least one example of is substituted or unsubstituted aryl. In certain embodiments, R a At least one example of is substituted or unsubstituted phenyl. In certain embodiments, R a At least one example of is substituted or unsubstituted naphthyl. In certain embodiments, R a At least one example of is substituted or unsubstituted heteroaryl. In certain embodiments, R a At least one example of is a substituted or unsubstituted 5-6 membered monocyclic heteroaryl. In certain embodiments, R aAt least one example of is substituted or unsubstituted furanyl, substituted or unsubstituted thienyl, substituted or unsubstituted pyrrolyl, substituted or unsubstituted imidazolyl, substituted or unsubstituted oxazolyl, substituted or unsubstituted isoxazolyl, substituted or unsubstituted thiazolyl or substituted or unsubstituted isothiazolyl. In certain embodiments, R a At least one example of is substituted or unsubstituted pyridyl, substituted or unsubstituted pyrazinyl, substituted or unsubstituted pyrimidinyl or substituted or unsubstituted pyridazinyl. In certain embodiments, R a At least one example is a substituted or unsubstituted 9-10 membered bicyclic heteroaryl. In certain embodiments, R a At least one example of is a nitrogen protecting group attached to a nitrogen atom (e.g., Bn, Boc, Cbz, Fmoc, trifluoroacetyl, triphenylmethyl, acetyl, or Ts). In certain embodiments, R a At least one example of is an oxygen protecting group attached to an oxygen atom (e.g., silyl, TBDPS, TBDMS, TIPS, TES, TMS, MOM, THP, t-Bu, Bn, allyl, acetyl, pivaloyl, or benzoyl). In certain embodiments, R a Two instances of are connected to form a substituted or unsubstituted heterocyclyl (e.g., a substituted or unsubstituted 3-7 membered monocyclic heterocyclyl). a Two instances of are linked to form a substituted or unsubstituted heteroaryl (eg, a substituted or unsubstituted 5- to 6-membered monocyclic heteroaryl).
[0209] In certain embodiments, the compound is of the formula:
[0210]
[0211] or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotope-labeled derivative or prodrug thereof.
[0212] In certain embodiments, the compound is of the formula:
[0213]
[0214]
[0215] or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotope-labeled derivative or prodrug thereof.
[0216] In certain embodiments, the compound is of the formula:
[0217]
[0218] or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotope-labeled derivative or prodrug thereof.
[0219] In certain embodiments, the compound is of the formula:
[0220]
[0221]
[0222] or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotope-labeled derivative or prodrug thereof.
[0223] In certain embodiments, the compound is of the formula:
[0224]
[0225] or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotope-labeled derivative or prodrug thereof.
[0226] In certain embodiments, the compound is of the formula:
[0227]
[0228]
[0229] or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotope-labeled derivative or prodrug thereof.
[0230] In certain embodiments, the compound is of the formula:
[0231]
[0232] or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotope-labeled derivative or prodrug thereof.
[0233] In certain embodiments, the compound is of the formula:
[0234]
[0235]
[0236] or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotope-labeled derivative or prodrug thereof.
[0237] In certain embodiments, the compound is of the formula:
[0238]
[0239] or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotope-labeled derivative or prodrug thereof.
[0240] In certain embodiments, the compound is of the formula:
[0241]
[0242]
[0243] or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotope-labeled derivative or prodrug thereof.
[0244] In certain embodiments, the compound is of the formula:
[0245]
[0246] or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotope-labeled derivative or prodrug thereof.
[0247] In certain embodiments, the compound is of the formula:
[0248]
[0249]
[0250] or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotope-labeled derivative or prodrug thereof.
[0251] In certain embodiments, the compound is of the formula:
[0252]
[0253] or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, cocrystal, tautomer, stereoisomer, isotope-labeled derivative or prodrug thereof, provided that R 10 Not hydrogen.
[0254] In certain embodiments, the compound is of the formula:
[0255]
[0256]
[0257] or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, cocrystal, tautomer, stereoisomer, isotope-labeled derivative or prodrug thereof, provided that R 10 Not hydrogen.
[0258] In certain embodiments, the compound is of the formula:
[0259]
[0260] or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, cocrystal, tautomer, stereoisomer, isotopically labeled derivative or prodrug thereof, optionally, for
[0261] In certain embodiments, the compound is of the formula:
[0262]
[0263] or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, cocrystal, tautomer, stereoisomer, isotopically labeled derivative or prodrug thereof, optionally, for
[0264] In certain embodiments, the compound is of the formula:
[0265]
[0266] or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, cocrystal, tautomer, stereoisomer, isotopically labeled derivative or prodrug thereof, optionally, for
[0267] In certain embodiments, the compound is of the formula:
[0268]
[0269] or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, cocrystal, tautomer, stereoisomer, isotopically labeled derivative or prodrug thereof, optionally, for
[0270] In certain embodiments, the compound is of the formula:
[0271]
[0272]
[0273] or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotope-labeled derivative or prodrug thereof.
[0274] In certain embodiments, the compound is of the formula:
[0275]
[0276] or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotope-labeled derivative or prodrug thereof.
[0277] In certain embodiments, the compound is of the formula:
[0278]
[0279] or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotope-labeled derivative or prodrug thereof.
[0280] In certain embodiments, the compound is of the formula:
[0281]
[0282] or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotope-labeled derivative or prodrug thereof.
[0283] In certain embodiments, the compound is of the formula:
[0284]
[0285] or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, cocrystal, tautomer, stereoisomer, isotopically labeled derivative or prodrug thereof, optionally, for
[0286] In certain embodiments, the compound is of the formula:
[0287]
[0288] or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, cocrystal, tautomer, stereoisomer, isotopically labeled derivative or prodrug thereof, optionally, for
[0289] In certain embodiments, the compound is of the formula:
[0290]
[0291] or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotope-labeled derivative or prodrug thereof.
[0292] In certain embodiments, the compound is of the formula:
[0293]
[0294] or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotope-labeled derivative or prodrug thereof.
[0295] In certain embodiments, the compound is of the formula:
[0296]
[0297] or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotope-labeled derivative or prodrug thereof.
[0298] In certain embodiments, the compound provided (compounds described herein, compounds of the present disclosure) is a compound of formula (I), or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotope-labeled derivative or prodrug thereof. In certain embodiments, the compound provided is a compound of formula (I), or a pharmaceutically acceptable salt, solvate, hydrate, tautomer or stereoisomer thereof. In certain embodiments, the compound provided is a compound of formula (I), or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof. In certain embodiments, the compound provided is a compound of formula (I), or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof. In certain embodiments, the compound provided is a compound of formula (I), or a pharmaceutically acceptable salt thereof. In certain embodiments, the compound provided is a mixture of tautomers. In certain embodiments, the compound provided is a mixture of enantiomers and / or diastereomers (e.g., a racemic mixture).
[0299] In certain embodiments, the molecular weight of the compound in the non-salt, solvate, hydrate, cocrystal or prodrug form provided is less than 2,000 g / mol, less than 1,500 g / mol, less than 1,200 g / mol, less than 1000 g / mol, less than 800 g / mol, less than 700 g / mol or less than 600 g / mol. In certain embodiments, the molecular weight of the compound in the non-salt, solvate, hydrate, cocrystal or prodrug form provided is less than 1000 g / mol. In certain embodiments, the molecular weight of the compound in the non-salt, solvate, hydrate, cocrystal or prodrug form provided is less than 600 g / mol.
[0300] In certain embodiments, provided compounds inhibit the activity of a kinase (e.g., abnormal activity (e.g., higher than normal activity, increased activity)). In certain embodiments, the kinase is a CDK (e.g., wild-type or mutant CDK). In certain embodiments, the kinase is CDK1, CDK2, CDK3, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, CDK10, CDK11, CDK12, CDK13, CDK14, CDK15, CDK16, CDK17, CDK18, CDK19, or CDK20. In certain embodiments, the kinase is CDK7 (e.g., wild-type or mutant CDK7). In certain embodiments, the kinase is CDK2. In certain embodiments, the kinase is CDK9. In certain embodiments, the kinase is CDK12. In certain embodiments, the kinase is a human kinase. In certain embodiments, the kinase is a non-human mammalian kinase. In certain embodiments, the kinase is a wild-type kinase. In certain embodiments, the kinase is a mutant kinase. In certain embodiments, provided compounds inhibit the activity of kinases as measured by assays described herein or known in the art. In certain embodiments, provided compounds inhibit the activity of kinases, IC 50 Less than or equal to 30 μM, less than or equal to 10 μM, less than or equal to 3 μM, less than or equal to 1 μM, less than or equal to 0.3 μM, or less than or equal to 0.1 μM.
[0301] It has been reported that certain CDK7 inhibitors also inhibit the activity of CDK12 and / or CDK13 (Kwiatowski et al., Nature, 511, 616-620 (2014)). The compounds of the present disclosure can selectively inhibit the activity of a first kinase relative to a second kinase, wherein the first and second kinases are different from each other. In certain embodiments, the first kinase is a CDK. In certain embodiments, the first kinase is CDK7. In certain embodiments, the second kinase is a kinase that is not a CDK (e.g., a kinase that is not CDK7). In certain embodiments, the second kinase is CDK2, CDK9, or CDK12. The selectivity of the compounds or pharmaceutical compositions of the present disclosure in inhibiting the activity of the first kinase relative to the second kinase can be determined by the IC of the compound or pharmaceutical composition inhibiting the activity of the second kinase. 50 The IC value of the compound or pharmaceutical composition for inhibiting the activity of the first kinase 50 The selectivity of the disclosed compounds or pharmaceutical compositions for inhibiting the activity of a first kinase relative to a second kinase can also be determined by measuring the K of the adduct of the compound or pharmaceutical composition with the second kinase. d The K value of the adduct of the compound or pharmaceutical composition with the first kinase dIn some embodiments, the compounds provided selectively inhibit the first kinase activity at least 2 times, at least 3 times, at least 4 times, at least 5 times, at least 7 times, at least 10 times, at least 20 times, at least 50 times, at least 100 times, at least 300 times, or at least 1000 times more than the second kinase activity (e.g., in an in vitro assay or an assay described herein). In some embodiments, the compounds provided selectively inhibit the first kinase activity at most 3 times, at most 4 times, at most 5 times, at most 7 times, at most 10 times, at most 20 times, at most 50 times, at most 100 times, at most 300 times, or at most 1000 times more than the second kinase activity (e.g., in an in vitro assay or an assay described herein). The compounds disclosed herein are more advantageous in treating and / or preventing diseases in subjects in need thereof relative to non-selective or less selective kinase inhibitors. The compounds disclosed herein are more selectively inhibiting the activity of CDK (e.g., CDK7) relative to other kinases (e.g., kinases other than CDK, kinases other than CDK7, CDKs other than CDK7) than other compounds (e.g., non-selective kinase inhibitors, less selective kinase inhibitors). In certain embodiments, the compounds provided are more selectively inhibiting the activity of CDK7 relative to CDK2 (e.g., at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold, at least 7-fold, at least 10-fold, at least 20-fold, at least 50-fold, at least 100-fold, at least 300-fold, or at least 1000-fold). In certain embodiments, the compounds provided are more selectively inhibiting the activity of CDK7 relative to CDK9 (e.g., at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold, at least 7-fold, at least 10-fold, at least 20-fold, at least 50-fold, at least 100-fold, at least 300-fold, or at least 1000-fold). In certain embodiments, the provided compounds more selectively inhibit the activity of CDK7 than CDK12 (e.g., at least 2 times, at least 3 times, at least 4 times, at least 5 times, at least 7 times, at least 10 times, at least 20 times, at least 50 times, at least 100 times, at least 300 times, or at least 1000 times). In certain embodiments, the provided compounds are reversibly (e.g., non-covalently) bound to kinases. In certain embodiments, the provided compounds are irreversibly (e.g., covalently) bound to kinases. Certain compounds disclosed herein can covalently modify cysteine residues (e.g., Cys312) located outside the typical kinase domain of CDK7. Cys312 is present only in CDK7. Without wishing to be bound by any particular theory, the ability of certain compounds disclosed herein to covalently modify Cys312 of CDK7 may contribute to one or more of the above-mentioned advantages of these compounds compared to certain other compounds (e.g., selectively inhibiting the activity of CDK7 relative to certain other kinases (e.g., CDKs other than CDK7)).Irreversible binding of certain compounds disclosed herein to CDK7 can lead to prolonged interruption of transcription in certain malignant and / or precancerous cells and induce apoptosis. Whole genome transcript analysis after inhibitor treatment showed that CDK7 response genes are very important in maintaining the malignant or precancerous cell state, especially MYC and MCL-1 genes. Selective inhibition of CDK7 may help treat or prevent proliferative diseases.
[0302] Compared to other compounds, the compounds of the present disclosure may be even more powerful, more effective and / or less toxic when used to treat and / or prevent diseases in subjects in need. Compared to other compounds, the compounds of the present disclosure may also reduce the frequency of side effects, reduce the severity of side effects, increase the compliance of the subject, and / or reduce drug resistance when used to treat and / or prevent diseases in subjects in need. In addition, compared to other compounds, the compounds of the present disclosure may be more soluble, more permeable, more micro-stable and / or more bioavailable, and / or may show improved pharmacokinetic properties. The compounds of the present disclosure include a carbocyclic group or a heterocyclic group as ring D. Without wishing to be bound by any particular theory, ring D may contribute to one or more of the above-mentioned advantages of the compounds of the present disclosure relative to certain other compounds.
[0303] In another aspect, the present disclosure provides methods of preparing the compounds described herein. In certain embodiments, the method of preparation is a method described herein (eg, a method described in Example 1).
[0304] Pharmaceutical compositions, kits and administration
[0305] In another aspect, the present disclosure provides pharmaceutical compositions comprising a compound of the present disclosure and optionally a pharmaceutically acceptable excipient. In certain embodiments, the pharmaceutical compositions of the present disclosure comprise an effective amount of a compound of the present disclosure.
[0306] The pharmaceutical compositions of the present disclosure can be used to treat and / or prevent diseases in subjects in need thereof (e.g., proliferative diseases (e.g., cancer, benign neoplasms, inflammatory diseases, autoimmune diseases, pathological angiogenesis) cystic fibrosis). The compositions of the present disclosure can also be used to inhibit the activity of protein kinases (e.g., CDKs) in subjects, biological samples, tissues, or cells. The compositions of the present disclosure can be used to treat and / or prevent diseases associated with overexpression or abnormal activity of cyclin-dependent kinases (CDKs). The compositions of the present disclosure can also be used to induce apoptosis of cells (e.g., malignant cells or precancerous cells).
[0307] In certain embodiments, an effective amount is a therapeutically effective amount (e.g., an amount that effectively treats a disease in a subject in need thereof). In certain embodiments, an effective amount is an amount that effectively inhibits the activity of a protein kinase (e.g., a CDK (e.g., CDK7)) in a subject in need thereof. In certain embodiments, an effective amount is an amount that effectively inhibits the activity of a protein kinase (e.g., a CDK (e.g., CDK7)) in a subject, a biological sample, a tissue, or a cell. In certain embodiments, an effective amount is an amount that is effective for inducing apoptosis. In certain embodiments, an effective amount is a preventive effective amount (e.g., an amount that is effective for preventing a disease in a subject in need thereof and / or for alleviating a disease in a subject in need thereof).
[0308] In certain embodiments, an effective amount is an amount that effectively inhibits protein kinase (e.g., CDK (e.g., CDK7)) activity by at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, or at least about 98%. In certain embodiments, an effective amount is an amount that effectively inhibits protein kinase (e.g., CDK (e.g., CDK7)) activity by no more than 10%, no more than 20%, no more than 30%, no more than 40%, no more than 50%, no more than 60%, no more than 70%, no more than 80%, no more than 90%, no more than 95%, or no more than 98%. In certain embodiments, an effective amount is an amount that effectively inhibits protein kinase (e.g., CDK (e.g., CDK7)) activity within the range (including two endpoint values) between the percentages described in this paragraph and another percentage described in this paragraph.
[0309] In certain embodiments, the subject is an animal. This animal may be of any gender and may be at any stage of development. In certain embodiments, the subject described herein is a person. In certain embodiments, the subject is a non-human animal. In certain embodiments, the subject is a mammal. In certain embodiments, the subject is a non-human mammal. In certain embodiments, the subject is a domesticated animal, such as a dog, cat, cow, pig, horse, sheep or goat. In certain embodiments, the subject is a dog. In certain embodiments, the subject is a companion animal, such as a dog or a cat. In certain embodiments, the subject is a livestock animal, such as a cow, pig, horse, sheep or goat. In certain embodiments, the subject is a zoo animal. In another embodiment, the subject is a research animal, such as a rodent (e.g., mouse, rat), dog, pig or non-human primate. In certain embodiments, the animal is a genetically engineered animal. In certain embodiments, the animal is a transgenic animal (e.g., transgenic mouse, transgenic pig). In certain embodiments, the subject is a fish or a reptile.
[0310] In certain embodiments, the biological sample, tissue or cell (e.g., a biological sample, tissue or cell contacted with a compound or pharmaceutical composition described herein) is in vitro. In certain embodiments, the biological sample, tissue or cell is in vivo or ex vivo. In certain embodiments, the cell is a malignant cell or a precancerous cell. In certain embodiments, the biological sample is a tissue from a tumor (e.g., a malignant or benign neoplasm).
[0311] The pharmaceutical compositions described herein can be prepared by any method known in the art of pharmacology. Generally, such preparation methods include combining the compounds described herein (i.e., "active ingredients") with carriers or excipients and / or one or more other auxiliary ingredients, and then, if necessary and / or desired, forming and / or packaging the product into desired single or multiple dose units.
[0312] Pharmaceutical compositions can be prepared, packaged, and / or sold in bulk as a single unit dose and / or as a plurality of single unit doses. A "unit dose" is a discrete amount of a pharmaceutical composition containing a predetermined amount of an active ingredient. The amount of the active ingredient is generally equal to the dose of the active ingredient to be administered to a subject and / or a convenient fraction of such a dose, such as one-half or one-third of such a dose.
[0313] The relative amounts of the active ingredient, pharmaceutically acceptable excipients and / or any additional ingredients in the pharmaceutical compositions described herein will vary depending on the characteristics, size and / or condition of the subject being treated, and further vary depending on the route of administration of the composition. The composition may contain 0.1% to 100% (w / w) of the active ingredient.
[0314] Pharmaceutically acceptable excipients for preparing the provided pharmaceutical compositions include inert diluents, dispersants and / or granulating agents, surfactants and / or emulsifiers, disintegrants, binders, preservatives, buffers, lubricants and / or oils. Excipients such as cocoa butter and suppository waxes, colorants, coating agents, sweeteners, flavoring agents and fragrances may also be present in the compositions.
[0315] Exemplary diluents include calcium carbonate, sodium carbonate, calcium phosphate, dicalcium phosphate, calcium sulfate, calcium hydrogen phosphate, sodium lactose phosphate, sucrose, cellulose, microcrystalline cellulose, kaolin, mannitol, sorbitol, inositol, sodium chloride, dry starch, corn starch, powdered sugar, and mixtures thereof.
[0316] Exemplary granulating and / or dispersing agents include potato starch, corn starch, tapioca starch, sodium starch glycolate, clays, alginic acid, guar gum, citrus pulp, agar, bentonite, cellulose and wood products, natural sponges, cation exchange resins, calcium carbonate, silicates, sodium carbonate, cross-linked poly(vinyl pyrrolidone) (crospovidone), sodium carboxymethyl starch (sodium starch glycolate), carboxymethyl cellulose, cross-linked sodium carboxymethyl cellulose (croscarmellose), methyl cellulose, pregelatinized starch (starch 1500), microcrystalline starch, water insoluble starch, calcium carboxymethyl cellulose, magnesium aluminum silicate (Veegum), sodium lauryl sulfate, quaternary ammonium compounds, and mixtures thereof.
[0317] Exemplary surfactants and / or emulsifiers include natural emulsifiers (e.g., acacia, agar, alginic acid, sodium alginate, cascara gum, chondrux, cholesterol, xanthan gum, pectin, gelatin, egg yolk, casein, wool fat, cholesterol, waxes, and lecithin), colloidal clays (e.g., bentonite (aluminum silicate) and Veegum (magnesium aluminum silicate)), long chain amino acid derivatives, high molecular weight alcohols (e.g., stearyl alcohol, cetyl alcohol, oleyl alcohol, triacetin monostearate, ethylene glycol distearate, glyceryl monostearate, propylene glycol monostearate, polyvinyl alcohol), carbomers (e.g., carboxypolymethylene, polyacrylic acid, acrylic acid polymers, and carboxyvinyl polymers), carrageenan, cellulose derivatives (e.g., sodium carboxymethylcellulose, powdered cellulose, hydroxymethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, methylcellulose), sorbitan fatty acid esters (e.g., polyoxyethylene sorbitan monolaurate ( 20) Polyoxyethylene sorbitan ( 60), polyoxyethylene sorbitan monooleate ( 80), Sorbitan monopalmitate ( 40) Sorbitan monostearate ( 60), sorbitan tristearate ( 65), monoolein, sorbitan monooleate ( 80), polyoxyethylene esters (e.g., polyoxyethylene monostearate ( 45), polyoxyethylene hydrogenated castor oil, polyethoxylated castor oil, polyoxymethylene stearate and ), sucrose fatty acid esters, polyethylene glycol fatty acid esters (e.g., ), polyoxyethylene ethers, (e.g., polyoxyethylene lauryl ether ( 30)), poly(vinyl-pyrrolidone), diethylene glycol monolaurate, triethanolamine oleate, sodium oleate, potassium oleate, ethyl oleate, oleic acid, ethyl laurate, sodium lauryl sulfate, F-68, poloxamer P-188, cetrimide bromide, cetylpyridinium chloride, benzalkonium chloride, docusate sodium and / or mixtures thereof.
[0318] Exemplary binders include starches (e.g., corn starch and starch paste), gelatin, sugars (e.g., sucrose, glucose, dextrose, dextrin, molasses, lactose, lactitol, mannitol, etc.), natural and synthetic gums (e.g., acacia, sodium alginate, Irish moss extract, panwar gum, ghatti gum, isapol shell mucilage, carboxymethyl cellulose, methyl cellulose, ethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, microcrystalline cellulose, cellulose acetate, polyvinyl pyrrolidone, magnesium aluminum silicate, and larch arabinogalactan), alginate, polyethylene oxide, polyethylene glycol, inorganic calcium salt, silicic acid, polymethacrylate, wax, water, alcohol and / or mixtures thereof.
[0319] Exemplary preservatives include antioxidants, chelating agents, antimicrobial preservatives, antifungal preservatives, antiprotozoal preservatives, alcohol preservatives, acidic preservatives and other preservatives. In certain embodiments, the preservative is an antioxidant. In other embodiments, the preservative is a chelating agent.
[0320] Exemplary antioxidants include alpha-tocopherol, ascorbic acid, ascorbyl palmitate, butylated hydroxyanisole, butylated hydroxytoluene, monothioglycerol, potassium metabisulfite, propionic acid, propyl gallate, sodium ascorbate, sodium bisulfite, sodium metabisulfite, and sodium sulfite.
[0321] Exemplary chelating agents include ethylenediaminetetraacetic acid (EDTA) and its salts and hydrates (e.g., edetate sodium, disodium edetate, trisodium edetate, calcium disodium edetate, dipotassium edetate, etc.), citric acid and its salts and hydrates (e.g., citric acid monohydrate), fumaric acid and its salts and hydrates, malic acid and its salts and hydrates, phosphoric acid and its salts and hydrates, and tartaric acid and its salts and hydrates. Exemplary antimicrobial preservatives include benzalkonium chloride, benzethonium chloride, benzyl alcohol, bronopol, cetrimide, cetylpyridinium chloride, chlorhexidine, chlorobutanol, chlorocresol, chlorooxycresol, cresol, ethanol, glycerin, hexetidine, imidazole, phenol, phenoxyethanol, phenylethyl alcohol, phenylmercuric nitrate, propylene glycol, and thimerosal.
[0322] Exemplary antifungal preservatives include butyl paraben, methyl paraben, ethyl paraben, propyl paraben, benzoic acid, hydroxybenzoic acid, potassium benzoate, potassium sorbate, sodium benzoate, sodium propionate, and sorbic acid.
[0323] Exemplary alcohol preservatives include ethanol, polyethylene glycol, phenol, phenolic compounds, bisphenol, chlorobutanol, hydroxybenzoic acid esters, and phenethyl alcohol.
[0324] Exemplary acidic preservatives include vitamin A, vitamin C, vitamin E, beta-carotene, citric acid, acetic acid, dehydroacetic acid, ascorbic acid, sorbic acid, and phytic acid.
[0325] Other preservatives include tocopherol, tocopheryl acetate, mesylate eluted oxime, cetramide, butylated hydroxyanisol (BHA), butylated hydroxytoluene (BHT), ethylenediamine, sodium lauryl sulfate (SLS), sodium lauryl ether sulfate (SLES), sodium bisulfite, sodium metabisulfite, potassium sulfite, potassium metabisulfite, Plus, Methylparaben, 115. II. and
[0326] Exemplary buffers include citrate buffer, acetate buffer solution, phosphate buffer solution, ammonium chloride, calcium carbonate, calcium chloride, calcium citrate, calcium glucuronate, calcium glucoheptonate, D-gluconic acid, calcium glycerophosphate, calcium lactate, propionic acid, calcium valerate, valeric acid, dibasic calcium phosphate, phosphoric acid, tricalcium phosphate, dibasic calcium phosphate, potassium acetate, potassium chloride, potassium gluconate, potassium mixtures, monopotassium phosphate, monopotassium phosphate, potassium phosphate mixtures, sodium acetate, sodium bicarbonate, sodium chloride, sodium citrate, sodium lactate, monosodium phosphate, monosodium phosphate, sodium phosphate mixtures, tromethamine, magnesium hydroxide, aluminum hydroxide, alginic acid, pyrogen-free water, isotonic saline, Ringer's solution, ethanol, and mixtures thereof.
[0327] Exemplary lubricants include magnesium stearate, calcium stearate, stearic acid, silicon dioxide, talc, malt, glyceryl behenate, hydrogenated vegetable oils, polyethylene glycol, sodium benzoate, sodium acetate, sodium chloride, leucine, magnesium lauryl sulfate, sodium lauryl sulfate, and mixtures thereof.
[0328] Exemplary natural oils include almond, apricot, avocado, babassu, bergamot, black currant seed, borage, juniper, chamomile, canola, coriander, carnauba, castor, cinnamon, cocoa butter, coconut, cod liver, coffee, corn, cottonseed, emu, eucalyptus, evening primrose, fish, flaxseed, geraniol, gourd, grape seed, hazelnut, hyssop, isopropyl myristate, jojoba, kuju, lavender, Lavender, lemon, litsea cubeba, macadamia nut, mallow, mango seed, meadowfoam seed, mink, nutmeg, olive, orange, orange roughy, palm, palm kernel, peach kernel, peanut, poppy seed, pumpkin seed, rapeseed, rice bran, rosemary, safflower, sandalwood, sasquana, savory, sea buckthorn, sesame, shea butter, silicone, soybean, sunflower, tea tree, thistle, tsubaki, vetiver, walnut, and wheat germ oil. Exemplary synthetic oils include butyl stearate, caprylic triglyceride, capric triglyceride, cyclomethicone, diethyl sebacate, dimethicone 360, isopropyl myristate, mineral oil, octyldodecanol, oleyl alcohol, silicone oil, and mixtures thereof.
[0329] Liquid dosage forms for oral and parenteral administration include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active ingredient, the liquid dosage form may contain inert diluents commonly used in the art, such as water or other solvents, solubilizers and emulsifiers, such as ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (e.g., cottonseed oil, peanut oil, corn oil, germ oil, olive oil, castor oil and sesame oil), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycol and fatty acid esters of sorbitol, and mixtures thereof. In addition to inert diluents, the oral composition may include adjuvants such as wetting agents, emulsifiers, suspending agents, sweeteners, flavoring agents and fragrances. In certain embodiments for parenteral administration, the conjugates described herein are mixed with a solubilizer, such as Alcohols, oils, modified oils, glycols, polysorbates, cyclodextrins, polymers, and mixtures thereof.
[0330] Injectable preparations, such as sterile injectable aqueous or oily suspensions can be prepared according to known techniques using suitable dispersants or wetting agents and suspending agents. The sterile injectable preparation can be a sterile injectable solution, suspension or emulsion in a non-toxic parenterally acceptable diluent or solvent, such as a solution in 1,3-butanediol. Acceptable available vehicles and solvents are water, USP Ringer's solution and isotonic sodium chloride solution. In addition, sterile fixed oils are used as solvents or suspension media as a rule. For this purpose, any mild fixed oil can be used, including synthetic mono- or di-glycerides. In addition, fatty acids such as oleic acid can be used for the preparation of injectable preparations.
[0331] The injection preparations can be sterilized, for example, by filtration through a bacteria filter or by incorporating sterilizing agents in the form of sterile solid compositions that can be dissolved or dispersed in sterile water or other sterile injectable media prior to use.
[0332] In order to prolong the effect of the drug, it is usually desirable to slow down the absorption of the drug from subcutaneous or intramuscular injection. This can be achieved by using a liquid suspension of a crystalline or amorphous material with poor water solubility. The absorption rate of the drug then depends on its dissolution rate, which in turn depends on the crystal size and crystal morphology. Alternatively, delayed absorption of a parenteral administration form can be achieved by dissolving or suspending the drug in an oily vehicle.
[0333] Compositions for rectal or vaginal administration are typically suppositories, which can be prepared by mixing the conjugates described herein with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax, which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active ingredients.
[0334] Oral solid dosage forms include capsules, tablets, pills, powders and granules. In such solid dosage forms, the active ingredient is mixed with at least one inert pharmaceutically acceptable excipient or carrier (such as sodium citrate or dicalcium phosphate) and / or the following: (a) fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol and silicic acid, (b) binders, such as carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and gum arabic, (c) humectants, such as glycerol, (d) disintegrants, such as agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates and sodium carbonate, (e) solution retarding agents, such as paraffin, (f) absorption promoters, such as quaternary ammonium compounds, (g) wetting agents, such as cetyl alcohol and glyceryl monostearate, (h) absorbents, such as kaolin and bentonite clays, and (i) lubricants, such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets and pills, the dosage form may comprise buffering agents.
[0335] Solid compositions of similar types can be used as fillers in soft-filled and hard-filled gelatin capsules using excipients such as lactose or milk sugar and high molecular weight polyethylene glycols. Solid dosage forms of tablets, dragees, capsules, pills and granules can be prepared with coatings and shells, such as enteric coatings and other coatings known in the field of pharmacology. They can optionally contain opacifiers and can be compositions that release active ingredients only or preferably in a specific part of the intestinal tract, optionally in a delayed manner. Examples of encapsulated compositions that can be used include polymeric substances and waxes. Solid compositions of similar types can be used as fillers in soft-filled and hard-filled gelatin capsules using excipients such as lactose or milk sugar and high molecular weight polyethylene glycols.
[0336] The active ingredient can be in the form of a microcapsule with one or more excipients as described above. The solid dosage forms of tablets, dragees, capsules, pills and granules can be prepared with coatings and shells, such as enteric coatings, controlled release coatings and other coatings known in the field of pharmacology. In this solid dosage form, the active ingredient can be mixed with at least one inert diluent such as sucrose, lactose or starch. As in conventional practice, in addition to inert diluents, this dosage form can also include additional substances, such as tableting lubricants and other tableting aids, such as magnesium stearate and microcrystalline cellulose. In the case of capsules, tablets and pills, the dosage form can include a buffer. They can optionally contain an emulsifier, and can be a composition that they only or preferably release the active ingredient in a delayed manner in a specific part of the intestinal tract. Examples of encapsulating agents that can be used include polymeric substances and waxes.
[0337] The dosage form for topical and / or transdermal administration of the compounds described herein may include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants and / or patches. Typically, active ingredients are mixed with pharmaceutically acceptable carriers or excipients and / or any desired preservatives and / or buffers under aseptic conditions. In addition, the disclosure contemplates the use of transdermal patches, which typically have the added advantage of providing controlled delivery of active ingredients to the body. Such dosage forms can be prepared, for example, by dissolving and / or dispersing active ingredients in an appropriate medium. Alternatively or additionally, rate control can be performed by providing a rate-controlled membrane and / or by dispersing active ingredients in a polymer matrix and / or a gel.
[0338] Suitable devices for delivering intradermal pharmaceutical compositions described herein include short needle devices. Intradermal compositions can be applied by devices that limit the effective penetration length of the needle into the skin. Alternatively or additionally, conventional syringes can be used for the classic mantoux method of intradermal administration. It is suitable to deliver liquid preparations to the dermis via a liquid jet injector and / or via a needle, which pierces the stratum corneum and produces a jet that reaches the dermis. It is suitable to use a ballistic powder / particle delivery device that accelerates the compound in powder form to reach the dermis through the skin outer layer to accelerate the compound in powder form.
[0339] Preparations suitable for topical administration include liquid and / or semi-liquid preparations, such as liniments, lotions, oil-in-water and / or water-in-oil emulsions, such as creams, ointments and / or pastes, and / or solutions and / or suspensions. Topical preparations may contain, for example, about 1% to about 10% (w / w) of the active ingredient, although the concentration of the active ingredient may be as high as the solubility limit of the active ingredient in the solvent. Topical preparations may further include one or more additional ingredients described herein.
[0340] The pharmaceutical compositions described herein can be prepared, packaged and / or sold in the form of a formulation suitable for pulmonary administration via the oral cavity. Such a formulation may include dry particles comprising an active ingredient and having a diameter of about 0.5 to about 7 nanometers, or about 1 to about 6 nanometers. Such a composition is conveniently in the form of a dry powder for use with a device comprising a dry powder reservoir into which a propellant stream can be directed to disperse the powder and / or with a self-propelling solvent / powder dispensing container (e.g., a device comprising an active ingredient dissolved and / or suspended in a sealed container). Such a powder includes particles in which at least 98% by weight of the particles have a diameter greater than 0.5 nanometers and at least 95% by number of the particles have a diameter less than 7 nanometers. Alternatively, at least 95% by weight of the particles have a diameter greater than 1 nanometer and at least 90% by number of the particles have a diameter less than 6 nanometers. The dry powder composition can include a solid fine powder diluent, such as sugar, and can be conveniently provided in a unit dose form.
[0341] Low boiling point propellants generally include liquid propellants with a boiling point below 65°F at atmospheric pressure. Typically, the propellant may comprise 50-99.9% (w / w) of the composition, and the active ingredient may comprise 0.1-20% (w / w) of the composition. The propellant may further comprise additional ingredients, such as liquid nonionic and / or solid anionic surfactants and / or solid diluents (which may have a particle size of the same order as the particles comprising the active ingredient).
[0342] The pharmaceutical compositions prepared for pulmonary delivery described herein can provide active ingredients in the form of droplets of solutions and / or suspensions. Such preparations can be prepared, packaged and / or sold as aqueous and / or dilute alcoholic solutions and / or suspensions containing the active ingredients that are optionally sterile, and can be conveniently administered using any spray and / or atomizing device. Such preparations can also include one or more additional ingredients, including flavorings such as sodium saccharin, volatile oils, buffers, surfactants and / or preservatives such as methyl hydroxybenzoate. The average diameter of the droplets provided by this route of administration can be in the range of about 0.1 to about 200 nanometers.
[0343] The formulations described herein that can be used for pulmonary delivery can be used for nasal delivery of the pharmaceutical compositions described herein. Another formulation suitable for nasal administration is a coarse powder containing the active ingredient and having an average particle size of about 0.2 to 500 microns. Such a formulation is administered by rapid inhalation through the nasal passages from a powder container close to the nostrils.
[0344] The formulation for nasal administration may contain, for example, as little as about 0.1% (w / w) to as much as 100% (w / w) of the active ingredient, and may contain one or more additional ingredients described herein. The pharmaceutical compositions described herein may be prepared, packaged and / or sold in the form of an oral formulation. Such a formulation may be in the form of tablets and / or lozenges, for example, prepared using conventional methods, and may contain, for example, 0.1 to 20% (w / w) of the active ingredient, the remainder comprising an orally soluble and / or degradable composition and optionally one or more additional ingredients described herein. Alternatively, the formulation for oral administration may include a powder and / or atomized and / or atomized solution and / or suspension containing the active ingredient. When dispersed, the average particle and / or droplet size of such a powdered, atomized and / or atomized formulation may be in the range of about 0.1 to about 200 nanometers, and may further comprise one or more additional ingredients described herein.
[0345] The pharmaceutical compositions described herein can be prepared, packaged and / or sold in the form of formulations for ocular administration. Such formulations can be, for example, in the form of eye drops, including, for example, a solution and / or suspension of 0.1-1.0% (w / w) active ingredient in an aqueous or oily liquid carrier or excipient. Such drops can further include a buffer, a salt and / or one or more other additional ingredients described herein. Other available ocular formulations include formulations comprising active ingredients in microcrystalline form and / or liposomal formulations. Ear drops and / or eye drops are also contemplated within the scope of the present disclosure.
[0346] Although the description of the pharmaceutical compositions provided herein is primarily directed to pharmaceutical compositions suitable for administration to humans, it will be appreciated by those skilled in the art that such compositions are generally suitable for administration to various animals. Modification of pharmaceutical compositions suitable for administration to humans to make the compositions suitable for administration to various animals is well understood, and ordinary veterinary pharmacologists can design and / or perform such modifications using ordinary experiments.
[0347] The compounds provided herein are generally formulated in dosage unit form for ease of administration and dosage uniformity. However, it should be understood that the total daily usage of the compositions described herein will be determined by the physician within the scope of reasonable medical judgment. The specific therapeutically effective dosage level for any particular subject or organism will depend on a variety of factors, including the disease being treated and the severity of the disease; the activity of the specific active ingredient used; the specific composition used; the age, weight, general health, sex and diet of the subject; the administration time, route of administration and excretion rate of the specific active ingredient used; the duration of treatment; drugs used in combination or in concert with the specific active ingredient used; and factors well known in the medical field.
[0348] The compounds and compositions provided herein can be administered by any route, including enteral administration (e.g., oral), parenteral, intravenous, intramuscular, intraarterial, intramedullary, intrathecal, subcutaneous, intraventricular, transdermal, interdermal, rectal, intravaginal, intraperitoneal, topical (e.g., by powder, ointment, cream and / or drops), mucosal, nasal, oral, sublingual; by intratracheal instillation, bronchial instillation and / or inhalation; and / or as oral spray, nasal spray and / or aerosol. Particularly contemplated routes are oral administration, intravenous administration (e.g., systemic intravenous injection), administration via blood and / or lymphatic supply areas, and / or direct administration to affected sites. In general, the most appropriate route of administration will depend on a variety of factors, including the properties of the medicament (e.g., its stability in the gastrointestinal environment), and / or the condition of the subject (e.g., whether the subject can tolerate oral administration). In certain embodiments, the compounds or pharmaceutical compositions described herein are suitable for topical administration to the subject's eyes.
[0349] The exact amount of compound required to reach an effective amount varies from subject to subject, for example, depending on the species, age and general condition of the subject, the severity of the side effects or obstacles, the characteristics of a specific compound, the mode of administration, etc. The effective amount may be included in a single dose (e.g., a single oral dose) or multiple doses (e.g., multiple oral doses). In certain embodiments, when multiple doses are applied to a subject or multiple doses are applied to a biological sample, tissue or cell, any two doses of the multiple doses include different or substantially the same amount of compounds as described herein. In certain embodiments, when multiple doses are applied to a subject or multiple doses are applied to a biological sample, tissue or cell, the frequency of applying multiple doses to the subject or multiple doses to the biological sample, tissue or cell is three doses per day, two doses per day, one dose per day, one dose every other day, one dose every third day, one dose per week, one dose every two weeks, one dose every three weeks, or one dose every four weeks. In certain embodiments, the frequency of applying multiple doses to a subject or applying multiple doses to a biological sample, tissue or cell is one dose per day. In certain embodiments, the frequency of applying multiple doses to a subject or applying multiple doses to a biological sample, tissue or cell is two doses per day. In certain embodiments, the frequency of applying multiple doses to a subject or applying multiple doses to a biological sample, tissue or cell is three doses per day. In certain embodiments, when multiple doses are applied to a subject or multiple doses are applied to a biological sample, tissue or cell, the duration between the first dose of the multiple dose and the last dose is one day, two days, four days, one week, two weeks, three weeks, one month, two months, three months, four months, six months, nine months, one year, two years, three years, four years, five years, seven years, ten years, fifteen years, twenty years or the life span of the subject or cell. In certain embodiments, the duration between the first dose of the multiple dose and the last dose is three months, six months or one year. In certain embodiments, the duration between the first dose of the multiple dose and the last dose is the life span of the subject or cell. In certain embodiments, a dose (e.g., a single dose, or any one of multiple doses) independently includes 0.1 μg to 1 μg, 0.001 mg to 0.01 mg, 0.01 mg to 0.1 mg, 0.1 mg to 1 mg, 1 mg to 3 mg, 3 mg to 10 mg, 10 mg to 30 mg, 30 mg to 100 mg, 100 mg to 300 mg, 300 mg to 1000 mg, or 1 g to 10 g (including endpoints) of a compound described herein. In certain embodiments, a dose described herein independently includes 1 mg to 3 mg (including endpoints) of a compound described herein. In certain embodiments, a dose described herein independently includes 3 mg to 10 mg (including endpoints) of a compound described herein. In certain embodiments, a dose described herein independently includes 10 mg to 30 mg (including endpoints) of a compound described herein.In certain embodiments, the dosages described herein independently comprise 30 mg to 100 mg (inclusive) of a compound described herein.
[0350] The dosage ranges described herein provide guidance for administering the provided pharmaceutical compositions to adults. The amount administered to, for example, a child or adolescent can be determined by a physician or person skilled in the art, and may be lower than or the same as that administered to an adult. In certain embodiments, the dosages described herein are for an adult weighing about 70 kg.
[0351] Compounds or compositions described herein can be administered in combination with one or more additional agents different from compounds disclosed herein. In certain embodiments, additional agents are additional therapeutic agents, additional preventive agents, or combinations thereof. The compound or composition can be administered in combination with additional agents, which improve the activity of the compound or composition (e.g., improve its activity (e.g., efficacy and / or efficacy) in terms of the disease in the subject in need of treatment, the disease in the subject in need of prevention, and the activity (e.g., efficacy and / or efficacy) in terms of the activity of kinases (e.g., CDK) in the subject, biological sample, tissue, or cell), improve bioavailability, improve safety, reduce drug resistance, reduce and / or change metabolism, inhibit excretion, and / or change the distribution in the subject, biological sample, tissue, or cell. It should also be understood that the therapy used can achieve the desired effect for the same disease, and / or different effects can be achieved. In certain embodiments, the pharmaceutical composition described herein comprising compounds described herein and additional agents shows a synergistic effect, and when the pharmaceutical composition comprises one of the compound and additional agents but not both, this synergistic effect does not exist.
[0352] The compound or composition can be used simultaneously, before or after one or more additional agents used as conjoint therapy. Medicaments include therapeutic active agents. Medicaments also include preventive active agents. Medicaments include small organic molecules, such as pharmaceutical compounds (e.g., compounds approved by the U.S. Food and Drug Administration for human or veterinary use as specified in the Federal Regulations (CFR)), peptides, proteins, carbohydrates, monosaccharides, oligosaccharides, polysaccharides, nucleoproteins, mucins, lipoproteins, synthetic polypeptides or proteins, small molecules connected to proteins, glycoproteins, steroids, nucleic acids, DNA, RNA, nucleotides, nucleosides, oligonucleotides, antisense oligonucleotides, lipids, hormones, vitamins, and cells. In certain embodiments, the additional medicament is an agent that can be used to treat and / or prevent diseases (e.g., proliferative diseases, cancer, inflammatory diseases, autoimmune diseases, genetic diseases, blood diseases, neurological diseases, pain symptoms, mental disorders or metabolic disorders) or precancerous conditions. Each additional medicament can be administered according to the dosage and / or schedule determined for the medicament. Additional agents may also be administered in a single dose together with each other and / or with the compounds or compositions described herein, or separately in different doses. The specific combination used in the protocol will take into account the compatibility of the compounds described herein with the additional agents and / or the desired therapeutic and / or preventive effects to be achieved. Generally, it is contemplated that the level of use of the additional agents in the combination will not exceed the level when they are used alone. In some embodiments, the level of combined use will be lower than the level when used alone.
[0353] Additional agents include cytotoxic chemotherapeutic agents, epigenetic modifiers, glucocorticoids, immunotherapeutic agents, antiproliferative agents, anticancer agents, cytotoxic agents, antiangiogenic agents, anti-inflammatory agents, immunosuppressants, antibacterial agents, antiviral agents, cardiovascular agents, cholesterol-lowering agents, antidiabetic agents, antiallergic agents, contraceptives, analgesics, and combinations thereof. In certain embodiments, the additional agent is an antiproliferative agent (e.g., an anticancer agent). In certain embodiments, the additional agent is abiraterone acetate (e.g., ZYTIGA), ABVD, ABVE, ABVE-PC, AC, AC-T, ADE, ado-trastuzumab (e.g., KADCYLA), afatinib maleate (e.g., GILOTRIF), aldesleukin (e.g., PROLEUKIN), alemtuzumab (e.g., CAMPATH), anastrozole (e.g., ARIMIDEX), arsenic trioxide (e.g., TRISENOX), Erwinia chrysanthemi asparaginase (e.g., ERWINAZE), axitinib (e.g., INLYTA), azacitidine (e.g., MYLOSAR, VIDAZA), BEACOPP, belinostat (e.g., BELEODAQ), bendamustine hydrochloride (e.g., TREANDA), BEP , bevacizumab (e.g., AVASTIN), bicalutamide (e.g., CASODEX), bleomycin (e.g., BLENOXANE), blinatumomab (e.g., BLINCYTO), bortezomib (e.g., VELCADE), bosutinib (e.g., BOSULIF), brentuximab (e.g., ADCETRIS), busulfan (e.g., BUSULFEX, MYLERAN), cabazitaxel (e.g., JEVTANA), cabozantinib malate (e.g., COMETRIQ), CAF, capecitabine (e.g., XELODA), CAPOX, carboplatin (e.g., PARAPLAT, PARAPLATIN), carboplatin-paclitaxel, carfilzomib (e.g., KYPROLIS), carmustine (e.g., BECENUM, BICNU, CARMUBRIS), carmustine implant (e.g., GLIADEL WAFER, GLIADEL), ceritinib (e.g., ZYKADIA), cetuximab (e.g., ERBITUX), chlorambucil (e.g., AMBOCHLORIN, AMBOCLORIN, LEUKERAN, LINFOLIZIN), chlorambucil-prednisone, CHOP, cisplatin (e.g., PLATINOL, PLATINOL-AQ), clofarabine (e.g., CLOFAREX, CLOLAR), CMF, COPP, COPP-ABV, crizotinib (e.g., XALKORI), CVP, cyclophosphamide (e.g.,CLAFEN, CYTOXAN, NEOSAR), cytarabine (e.g., CYTOSAR-U, TARABINE PFS), dabrafenib (e.g., TAFINLAR), dacarbazine (e.g., DTIC-DOME), dactinomycin (e.g., COSMEGEN), dasatinib (e.g., SPRYCEL), daunorubicin hydrochloride (e.g., CERUBIDINE), decitabine (e.g., DACOGEN), degarelix, denileukin diftitox (e.g., ONTAK), denosumab (e.g., PROLIA, XGEVA), dinutuximab (e.g., UNITUXIN), docetaxel (e.g., TAXOTERE), doxorubicin hydrochloride (e.g., ADRIAMYCIN PFS, ADRIAMYCIN RDF), liposomal doxorubicin hydrochloride (e.g., DOXIL, DOX-SL, EVACET, LIPODOX), enzalutamide (e.g., XTANDI), epirubicin hydrochloride (e.g., ELLENCE), EPOCH, erlotinib hydrochloride (e.g., TARCEVA), etoposide (e.g., TOPOSAR, VEPESID), etoposide phosphate (e.g., ETOPOPHOS), everolimus (e.g., AFINITOR DISPERZ, AFINITOR), exemestane (e.g., AROMASIN), FEC, fludarabine phosphate (e.g., FLUDARA), fluorouracil (e.g., ADRUCIL, EFUDEX, FLUOROPLEX), FOLFIRI, FOLFIRI-BEVACIZUMAB, FOLFIRI-CETUXIMAB, FOLFIRINOX, FOLFOX, FU-LV, fulvestrant (e.g., FASLODEX), gefitinib (e.g., IRESSA), gemcitabine hydrochloride (e.g., GEMZAR), gemcitabine-cisplatin, gemcitabine-oxaliplatin , goserelin acetate (e.g., ZOLADEX), Hyper-CVAD, ibritumomab tiuxetan (e.g., ZEVALIN), ibrutinib (e.g., IMBRUVICA), ICE, idelalisib (e.g., ZYDELIG), ifosfamide (e.g., CYFOS, IFEX, IFOSFAMIDUM), imatinib mesylate (e.g., GLEEVEC), imiquimod (e.g., ALDARA), ipilimumab (e.g., YERVOY), irinotecan hydrochloride (e.g., CAMPTOSAR), ixabepilone (e.g., IXEMAPR), lanreotide acetate (e.g., SOMATULINE DEPOT), lapatinib ditosylate (e.g., TYKERB), lenalidomide (e.g., REVLIMID), lenvatinib (e.g.,LENVIMA), letrozole (e.g., FEMARA), leucovorin (e.g., WELLCOVORIN), leuprolide acetate (e.g., LUPRON DEPOT, LUPRON DEPOT-3MONTH, LUPRON DEPOT-4MONTH, LUPRON DEPOT-PED, LUPRON, VIADUR), liposomal cytarabine (e.g., DEPOCYT), lomustine (e.g., CEENU), mechlorethamine hydrochloride (e.g., MUSTARGEN), megestrol acetate (e.g., MEGACE), mercaptopurine (e.g., PURINETHOL, PURIXAN), methotrexate (e.g., ABITREXATE, FOLEX PFS, FOLEX, METHOTREXATE LPF, MEXATE, MEXATE-AQ), mitomycin c (e.g., MITOZYTREX, MUTAMYCIN), mitoxantrone hydrochloride, MOPP, nelarabine (e.g., ARRANON), nilotinib (e.g., TASIGNA), nivolumab (e.g., OPDIVO), obinutuzumab (e.g., GAZYVA), OEPA, ofatumumab (e.g., ARZERRA), OFF, olaparib (e.g., LYNPARZA), homoharringtonine (e.g., SYNRIBO), OPPA, oxaliplatin (e.g., ELOXATIN), paclitaxel (e.g., TAXOL), albumin-stabilized nanoparticle formulations of paclitaxel (e.g., ABRAXANE), PAD, palbociclib (e.g., IBRANCE), pamidronate disodium (e.g., AREDIA), panitumumab (e.g., , VECTIBIX), panobinostat (e.g., FARYDAK), pazopanib hydrochloride (e.g., VOTRIENT), pegaspargase (e.g., ONCASPAR), peginterferon alfa-2b (e.g., PEG-INTRON), peginterferon alfa-2b (e.g., SYLATRON), pembrolizumab (e.g., KEYTRUDA), pemetrexed disodium (e.g., ALIMTA), pertuzumab (e.g., PERJETA), plerixafor (e.g., MOZOBIL), pomalidomide (e.g., POMALYST), ponatinib hydrochloride (e.g., ICLUSIG), pralatrexate (e.g., FOLOTYN), prednisone, procarbazine hydrochloride (e.g., MATULANE), radium 223 dichloride (e.g., XOFIGO), raloxifene hydrochloride (e.g., EVISTA, KEOXIFENE), ramucirumab (e.g.,CYRAMZA), R-CHOP, recombinant HPV bivalent vaccine (e.g., CERVARIX), recombinant human papillomavirus (e.g., HPV) 9-valent vaccine (e.g., GARDASIL 9), recombinant human papillomavirus (e.g., HPV) quadrivalent vaccine (e.g., GARDASIL), recombinant interferon alfa-2b (e.g., INTRON A), regorafenib (e.g., STIVARGA), rituximab (e.g., RITUXAN), romidepsin (e.g., ISTODAX), ruxolitinib phosphate (e.g., JAKAFI), cetuximab (e.g., SYLVANT), sipuleucel-t (e.g., PROVENGE), sorafenib tosylate (e.g., NEXAVAR), STANFORD V, sunitinib malate (e.g., SUTENT), TAC, tamoxifen citrate (e.g., NOLVADEX, NOVALDEX), temozolomide (e.g., METHAZOLASTONE, TEMODAR), temsirolimus (e.g., TORISEL), thalidomide (e.g., SYNOVIR, THALOMID), thiotepa, topotecan hydrochloride (e.g., HYCAMTIN), toremifene (e.g., FARESTON), tositumomab and iodine I 131 tositumomab (e.g., BEXXAR), TPF, trametinib (e.g., MEKINIST), trastuzumab (e.g., Herceptin), VAMP, vandetanib (e.g., CAPRELSA), VEIP (e.g., ZELBORAF), vinblastine sulfate (e.g., VELBAN, VELSAR), vincristine sulfate (e.g., VINCASAR PFS), liposomal vincristine sulfate (e.g., MARQIBO), vinorelbine tartrate (e.g., NAVELBINE), vismodegib (e.g., ERIVEDGE), vorinostat (e.g., ZOLINZA), XELIRI, XELOX, aflibercept (e.g., ZALTRAP) or zoledronic acid (e.g., ZOMETA). In certain embodiments, the additional agent is ENMD-2076, PCI-32765, AC220, dovitinib lactate (e.g., TKI258, CHIR-258), BIBW 2992 (e.g., TOVOK, TM )、SGX523、PF-04217903、PF-02341066、PF-299804、BMS-777607、ABT-869、MP470、BIBF 1120(for example, ), AP24534, JNJ-26483327, MGCD265, DCC-2036, BMS-690154, CEP-11981, tivozanib (e.g., AV-951), OSI-930, MM-121, XL-184, XL-647 and / or XL228, proteasome inhibitors (e.g., bortezomib (e.g., Velcade)), mTOR inhibitors (e.g., rapamycin, temsirolimus (e.g., CCI-779), everolimus (e.g., RAD-001), defolimus, AP23573 (e.g., Ariad), AZD8055, BEZ235, BGT226, XL 765, PF-4691502, GDC0980, SF1126 and OSI-027, oblimersen, gemcitabine, carminomycin, folinic acid, pemetrexed, cyclophosphamide, dacarbazine, procarbazine, prednisolone, dexamethasone, camptothecin, plicamycin, asparaginase, aminopterin, methotrexate, methyl mitomycin, melphalan, isovinblastine, vinblastine, chlorambucil, tabitril, procarbazine, sphingolide, carminomycin, aminopterin, hexamethylmelamine, or a combination thereof. In certain embodiments, the additional agent is a cytotoxic chemotherapy (e.g., a cytotoxic chemotherapeutic agent (e.g., gemcitabine, cytarabine, daunomycin, doxorubicin, vincristine, L- In some embodiments, the additional agent is an epigenetic modifier, such as azacitidine or romidepsin. In some embodiments, the additional agent is ruxolitinib, BBT594, CHZ868, CYT387, or BMS911543. In some embodiments, the additional agent is an inhibitor of tyrosine kinase. In some embodiments, the additional agent is a topoisomerase inhibitor, an MCL1 inhibitor, a BCL-2 inhibitor, a BCL-xL inhibitor, a BRD4 inhibitor, a BRCA1 inhibitor, a BRCA2 inhibitor, a HER1 inhibitor, a HER2 inhibitor, a CDK9 inhibitor, a Jumonji histone demethylase inhibitor, or a tyrosine kinase inhibitor. Enzyme inhibitors or DNA damage inducers. In some embodiments, the additional agent is etoposide, obatoclax, navitoclax, JQ1, 4-(((5′-chloro-2′-(((1R, 4R)-4-(((R)-1-methoxypropyl-2-yl)amino)cyclohexyl)amino)-[2,4′-bipyridine]-6-yl)amino)methyl)tetrahydro-2H-pyran-4-carbonitrile, JIB04 or cisplatin. In certain embodiments, the additional agent is a binder or inhibitor of a kinase (e.g., CDK). In certain embodiments, the additional agent is an antibody or fragment thereof (e.g., a monoclonal antibody). In certain embodiments, the additional agent is a tyrosine kinase inhibitor.In certain embodiments, the additional agent is selected from epigenetic or transcriptional regulators (e.g., DNA methyltransferase inhibitors, histone deacetylase inhibitors (HDAC inhibitors), lysine methyltransferase inhibitors), anti-mitotic drugs (e.g., taxanes and vinca alkaloids), hormone receptor modulators (e.g., estrogen receptor modulators and androgen receptor modulators), cell signaling pathway inhibitors (e.g., tyrosine protein kinase inhibitors), protein stability regulators (e.g., proteasome inhibitors), Hsp90 inhibitors, glucocorticoids, all trans-retinoic acid and other agents that promote differentiation. In certain embodiments, the additional agent is a glucocorticoid (e.g., cortisol, cortisone, prednisone, methylprednisolone, dexamethasone, betamethasone, triamcinolone acetonide, fluocortolone acetate or deoxycorticosterone acetate). In certain embodiments, the additional therapy is immunotherapy (e.g., immunotherapy monoclonal antibodies). In certain embodiments, the additional agent is an immunomodulator. In certain embodiments, the additional agent is an immune checkpoint inhibitor. In certain embodiments, the additional agent is a programmed cell death 1 protein (PD-1) inhibitor. In certain embodiments, the additional agent is a programmed cell death 1 protein ligand 1 (PD-L1) inhibitor. In certain embodiments, the additional agent is a cytotoxic T lymphocyte-associated protein 4 (CTLA-4) inhibitor. In certain embodiments, the additional agent is a T cell immunoglobulin domain and mucin domain 3 (TIM3) inhibitor, a lymphocyte activation gene-3 (LAG3) inhibitor, a V-set domain-containing T cell activation inhibitor 1 (VTCN1 or B7-H4) inhibitor, a cluster of differentiation 276 (CD276 or B7-H3) inhibitor, a B and T lymphocyte attenuator (BTLA) inhibitor, a galectin-9 (GAL9) inhibitor, a checkpoint kinase 1 (Chk1) inhibitor, an adenosine A2A receptor (A2AR) inhibitor, an indoleamine 2,3-dioxygenase (IDO) inhibitor, a killer cell immunoglobulin-like receptor (KIR) inhibitor, or a T cell activation V domain Ig inhibitor (VISTA) inhibitor. In certain embodiments, the PD-1 inhibitor is nivolumab, pidilizumab, pembrolizumab, MEDI-0680, REGN2810, or AMP-224. In certain embodiments, the PD-L1 inhibitor is atezolizumab, durvalumab, BMS-936559, avelumab, or CA-170. In certain embodiments, the CTLA-4 inhibitor is ipilimumab or tremilimumab.In certain embodiments, the additional agent is an aromatase inhibitor. In certain embodiments, the additional agent is a PI3K inhibitor. In certain embodiments, the additional agent is a TOR inhibitor. In certain embodiments, the additional agent is an endocrine therapy. In certain embodiments, the compound or pharmaceutical composition is administered in combination with surgery, radiation therapy and / or transplantation (e.g., stem cell transplantation, bone marrow transplantation). In certain embodiments, the compound or pharmaceutical composition disclosed herein is administered in combination with radiation therapy.
[0354] The present disclosure also includes a kit (e.g., a pharmaceutical package). In certain embodiments, the kit includes a compound or pharmaceutical composition as described herein, and instructions for using the compound or pharmaceutical composition. In certain embodiments, the kit includes a first container, wherein the first container includes the compound or pharmaceutical composition. In certain embodiments, the kit also includes a second container. In certain embodiments, the second container includes an excipient (e.g., an excipient for diluting or suspending the compound or pharmaceutical composition). In certain embodiments, the second container includes an additional medicament. In certain embodiments, the kit also includes a third container. In certain embodiments, the third container includes an additional medicament. In some embodiments, the compound or pharmaceutical composition included in the first container and the excipient or additional medicament included in the second container are combined to form a unit dosage form. In some embodiments, the compound or pharmaceutical composition included in the first container, the excipient included in the second container, and the additional medicament included in the third container are combined to form a unit dosage form. In certain embodiments, each of the first, second, and third containers is independently a vial, an ampoule, a bottle, a syringe, a dispenser package, a tube, or an inhaler.
[0355] In certain embodiments, instructions are used to guide the administration of a compound or pharmaceutical composition to a subject (a subject in need of treatment or prevention of a disease described herein). In certain embodiments, instructions are used to guide contacting a biological sample, tissue or cell with a compound or pharmaceutical composition. In certain embodiments, instructions include information required by regulatory agencies, such as the U.S. Food and Drug Administration (FDA) or the European Medicines Evaluation Agency (EMA). In certain embodiments, instructions include prescription information.
[0356] Usage and Purpose
[0357] The present disclosure also provides methods of using the compounds and pharmaceutical compositions of the present disclosure. In another aspect, the present disclosure provides a method of inhibiting kinase activity in a subject, the method comprising administering to the subject an effective amount of a compound or pharmaceutical composition of the present disclosure.
[0358] In another aspect, the present disclosure provides a method for inhibiting kinase activity in a biological sample or tissue, the method comprising administering an effective amount of a compound or pharmaceutical composition of the present disclosure to the biological sample or tissue, or contacting the biological sample or tissue with an effective amount of a compound or pharmaceutical composition of the present disclosure.
[0359] In another aspect, the present disclosure provides a method of inhibiting kinase activity in a cell, the method comprising contacting the cell with an effective amount of a compound or pharmaceutical composition of the present disclosure.
[0360] In another aspect, the present disclosure provides a method of down-regulating MYC or MCL-1 transcription in a subject, the method comprising administering to the subject an effective amount of a compound or pharmaceutical composition of the present disclosure.
[0361] In another aspect, the present disclosure provides a method for down-regulating MYC or MCL-1 transcription in a biological sample or tissue, the method comprising administering an effective amount of a compound or pharmaceutical composition of the present disclosure to the biological sample or tissue, or contacting the biological sample or tissue with an effective amount of a compound or pharmaceutical composition of the present disclosure.
[0362] In another aspect, the present disclosure provides a method for downregulating MYC or MCL-1 transcription in a cell, the method comprising contacting the cell with an effective amount of a compound or pharmaceutical composition of the present disclosure.
[0363] Kinase is relevant with a series of diseases.In certain embodiments, the kinase is CDK (for example, CDK7).The division process of eukaryotic cells can be roughly divided into a series of continuous stages of G1, S, G2 and M.The correct progress of each stage of the cell cycle has been shown to mainly rely on the spatiotemporal regulation of the protein family called CDK and the various homologous protein partners called cell cycle proteins.CDK is a serine-threonine kinase protein homologous to CDC2 (also referred to as CDK1), which can utilize ATP as a substrate to phosphorylate different polypeptides in the context of sequence dependence.Cell cycle protein is a protein family characterized by a homology region containing about 100 amino acids, called "cell cycle box", which is used to bind to specific CDK chaperone proteins and determine its selectivity.
[0364] Regulating the expression level, degradation rate, protein level and activity level of various CDKs and cell cycle proteins throughout the cell cycle leads to the periodic formation of a series of CDK / cell cycle protein complexes, in which CDK has enzymatic activity. The formation of these complexes controls the passage of discrete cell cycle checkpoints, thereby allowing the cell division process to continue. Failure to meet the prerequisite biochemical criteria at a given cell cycle checkpoint, i.e., failure to form the required CDK / cell cycle protein complex, can lead to cell cycle arrest and / or apoptosis. Abnormal cell proliferation can generally be attributed to the loss of correct cell cycle control. Therefore, inhibiting CDK enzyme activity provides a method by which the division of abnormally divided cells can be prevented and / or cells that normally divide can be killed. The diversity of CDKs and CDK complexes and their important role in cell cycle regulation provide a wide spectrum of potential therapeutic targets selected according to defined biochemical principles, which are.
[0365] CDK7 is a member of the CDK family and was originally isolated as the catalytic subunit of the CDK-activated kinase (CAK) trimer complex. The complex composed of CDK7, cyclin H, and MAT1 is responsible for the activation of mitosis-promoting factors in vitro. CDK7 is also a component of the basic transcription repair factor IIH (TFIIH), a finding that suggests a dual role for CDK7 in transcription as part of TFIIH and in cell cycle control as a trimeric CAK complex. TFIIH is a multi-subunit protein complex that was identified as a factor required for RNA polymerase II (RNAP II) to catalyze transcription and was later found to play a key role in nucleotide excision repair. CDK7 is a component of at least three complexes, namely the CAK trimer complex, the quaternary complex with XPD (or ERCC2, a protein involved in nucleotide excision repair coupled to transcription), and the nine-subunit TFIIH complex. In summary, the two functions of CDK7 in CAK and CTD phosphorylation support key aspects of cell proliferation, cell cycle, and transcription. Overexpression of CDK7 can inhibit apoptosis, promote transcription and cell proliferation, and / or impair DNA repair, leading to proliferative diseases.
[0366] The diseases described herein may be associated with abnormal activity of a kinase (e.g., a CDK (e.g., CDK7)). Abnormal activity of a kinase may be increased and / or abnormal activity. Deregulation of cell cycle progression is a characteristic of proliferative diseases. Certain proliferative disease kinase activities are abnormal, some of which are activated by elevated and / or abnormal kinases. Inhibiting the catalytic activity of CDKs can inhibit the progression of the cell cycle by blocking the phosphorylation of cell cycle CDKs, and can also inhibit the transcription of cell division effectors. In certain embodiments, the kinase is not overexpressed, and the activity of the kinase is elevated and / or abnormal. In certain embodiments, the kinase is overexpressed, and the activity of the kinase is elevated and / or abnormal. The compounds and pharmaceutical compositions disclosed herein can inhibit the activity of CDK7 and can be used to treat and / or prevent proliferative diseases.
[0367] Diseases described herein may also be associated with inhibition of apoptosis in a subject. Apoptosis is the process of programmed cell death. Inhibition of apoptosis may lead to uncontrolled cell proliferation, and therefore may cause proliferative diseases. Cell cycle CDKs (e.g., CDK1, 2, 4, and 6) are activated by phosphorylation by CDK7 / cyclin H (also referred to as CAK). Therefore, inhibition of CDK7 may lead to cell cycle arrest at multiple points in the cell cycle, due to failure to activate cell cycle CDKs. CDK7 activates transcription by phosphorylating the CTD of RNAP II. Inhibition of CTD phosphorylation has been shown to inhibit transcription of short-lived proteins and reduce expression of short-lived proteins (including those involved in apoptosis regulation). It should be understood in the art that the stagnation of RNA polymerase can activate p53 (also referred to as protein 53 or tumor protein 53, a tumor suppressor protein encoded by the TP53 gene in humans), leading to apoptosis. Therefore, inhibition of the activity of CDK7 is expected to cause cytotoxicity by inducing apoptosis. The compounds and pharmaceutical compositions disclosed herein can induce apoptosis and thus can be used to treat and / or prevent diseases (eg, proliferative diseases, cystic fibrosis).
[0368] On the other hand, the present disclosure provides a method for treating a disease in a subject in need thereof, the method comprising administering an effective amount of a compound or pharmaceutical composition of the present disclosure to a subject in need thereof. In certain embodiments, the effective amount is effective for treating the disease. In certain embodiments, the effective amount is effective in treating the disease and inhibiting kinase activity. In certain embodiments, the effective amount is effective in treating the disease and downregulating the transcription of MYC or MCL-1.
[0369] On the other hand, the present disclosure provides a method for preventing a disease in a subject in need thereof, the method comprising administering an effective amount of a compound or pharmaceutical composition of the present disclosure to a subject in need thereof. In certain embodiments, the effective amount is effective for preventing a disease. In certain embodiments, the effective amount is effective in preventing a disease and inhibiting kinase activity. In certain embodiments, the effective amount is effective in preventing a disease and downregulating the transcription of MYC or MCL-1.
[0370] In another aspect, the present disclosure provides a method of inhibiting cell growth, the method comprising contacting the cell with an effective amount of a compound or pharmaceutical composition of the present disclosure.
[0371] In another aspect, the present disclosure provides a method of inducing apoptosis in a cell, the method comprising contacting the cell with an effective amount of a compound or pharmaceutical composition of the present disclosure.
[0372] In certain embodiments, the subject is a mammal. In certain embodiments, the subject is a human. In certain embodiments, the subject is a non-human mammal.
[0373] In certain embodiments, the biological sample or tissue is bone marrow, lymph node, spleen or blood. In certain embodiments, the biological sample or tissue is in vitro. In certain embodiments, the biological sample or tissue is ex vivo.
[0374] In certain embodiments, the cell is in vitro. In certain embodiments, the cell is ex vivo. In certain embodiments, the cell is in vivo. In certain embodiments, the cell is in a subject. In certain embodiments, the cell is in a biological sample or tissue. In certain embodiments, the cell is a malignant cell. In certain embodiments, the cell is a precancerous cell.
[0375] In certain embodiments, the disease (e.g., a disease treated or prevented using a compound or pharmaceutical composition of the present disclosure) is cancer. In certain embodiments, the disease is associated with abnormal activity of a kinase (e.g., increased activity, undesirable activity). In certain embodiments, the disease is associated with abnormal activity of a CDK (e.g., CDK7). In certain embodiments, the disease is associated with abnormal activity of a kinase (e.g., overexpression). In certain embodiments, the disease is associated with overexpression of a CDK (e.g., CDK7). In certain embodiments, the disease is a proliferative disease. In certain embodiments, the disease is cancer. In certain embodiments, the disease is adenocarcinoma, blastoma, carcinoma, hematological malignancy, myeloma, or sarcoma. In certain embodiments, the disease is a precancerous condition. In certain embodiments, the disease is a hematological malignancy. In certain embodiments, the disease is a hematological malignancy. In certain embodiments, the disease is a leukemia. In certain embodiments, the disease is chronic lymphocytic leukemia (CLL). In certain embodiments, the disease is acute lymphocytic leukemia (ALL). In certain embodiments, the disease is T-cell acute lymphoblastic leukemia (T-ALL). In certain embodiments, the disease is chronic myeloid leukemia (CLL). In certain embodiments, the disease is acute myeloid leukemia (AML). In certain embodiments, the disease is acute monocytic leukemia (AMoL). In certain embodiments, the disease is lymphoma. In certain embodiments, the disease is Burkitt lymphoma. In certain embodiments, the disease is Hodgkin lymphoma. In certain embodiments, the disease is non-Hodgkin lymphoma. In certain embodiments, the disease is multiple myeloma. In certain embodiments, the disease is melanoma. In certain embodiments, the disease is adrenocortical carcinoma. In certain embodiments, the disease is colorectal cancer. In certain embodiments, the disease is breast cancer. In certain embodiments, the disease is triple negative breast cancer (TNBC). In certain embodiments, the disease is esophageal cancer. In certain embodiments, the disease is gastric cancer. In certain embodiments, the disease is liver cancer. In certain embodiments, the disease is ovarian cancer. In certain embodiments, the disease is pancreatic cancer. In certain embodiments, the disease is prostate cancer. In certain embodiments, the disease is testicular cancer. In certain embodiments, the disease is bone cancer. In certain embodiments, the disease is osteosarcoma. In certain embodiments, the disease is Ewing's sarcoma. In certain embodiments, the disease is brain cancer. In some embodiments, the disease is neuroblastoma. In some embodiments, the disease is lung cancer. In some embodiments, the disease is small cell lung cancer (SCLC).In some embodiments, the disease is non-small cell lung cancer. In some embodiments, the disease is a benign neoplasm. In some embodiments, the disease is pathological angiogenesis. In certain embodiments, the disease is an inflammatory disease. In certain embodiments, the disease is rheumatoid arthritis. In certain embodiments, the disease is an autoinflammatory disease. In certain embodiments, the disease is an autoimmune disease. In certain embodiments, the disease is cystic fibrosis.
[0376] In certain embodiments, the method further comprises administering additional therapy to the subject. In certain embodiments, the additional therapy is an additional agent. In certain embodiments, the additional therapy is an aromatase inhibitor, an HDAC inhibitor, a phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) inhibitor, a mammalian target of rapamycin (mTOR,mammalian target of rapamycin) inhibitor, endocrine therapy, cytotoxic chemotherapy, epigenetic modifiers, glucocorticoids, immunotherapy or radiotherapy. In certain embodiments, the additional therapy is cytotoxic chemotherapy. In certain embodiments, the additional therapy is immunotherapy. In certain embodiments, the additional therapy is radiotherapy.
[0377] The compounds or pharmaceutical compositions of the present disclosure and the additional therapy may exhibit synergistic effects in the methods and uses of the present disclosure.
[0378] In another aspect, provided herein is the use of a compound or pharmaceutical composition of the present disclosure in the preparation of a medicament for use in the methods of the present disclosure (e.g., a method of treating a disease in a subject in need thereof; a method of preventing a disease in a subject in need thereof; a method of inhibiting the activity of a kinase in a subject, a biological sample, a tissue or a cell; a method of inhibiting cell growth; a method of inducing apoptosis; a method of downregulating MYC or MCL-1 transcription in a subject, a biological sample, a tissue or a cell).
[0379] In another aspect, provided herein is the use of a compound or pharmaceutical composition of the present disclosure in a method of the present disclosure (e.g., a method of treating a disease in a subject in need thereof; a method of preventing a disease in a subject in need thereof; a method of inhibiting the activity of a kinase in a subject, a biological sample, a tissue, or a cell; a method of inhibiting cell growth; a method of inducing apoptosis; a method of downregulating MYC or MCL-1 transcription in a subject, a biological sample, a tissue, or a cell).
[0380] In another aspect, provided herein are compounds or pharmaceutical compositions of the present disclosure for use in the methods of the present disclosure (e.g., a method of treating a disease in a subject in need thereof; a method of preventing a disease in a subject in need thereof; a method of inhibiting the activity of a kinase in a subject, a biological sample, a tissue, or a cell; a method of inhibiting cell growth; a method of inducing apoptosis; a method of downregulating MYC or MCL-1 transcription in a subject, a biological sample, a tissue, or a cell).
[0381] Example
[0382] In order to more fully understand the disclosure described herein, the following examples are set forth.The synthetic and biological examples described in this application are provided to illustrate the compounds, pharmaceutical compositions and methods provided herein, and are not to be construed in any way as limiting their scope.
[0383] Example 1 Synthesis of Compounds
[0384] The compounds provided herein can be prepared from readily available starting materials using the following general methods and procedures. The reactions were monitored by thin layer chromatography (TLC) using 0.25 mm E. Merck pre-coated silica gel plates (60 F 254 ) and Waters LCMS system (Waters 2489 UV / visible detector, Waters 3100 mass spectrometer, Waters 515 HPLC pump, Waters 2545 binary gradient module, Waters reagent manager, Waters 2767 sample manager), and using SunFire TM C 18 Column (4.6 x 50 mm, 5 μm particle size): solvent gradient = 95% A (0 min), solvent gradient = 0% A (5 min); solvent A = 0.5% TFA in water; solvent B = methanol; flow rate = 1.5 mL / min. The reaction product was purified by flash chromatography using Rf and Teledyne Isco Rf High Performance Gold or SilicycleSiliaSep TM High performance columns (4 g, 12 g, 24 g, 40 g, 80 g or 120 g) or by Waters preparative HPLC system using C 18Column: solvent gradient = 100% A (0 min), solvent gradient = 0% A (15 min); solvent A = 0.5% TFA in water; solvent B = methanol; flow rate = 20 mL / min. All compounds were more than 95% pure and were analyzed using a Waters LCMS system. Acquisition was performed using a Varian Inova-600 or 400 MHz spectrometer. 1 HNMR and 13 C NMR spectrum. Reported relative to chloroform (δ = 7.24) 1 H NMR or dimethyl sulfoxide (δ=2.50) 1 H NMR and dimethyl sulfoxide (δ=39.51) 13 Chemical shifts for CNMR. Data are reported as (br = broad, s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet).
[0385] Example 1.1 (S)-N-(2-(dimethylamino)-1-(tetrahydro-2H-pyran-4-yl)ethyl)-6,6-dimethyl-3-((2-methylthieno[2,3-d]pyrimidin-4-yl)amino)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide (Compound 200)
[0386] The synthesis of compound 200 followed Scheme 1. The syntheses of compound 201 and compound 208 followed similar methods.
[0387] Solution 1
[0388]
[0389]
[0390] (S)-tert-Butyl (2-(dimethylamino)-2-oxo-1-(tetrahydro-2H-pyran-4-yl)ethyl)carbamate
[0391]
[0392] To a solution of (S)-2-((tert-butoxycarbonyl)amino)-2-(tetrahydro-2H-pyran-4-yl)acetic acid (3 g, 11.6 mmol) in DCM (50 mL) was added CDI (1.9 g, 11.6 mmol), the mixture was stirred at room temperature for 1 hour, and then dimethylamine (2M, 11.6 mL, 23.2 mmol) in THF was added. The mixture was stirred at room temperature overnight, concentrated under reduced pressure, and purified by silica gel column chromatography ((MeOH / DCM=0-5%) to give tert-butyl (S)-(2-(dimethylamino)-2-oxo-1-(tetrahydro-2H-pyran-4-yl)ethyl)carbamate as a white solid. LCMS: 287 [M+H] + .
[0393] (S)-2-Amino-N,N-dimethyl-2-(tetrahydro-2H-pyran-4-yl)acetamide
[0394]
[0395] (S)-tert-Butyl (2-(dimethylamino)-2-oxo-1-(tetrahydro-2H-pyran-4-yl)ethyl)carbamate was dissolved in DCM (30 mL) and stirred at 0°C for 5 minutes, then TFA (10 mL) was added. The mixture was stirred at room temperature for 1 hour, then concentrated under reduced pressure to give (S)-2-amino-N,N-dimethyl-2-(tetrahydro-2H-pyran-4-yl)acetamide, which was used in the next step without any purification. LCMS: 187 [M+H] + .
[0396] (S)-N 1 ,N 1 -Dimethyl-2-(tetrahydro-2H-pyran-4-yl)ethane-1,2-diamine
[0397]
[0398] A solution of (S)-2-amino-N,N-dimethyl-2-(tetrahydro-2H-pyran-4-yl)acetamide (11.6mmol) in dry THF (50mL) was stirred at 0°C for 10 minutes, and then LiAlH4 (2.5M, 9.28mL, 23.2mmol) in THF was carefully added under N2 atmosphere. After addition, the mixture was stirred at 60°C for 3 hours and then cooled to room temperature. Cold water (882μL) was added dropwise to the mixture at 0°C, and then NaOH solution (15% aqueous solution, 882μL) was carefully added, and then 3x 882μL of water was added again. The mixture was warmed to room temperature, and then ether was added. The mixture was stirred for 10 minutes and filtered. The filtrate was concentrated under reduced pressure and purified by silica gel column chromatography (1.75N NH3, MeOH / DCM=0-20%) to obtain (S)-N 1 ,N 1 -Dimethyl-2-(tetrahydro-2H-pyran-4-yl)ethane-1,2-diamine (1.6 g, 80%, 3 steps), as a yellow liquid. LCMS: 173 [M+H] + .
[0399] tert-Butyl 6,6-dimethyl-3-((2-methylthieno[2,3-d]pyrimidin-4-yl)amino)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxylate
[0400]
[0401] 4-Chloro-2-methylthieno[2,3-d]pyrimidine (221 mg, 1.2 mmol) and 3-amino-6,6-dimethyl-4,6-dihydropyrrolo[3,4-c]pyrazole-1,5-dicarboxylic acid-5-(tert-butyl)-1-ethyl ester (390 mg, 1.2 mmol) were added to a 4-chloro-2-methylthieno[2,3-d]pyrimidine (221 mg, 1.2 mmol) solution of 5-(tert-butyl)-1-ethyl ester (390 mg, 1.2 mmol) in a 5% ethanol solution. t Pd2(dba)3 (55 mg, 0.06 mmol), XPhos (57 mg, 0.12 mmol) and K2CO3 (497 mg, 3.6 mmol) were added to the solution in BuOH (6 mL). The mixture was stirred at 100 ° C for 4 hours under N2 protection, cooled to room temperature and filtered. The filtrate was concentrated under reduced pressure and then purified by silica gel column chromatography (EA / hexane=0-80%) to give 6,6-dimethyl-3-((2-methylthieno[2,3-d]pyrimidin-4-yl)amino)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxylic acid tert-butyl ester (445 mg, 92%). LCMS: 401 [M+H] + .
[0402] 6,6-Dimethyl-3-((2-methylthieno[2,3-d]pyrimidin-4-yl)amino)-5,6-dihydropyrrolo[3,4-c]pyrazole-1(4H)-carboxylic acid ethyl ester
[0403]
[0404] To a solution of tert-butyl 6,6-dimethyl-3-((2-methylthieno[2,3-d]pyrimidin-4-yl)amino)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxylate (445 mg, 1.1 mmol) and DIEA (363 μL, 2.2 mmol) in THF (10 mL) was added ethyl chloroformate (127 μL, 1.3 mmol) at 0°C. The mixture was stirred at 50°C for 1 hour, then concentrated under reduced pressure, extracted with EA, and washed twice with water. The organic layer was then concentrated under reduced pressure. The residue was dissolved in TFA / DCM (v / v=1 / 3, 10 mL). The resulting mixture was stirred at room temperature for 1 hour, concentrated under reduced pressure, and then purified by silica gel column chromatography (1.75N NH3, MeOH / DCM=0-10%) to give 6,6-dimethyl-3-((2-methylthieno[2,3-d]pyrimidin-4-yl)amino)-5,6-dihydropyrrolo[3,4-c]pyrazole-1(4H)-carboxylic acid ethyl ester (202 mg, 45%) as a TFA salt. LCMS: 373 [M+H] + .
[0405] (S)-N-(2-(dimethylamino)-1-(tetrahydro-2H-pyran-4-yl)ethyl)-6,6-dimethyl-3-((2-methylthieno[2,3-d]pyrimidin-4-yl)amino)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide (Compound 200)
[0406]
[0407] To (S)-N in dry toluene (2 mL) 1 ,N 1Phosgene (15 wt % in 0.2 mL toluene) was added to 2-dimethyl-2-(tetrahydro-2H-pyran-4-yl)ethane-1,2-diamine (45 mg, 0.26 mmol). The mixture was stirred at 80°C for 2 hours and then concentrated under reduced pressure. The residue was dissolved in dioxane (3 mL), and then 6,6-dimethyl-3-((2-methylthieno[2,3-d]pyrimidin-4-yl)amino)-5,6-dihydropyrrolo[3,4-c]pyrazole-1(4H)-carboxylic acid ethyl ester (80 mg, 0.16 mmol) and DIEA (129 μL, 0.78 mmol) were added. The mixture was stirred at 80°C for another 2 hours. The mixture was then concentrated under reduced pressure and the intermediate (28 mg, 22%) was obtained by silica gel column chromatography (1.75N NH3, MeOH / DCM=0-15%).
[0408] The intermediate was then dissolved in a mixture of isopropanol (IPA, 1 mL) and LiOH (1 M aqueous solution, 1 mL). The mixture was stirred at room temperature for 10 minutes, concentrated under reduced pressure, and purified by prep-HPLC (MeOH / water, 0.035% TFA) to give compound 200 (27.6 mg, 90%) as a TFA salt. LCMS: 499 [M+H] + .
[0409] 1 H NMR(500MHz,DMSO-d6)δ10.57(s,1H),9.11(s,1H),7.86(d,J=6.0Hz,1H),7.61(d,J=5.9Hz,1H) ,5.88(d,J=9.3Hz,1H),4.58(q,J=11.6Hz,2H),4.01–3.95(m,1H),3.90–3.81(m,2H),3.24(ddd ,J=15.3,8.5,4.0Hz,4H),2.83(d,J=4.8Hz,3H),2.79(d,J=4.8Hz,3H),2.61(s,3H),1.70(d,J= 1.9Hz, 6H), 1.65 (dt, J=11.0, 3.7Hz, 1H), 1.56 (d, J=13.0Hz, 2H), 1.27 (qt, J=12.2, 4.7Hz, 2H).
[0410] Example 1. 2(S)-N-(2-(dimethylamino)-1-(tetrahydro-2H-pyran-4-yl)ethyl)-6,6-dimethyl-3-((2-methylthieno[3,2-d]pyrimidin-4-yl)amino)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide (Compound 201)
[0411]
[0412] Compound 201 (42 mg, 22%) was obtained according to the synthetic route of compound 200, except that 4-chloro-2-methylthieno[2,3-d]pyrimidine was replaced by 4-chloro-2-methylthieno[3,2-d]pyrimidine. LCMS: 499 [M+H] + .
[0413] 1 H NMR (500MHz, DMSO-d6) δ11.65(s,1H),9.18(s,1H),8.45(d,J=5.5Hz,1H),7.52(d,J=5.4Hz,1 H),5.97(d,J=9.3Hz,1H),4.53(d,J=7.3Hz,2H),3.97(s,1H),3.87(dq,J=12.2,4.5Hz,2H),3. 29–3.19(m,4H),2.82(d,J=4.8Hz,3H),2.80(d,J=4.8Hz,3H),2.72(s,3H),1.71(d,J=3.1Hz, 6H), 1.66 (dt, J=7.6, 3.9Hz, 1H), 1.55 (d, J=13.1Hz, 2H), 1.26 (dtd, J=17.8, 12.2, 6.1Hz, 2H).
[0414] Example 1.3 (S)-N-(2-(dimethylamino)-1-(tetrahydro-2H-pyran-4-yl)ethyl)-6,6-dimethyl-3-((2-(trifluoromethyl)pyrimidin-4-yl)amino)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide (Compound 208)
[0415]
[0416] Compound 208 (43 mg, 20%) was obtained according to the synthetic route of compound 200, except that 4-chloro-2-methylthieno[2,3-d]pyrimidine was replaced by 4-chloro-2-(trifluoromethyl)pyrimidine. LCMS: 497 [M+H] + . 1H NMR(500MHz,DMSO-d6)δ12.53(s,1H),10.57(s,1H),8.42(s,1H),7.01(s,1H),4.49(s,2H),3.94–3.73(m,4H),3.24(t dd,J=11.7,4.8,2.1Hz,3H),2.36(s,6H),1.66(d,J=3.7Hz,7H),1.54–1.44(m,2H),1.28(qdd,J=12.1,7.1,4.5Hz,2H).
[0417] Example 1. 4(S)-3-((6-acrylamidoisoquinolin-1-yl)amino)-N-(2-(dimethylamino)-1-(tetrahydro-2H-pyran-4-yl)ethyl)-6,6-dimethyl-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide (Compound 202)
[0418] The synthesis of compound 202 followed Scheme 2. The syntheses of compound 203, compound 204, compound 206 and compound 209 followed similar methods.
[0419] Solution 2
[0420]
[0421]
[0422] 6,6-dimethyl-3-((6-nitroisoquinolin-1-yl)amino)-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxylic acid tert-butyl ester (Compound 4-173)
[0423]
[0424] 1-Chloro-6-nitroisoquinoline (250 mg, 1.2 mmol) and 3-amino-6,6-dimethyl-4,6-dihydropyrrolo[3,4-c]pyrazole-1,5-dicarboxylic acid-5-(tert-butyl)-1-ethyl ester (390 mg, 1.2 mmol) were added to a flask. t Pd2(dba)3 (55 mg, 0.06 mmol), XPhos (57 mg, 0.12 mmol) and K2CO3 (497 mg, 3.6 mmol) were added to a solution in BuOH (6 mL). The mixture was stirred at 100 ° C for 4 hours under N2 atmosphere, cooled to room temperature and filtered. The filtrate was concentrated under reduced pressure and purified by silica gel column chromatography (EA / hexane = 0-5%) to obtain compound 4-173 (309 mg, 61%) as a red solid. LCMS: 425 [M+H] + .
[0425] 6,6-Dimethyl-3-((6-nitroisoquinolin-1-yl)amino)-4,6-dihydropyrrolo[3,4-c]pyrazole-1,5-dicarboxylic acid-5-(tert-butyl)-1-ethyl ester (Compound 4-174)
[0426]
[0427] To a solution of compound 4-173 (309 mg, 0.73 mmol) and DIEA (241 uL, 1.46 mmol) in THF (5 mL) was added ethyl chloroformate (70 uL, 1.3 mmol) at 0°C. The mixture was stirred at 50°C for 1 hour and then concentrated and extracted with EA. The organic layer was washed twice with water and concentrated under reduced pressure to give compound 4-174, which was used in the next step without any purification. LCMS: 497 [M+H] + .
[0428] 6,6-Dimethyl-3-((6-nitroisoquinolin-1-yl)amino)-5,6-dihydropyrrolo[3,4-c]pyrazole-1(4H)-carboxylic acid ethyl ester TFA salt (Compound 4-175)
[0429]
[0430] The compound 4-174 (0.73 mmol) obtained in the last step was dissolved in TFA / DCM (v / v=1 / 3, 8 mL). The mixture was stirred at room temperature for 1 hour, concentrated under reduced pressure, and purified by prep-HPLC (MeOH / water, 0.035% TFA) to obtain compound 4-175 (162 mg, 44%, 2-step method) in the form of a TFA salt. LCMS: 397 [M+H] + .
[0431] (S)-5-((2-(dimethylamino)-1-(tetrahydro-2H-pyran-4-yl)ethyl)carbamoyl)-6,6-dimethyl-3-((6-nitroisoquinolin-1-yl)amino)-5,6-dihydropyrrolo[3,4-c]pyrazole-1(4H)-carboxylic acid ethyl ester (Compound 4-179)
[0432]
[0433] To (S)-N 1 ,N 1-Dimethyl-2-(tetrahydro-2H-pyran-4-yl)ethane-1,2-diamine (45 mg, 0.26 mmol) was added to a solution of phosgene (15 wt % in 0.2 mL toluene) in dry toluene (2 mL). The mixture was stirred at 80 ° C for 2 hours and then concentrated under reduced pressure. The residue was dissolved in dioxane (3 mL), and then compound 4-175 (85 mg, 0.17 mmol) and DIEA (129 uL, 0.78 mmol) were added. The mixture was stirred at 80 ° C for another 2 hours, concentrated under reduced pressure, and then purified by silica gel column chromatography (MeOH / DCM=0-15%) to obtain compound 4-179 (44 mg, 45%) as an orange solid. LCMS: 595 [M+H] + .
[0434] (S)-3-((6-acrylamidoisoquinolin-1-yl)amino)-5-((2-(dimethylamino)-1-(tetrahydro-2H-pyran-4-yl)ethyl)carbamoyl)-6,6-dimethyl-5,6-dihydropyrrolo[3,4-c]pyrazole-1(4H)-carboxylic acid ethyl ester (Compound 4-182)
[0435]
[0436] Pd / C was added to a solution of compound 4-179 (44 mg, 0.074 mmol) in MeOH (10 mL). The mixture was stirred at room temperature for 3 hours under H2 atmosphere and then filtered. The filtrate was concentrated under reduced pressure to give compound 4-182 (42 mg, 100%) as a white solid. LCMS: 565 [M+H] + .
[0437] (S)-3-(3-(4-acrylamidobenzamido)benzamido)-N-(2-(dimethylamino)-1-phenylethyl)-6,6-dimethyl-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide (Compound 202)
[0438]
[0439] Acryloyl chloride (diluted in acetonitrile) was added dropwise to a solution of compound 4-182 (42 mg, 0.074 mmol) in acetonitrile (2 mL) at 0°C until the reaction was completed. The mixture was then extracted with an excess of EA and washed twice with water. The organic layer was then concentrated under reduced pressure and dissolved in a mixture of isopropanol (IPA, 1 mL) and LiOH (1M aqueous solution, 1 mL). The mixture was stirred at room temperature for 10 minutes, concentrated under reduced pressure, and purified by prep-HPLC (MeOH / water, 0.035% TFA) to give the TFA salt of compound 202 (10.1 mg, 21%). LCMS: 547 [M+H] + . 1 H NMR (500MHz, DMSO-d6) δ11.62(s,1H),10.94(s,1H),9.21(s,1H),8.76(d,J=9.1Hz,1H),8.45(d,J=2.1Hz,1H),7.99(d d,J=9.1,2.2Hz,1H),7.93(d,J=6.9Hz,1H),7.46(d,J=6.9Hz,1H),6.55(dd,J=16.9,10.2Hz,1H),6.39(dd,J=17.0,1. 8Hz,1H),5.99–5.77(m,2H),4.52(dd,J=57.5,11.6Hz,2H),3.98(d,J=9.3Hz,1H),3.86(d,J=10.3Hz,2H),3.25(dd,J= 12.1,5.6Hz,4H),2.82(t,J=5.1Hz,6H),1.73(s,6H),1.67(d,J=7.0Hz,1H),1.55(d,J=13.0Hz,2H),1.32–1.24(m,2H).
[0440] Example 1. 5(S)-3-((5-acrylamidoisoquinolin-1-yl)amino)-N-(2-(dimethylamino)-1-(tetrahydro-2H-pyran-4-yl)ethyl)-6,6-dimethyl-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide (Compound 203)
[0441]
[0442] Compound 203 (4.5 mg, 14%) was obtained according to the synthetic route of compound 202 except that 1-chloro-6-nitroisoquinoline was replaced by 1-chloro-5-nitroisoquinoline. LCMS: 547 [M+H] + . 1H NMR (500MHz, DMSO-d6) δ10.69(s,1H),10.26(s,1H),8.97(s,1H),8.48(d,J=8.4Hz,1H),8.11(d,J=7.7Hz,1H),8.05(d,J=6. 4Hz,1H),7.73(t,J=8.0Hz,1H),7.40(s,1H),6.69(dd,J=17.0,10.2Hz,1H),6.34(dd,J=17.0,1.9Hz,1H),5.93–5.81(m,2H) ,4.59–4.42(m,2H),3.98(td,J=11.9,11.3,7.2Hz,1H),3.87(dd,J=10.8,4.1Hz,2H),3.24(td,J=11.4,10.6,4.0Hz,4H),2. 81(t,J=5.0Hz,6H), 1.71(d,J=6.5Hz,3H), 1.66(dd,J=7.7,3.8Hz,1H), 1.55(d,J=13.0Hz,2H), 1.26(dt,J=12.3,5.6Hz,2H).
[0443] Example 1. 6(S)-3-((5-acrylamidopyridin-2-yl)amino)-N-(2-(dimethylamino)-1-(tetrahydro-2H-pyran-4-yl)ethyl)-6,6-dimethyl-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide (Compound 204)
[0444]
[0445] Compound 204 (1.6 mg, 7%) was obtained according to the synthetic route of compound 202 except that 1-chloro-6-nitroisoquinoline was replaced by 2-chloro-5-nitropyridine. LCMS: 497 [M+H] + . 1H NMR (500MHz, DMSO-d6) δ10.29(s,1H),10.00(s,1H),9.01(s,1H),8.61(d,J=2.6Hz,1H),7.92(dd,J=9.1,2.6Hz,1 H),7.00(d,J=9.1Hz,1H),6.43(dd,J=17.0,10.2Hz,1H),6.26(dd,J=17.0,2.0Hz,1H),5.89(d,J=9.2Hz,1H),5.78 (dd,J=10.1,2.0Hz,1H),4.51(d,J=11.5Hz,1H),4.38(d,J=11.4Hz,1H),3.97(s,1H),3.88(td,J=11.9,4.0Hz,2H) ,3.22(d,J=13.7Hz,4H),2.81(dd,J=4.9,2.1Hz,6H),1.67(d,J=7.6Hz,6H),1.59–1.50(m,2H),1.28–1.20(m,2H).
[0446] Example 1. 7(S)-3-((5-acrylamidopyrimidin-2-yl)amino)-N-(2-(dimethylamino)-1-(tetrahydro-2H-pyran-4-yl)ethyl)-6,6-dimethyl-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide (Compound 206)
[0447]
[0448] Compound 206 (2.2 mg, 5%) was obtained according to the synthetic route of compound 202 except that 1-chloro-6-nitroisoquinoline was replaced by 2-chloro-5-nitropyrimidine. LCMS: 498 [M+H] + . 1H NMR (500MHz, DMSO-d6) δ12.07(s,1H),10.23(s,1H),9.70(s,1H),8.71(s,2H),6.42(dd,J=17. 0,10.1Hz,1H),6.27(dd,J=17.0,1.9Hz,1H),5.79(dd,J=10.1,2.0Hz,1H),5.38(s,1H),4.39( d,J=18.7Hz,2H),3.85(ddd,J=16.8,11.6,4.3Hz,2H),3.75(p,J=7.1Hz,1H),3.26–3.15(m,2H ), 2.31 (d, J = 7.5Hz, 2H), 2.16 (s, 6H), 1.62 (s, 6H), 1.51 (t, J = 14.8Hz, 2H), 1.35–1.26 (m, 2H).
[0449] Example 1.8 (S)-3-((4-acrylamidophenyl)amino)-N-(2-(dimethylamino)-1-(tetrahydro-2H-pyran-4-yl)ethyl)-6,6-dimethyl-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide (Compound 209)
[0450]
[0451] Compound 209 (2.4 mg, 7%) was obtained according to the synthetic route of compound 202 except that 1-chloro-6-nitroisoquinoline was replaced by 1-chloro-4-nitrobenzene. LCMS: 496 [M+H] + . 1 H NMR(500MHz,DMSO-d6)δ11.95(s,1H),9.91(s,1H),8.19(s,1H),7.50(d,J=8.5Hz,1H),6 .40(dd,J=17.0,10.1Hz,2H),6.20(dd,J=17.0,2.1Hz,1H),5.69(dd,J=10.1,2.1Hz,1H), 5.37(s,1H),4.20(s,2H),3.83(d,J=13.0Hz,2H),3.77–3.69(m,1H),3.20(d,J=9.6Hz,2 H), 2.28 (d, J = 7.3Hz, 1H), 2.14 (s, 6H), 1.62 (s, 6H), 1.49 (t, J = 16.8Hz, 2H), 1.24 (s, 2H).
[0452] Example 1. 9(S)-3-((4-acrylamidobenzamido)-N-(2-(dimethylamino)-1-(tetrahydro-2H-pyran-4-yl)ethyl)-6,6-dimethyl-4,6-dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxamide (Compound 205)
[0453] The synthesis of Compound 205 followed Scheme 3. The syntheses of Compound 207, Compound 210, Compound 065 and Compound 079 followed similar methods.
[0454] Solution 3
[0455]
[0456] 6,6-Dimethyl-3-(4-nitrobenzamido)-4,6-dihydropyrrolo[3,4-c]pyrazole-1,5-dicarboxylic acid-5-(tert-butyl)-1-ethyl ester
[0457]
[0458] DIEA (1.7 mL, 10.5 mmol) was added to a solution of 3-amino-6,6-dimethyl-4,6-dihydropyrrolo[3,4-c]pyrazole-1,5-dicarboxylic acid-5-(tert-butyl)-1-ethyl ester (1135 mg, 3.5 mmol) and 4-nitrobenzoyl chloride (775 mg, 4.2 mmol) in DCM (25 mL), and the mixture was stirred at room temperature for 4 hours, then concentrated under reduced pressure and purified by silica gel column chromatography (EA / hexane=0-35%) to give 6,6-dimethyl-3-(4-nitrobenzamido)-4,6-dihydropyrrolo[3,4-c]pyrazole-1,5-dicarboxylic acid-5-(tert-butyl)-1-ethyl ester (520 mg, 31%) as a yellow solid. LCMS: 474 [M+H] + .
[0459] 6,6-Dimethyl-3-(4-nitrobenzamido)-5,6-dihydropyrrolo[3,4-c]pyrazole-1(4H)-methylethyl ester
[0460]
[0461] The product of the last step was dissolved in TFA / DCM (v / v=1 / 3, 4 mL), stirred at room temperature for 1 hour, and then concentrated under reduced pressure and used in the next step without any purification. LCMS: 374 [M+H] + .
[0462] (S)-5-((2-(dimethylamino)-1-(tetrahydro-2H-pyran-4-yl)ethyl)carbamoyl)-6,6-dimethyl-3-(4-nitrobenzamido)-5,6-dihydropyrrolo[3,4-c]pyrazole-1(4H)-carboxylic acid ethyl ester
[0463]
[0464] To (S)-N in dry toluene (2 mL) 1 ,N 1 Phosgene (15% by weight in 0.4 mL toluene) was added to 1,2-dimethyl-2-(tetrahydro-2H-pyran-4-yl)ethane-1,2-diamine (103 mg, 0.6 mmol), and the mixture was stirred at 80°C for 2 hours. The mixture was then concentrated under reduced pressure and dissolved in dioxane (4 mL), followed by the addition of ethyl 6,6-dimethyl-3-(4-nitrobenzamido)-5,6-dihydropyrrolo[3,4-c]pyrazole-1(4H)-carboxylate (263 mg, 0.54 mmol) and DIEA (297 uL, 1.8 mmol)...
Claims
1. A compound, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein the compound is of the formula: in: A is aryl or heteroaryl; R 1 Formula: -NHC(O)CH=CH2; m = 0 or 1; R 9 for hydrogen and R 10 is -CH2N(CH3)2; L is a single bond or -C(=O)-, When L is a single bond, A is heteroaryl, p = 1, D = tetrahydropyranyl and q = 0; and when L is -C(=O)-, A is aryl, p is 0 or 1, such that when p=0, then D=piperidinyl, 1,2,3,4-tetrahydroisoquinolinyl or and when p=1, then D=tetrahydropyranyl or tetrahydrofuranyl; R 11 is unsubstituted C 1-3 Alkyl; and q=0 or 1.
2. The compound according to claim 1, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein ring A is an aryl group.
3. The compound according to claim 2, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein ring A is phenyl.
4. The compound according to claim 1, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein Ring A is a heteroaryl group.
5. The compound according to claim 4, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein ring A is selected from thieno[2,3-d]pyrimidinyl, thieno[3,2-d]pyrimidinyl, isoquinolyl, pyridinyl and pyrimidinyl.
6. A compound according to any one of claims 1 to 5, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein p = 0 and D = piperidinyl, 1,2,3,4-tetrahydroisoquinolinyl or 7. The compound according to claim 6, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein q=1 and R 11 It's methyl.
8. The compound according to any one of claims 1 to 5, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein p = 1 and D = tetrahydropyranyl or tetrahydrofuranyl.
9. The compound according to claim 8, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein q=0.
10. The compound according to claim 1, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein the compound is of the formula:
11. A pharmaceutical composition comprising: The compound according to any one of claims 1 to 10, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof; and Optionally a pharmaceutically acceptable excipient.
12. Use of the compound according to any one of claims 1 to 10, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof in the preparation of a medicament for treating cancer.
13. The use according to claim 12, wherein the cancer is adrenocortical carcinoma, bone cancer, breast cancer, brain cancer, colorectal cancer, esophageal cancer, Ewing's sarcoma, gastric cancer, liver cancer, lung cancer, melanoma, neuroblastoma, ovarian cancer, pancreatic cancer, prostate cancer or testicular cancer.
14. The use according to claim 12, wherein the cancer is leukemia or lymphoma.
15. The use according to claim 14, wherein the cancer is acute lymphoblastic leukemia.
16. A kit comprising: The compound according to any one of claims 1 to 10, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, or the pharmaceutical composition according to claim 11; and Instructions for use of the compound or its pharmaceutically acceptable salt, tautomer or stereoisomer or the pharmaceutical composition.
Citation Information
Patent Citations
Inhibitors of cyclin-dependent kinase 7 (CDK7)
WO2016105528A2
